

Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

L. Clifford McDonald,¹ Dale N. Gerding,² Stuart Johnson,^{2,3} Johan S. Bakken,⁴ Karen C. Carroll,⁵ Susan E. Coffin,⁶ Erik R. Dubberke,⁷ Kevin W. Garey,⁸ Carolyn V. Gould,¹ Ciaran Kelly,⁹ Vivian Loo,¹⁰ Julia Shaklee Sammons,⁶ Thomas J. Sandora,¹¹ and Mark H. Wilcox¹²

¹Centers for Disease Control and Prevention, Atlanta, Georgia; ²Edward Hines Jr Veterans Administration Hospital, Hines, and ³Loyola University Medical Center, Maywood, Illinois; ⁴St Luke's Hospital, Duluth, Minnesota; ⁵Johns Hopkins University School of Medicine, Baltimore, Maryland; ⁶Children's Hospital of Philadelphia, Pennsylvania; ⁷Washington University School of Medicine, St Louis, Missouri; ⁸University of Houston College of Pharmacy, Texas; ⁹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; ¹⁰McGill University Health Centre, McGill University, Montréal, Québec, Canada; ¹¹Boston Children's Hospital, Massachusetts; and ¹²Leeds Teaching Hospitals NHS Trust, United Kingdom

A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on *Clostridium difficile* infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. *Clostridium difficile* remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, *C. difficile* has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.

Keywords. *Clostridium difficile*; *Clostridioides difficile*; Guidelines; CDI; CDAD.

EXECUTIVE SUMMARY

Summarized below are recommendations intended to improve the diagnosis and management of *Clostridium difficile* infection (CDI) in adults and children. CDI is defined by the presence of symptoms (usually diarrhea) and either a stool test positive for *C. difficile* toxins or detection of toxigenic *C. difficile*, or colonoscopic or histopathologic findings revealing pseudomembranous colitis. In addition to diagnosis and management, recommended methods of infection control and environmental management of the pathogen

are presented. The panel followed a process used in the development of other Infectious Diseases Society of America (IDSA) guidelines, which included a systematic weighting of the strength of recommendation and quality of evidence using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) system (Figure 1). A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found in the full text of the guidelines. The extent to which these guidelines can be implemented is impacted by the size of the institution and the resources, both financial and laboratory, available in the particular clinical setting.

GUIDELINE RECOMMENDATIONS FOR CLOSTRIDIUM DIFFICILE INFECTION

EPIDEMIOLOGY

I. How are CDI cases best defined?

Recommendation

- To increase comparability between clinical settings, use available standardized case definitions for surveillance of (1) healthcare facility-onset (HO) CDI; (2) community-onset, healthcare facility-associated (CO-HCFA) CDI; and (3) community-associated (CA) CDI (*good practice recommendation*).

Received 6 December 2017; editorial decision 8 December 2017; accepted 14 December 2017; published online February 15, 2018.

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA and SHEA consider adherence to the guidelines listed below to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. While IDSA makes every effort to present accurate and reliable information, the information provided in these guidelines is "as is" without any warranty of accuracy, reliability, or otherwise, either express or implied. Neither IDSA nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with these guidelines or reliance on the information presented.

Correspondence: L. C. McDonald, Centers for Disease Control and Prevention, 1600 Clifton Road, MS A35, Atlanta, GA 30333 (cmcdonald1@cdc.gov).

Clinical Infectious Diseases® 2018;66(7):e1–e48

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
DOI: 10.1093/cid/cix1085




Figure 1. Approach and implications to rating the quality of evidence and strength of recommendations using the *Grading of Recommendations, Assessment, Development and Evaluation (GRADE)* methodology (unrestricted use of this figure granted by the US GRADE Network) [1–4].

II. What is the minimal surveillance recommendation for institutions with limited resources?

Recommendation

- At a minimum, conduct surveillance for HO-CDI in all inpatient healthcare facilities to detect elevated rates or outbreaks of CDI within the facility (*weak recommendation, low quality of evidence*).

III. What is the best way to express CDI incidence and rates?

Recommendation

- Express the rate of HO-CDI as the number of cases per 10 000 patient-days. Express the CO-HCFA prevalence rate as the number of cases per 1000 patient admissions (*good practice recommendation*).

IV. How should CDI surveillance be approached in settings of high endemic rates or outbreaks?

Recommendation

- Stratify data by patient location to target control measures when CDI incidence is above national and/or facility reduction goals or if an outbreak is noted (*weak recommendation, low quality of evidence*).

EPIDEMIOLOGY (PEDIATRIC CONSIDERATIONS)

V. What is the recommended CDI surveillance strategy for pediatric institutions?

Recommendations

- Use the same standardized case definitions (HO, CO-HCFA, CA) and rate expression (cases per 10 000 patient-days for HO,

cases per 1000 patient admissions for CO-HCFA) in pediatric patients as for adults (*good practice recommendation*).

2. Conduct surveillance for HO-CDI for inpatient pediatric facilities but do not include cases <2 years of age (*weak recommendation, low quality of evidence*).
3. Consider surveillance for CA-CDI to detect trends in the community (*weak recommendation, low quality of evidence*).

DIAGNOSIS

VI. What is the preferred population for *C. difficile* testing, and should efforts be made to achieve this target?

Recommendation

1. Patients with unexplained and new-onset ≥ 3 unformed stools in 24 hours are the preferred target population for testing for CDI (*weak recommendation, very low quality of evidence*).

VII. What is the best-performing method (ie, in use positive and negative predictive value) for detecting patients at increased risk for clinically significant *C. difficile* infection in commonly submitted stool specimens?

Recommendation

1. Use a stool toxin test as part of a multistep algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or

NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no preagreed institutional criteria for patient stool submission (*Figure 2*) (*weak recommendation, low quality of evidence*).

VIII. What is the most sensitive method of diagnosis of CDI in stool specimens from patients likely to have CDI based on clinical symptoms?

Recommendation

1. Use a NAAT alone or a multistep algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are preagreed institutional criteria for patient stool submission (*Figure 2*) (*weak recommendation, low quality of evidence*).

IX. What is the role of repeat testing, if any? Are there asymptomatic patients in whom repeat testing should be allowed, including test of cure?

Recommendation

1. Do not perform repeat testing (within 7 days) during the same episode of diarrhea and do not test stool from asymptomatic patients, except for epidemiological studies (*strong recommendation, moderate quality of evidence*).




Figure 2. *Clostridium difficile* infection laboratory test recommendations based on preagreed institutional criteria for patient stool submission. Abbreviations: CDI, *Clostridium difficile* infection; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification test.

X. Does detection of fecal lactoferrin or another biologic marker improve the diagnosis of CDI over and above the detection of toxigenic *C. difficile*? Can such a subset predict a more ill cohort?

Recommendation

1. There are insufficient data to recommend use of biologic markers as an adjunct to diagnosis (*no recommendation*).

DIAGNOSIS (PEDIATRIC CONSIDERATIONS)

XI. When should a neonate or infant be tested for *C. difficile*?

Recommendations

1. Because of the high prevalence of asymptomatic carriage of toxigenic *C. difficile* in infants, testing for CDI should never be routinely recommended for neonates or infants ≤ 12 months of age with diarrhea (*strong recommendation, moderate quality of evidence*).

XII. When should a toddler or older child be tested for *C. difficile*?

Recommendations

1. *Clostridium difficile* testing should not be routinely performed in children with diarrhea who are 1–2 years of age unless other infectious or noninfectious causes have been excluded (*weak recommendation, low quality of evidence*).
2. In children ≥ 2 years of age, *C. difficile* testing is recommended for patients with prolonged or worsening diarrhea and risk factors (eg, underlying inflammatory bowel disease or immunocompromising conditions) or relevant exposures (eg, contact with the healthcare system or recent antibiotics) (*weak recommendation, moderate quality of evidence*).

INFECTION PREVENTION AND CONTROL

Isolation Measures for Patients With CDI

XIII. Should private rooms and/or dedicated toilet facilities be used for isolated patients with CDI?

Recommendations

1. Accommodate patients with CDI in a private room with a dedicated toilet to decrease transmission to other patients. If there is a limited number of private single rooms, prioritize patients with stool incontinence for placement in private rooms (*strong recommendation, moderate quality of evidence*).
2. If cohorting is required, it is recommended to cohort patients infected or colonized with the same organism(s)—that is, do not cohort patients with CDI who are discordant for other multidrug-resistant organisms such as methicillin-resistant *Staphylococcus aureus* or vancomycin-resistant

Enterococcus (*strong recommendation, moderate quality of evidence*).

XIV. Should gloves and gowns be worn while caring for isolated CDI patients?

Recommendation

1. Healthcare personnel must use gloves (*strong recommendation, high quality of evidence*) and gowns (*strong recommendation, moderate quality of evidence*) on entry to a room of a patient with CDI and while caring for patients with CDI.

XV. When should isolation be implemented?

Recommendation

1. Patients with suspected CDI should be placed on preemptive contact precautions pending the *C. difficile* test results if test results cannot be obtained on the same day (*strong recommendation, moderate quality of evidence*).

XVI. How long should isolation be continued?

Recommendations

1. Continue contact precautions for at least 48 hours after diarrhea has resolved (*weak recommendation, low quality of evidence*).
2. Prolong contact precautions until discharge if CDI rates remain high despite implementation of standard infection control measures against CDI (*weak recommendation, low quality of evidence*).

XVII. What is the recommended hand hygiene method (assuming glove use) when caring for patients in isolation for CDI?

Recommendations

1. In routine or endemic settings, perform hand hygiene before and after contact of a patient with CDI and after removing gloves with either soap and water or an alcohol-based hand hygiene product (*strong recommendation, moderate quality of evidence*).
2. In CDI outbreaks or hyperendemic (sustained high rates) settings, perform hand hygiene with soap and water preferentially instead of alcohol-based hand hygiene products before and after caring for a patient with CDI given the increased efficacy of spore removal with soap and water (*weak recommendation, low quality of evidence*).

- Handwashing with soap and water is preferred if there is direct contact with feces or an area where fecal contamination is likely (eg, the perineal region) (*good practice recommendation*).

XVIII. Should patient bathing interventions be implemented to prevent CDI?

Recommendation

- Encourage patients to wash hands and shower to reduce the burden of spores on the skin (*good practice recommendation*).

XIX. Should noncritical devices or equipment be dedicated to or specially cleaned after being used on the isolated patient with CDI?

Recommendation

- Use disposable patient equipment when possible and ensure that reusable equipment is thoroughly cleaned and disinfected, preferentially with a sporicidal disinfectant that is equipment compatible (*strong recommendation, moderate quality of evidence*).

XX. What is the role of manual, terminal disinfection using a *C. difficile* sporicidal agent for patients in isolation for CDI?

Recommendation

- Terminal room cleaning with a sporicidal agent should be considered in conjunction with other measures to prevent CDI during endemic high rates or outbreaks, or if there is evidence of repeated cases of CDI in the same room (*weak recommendation, low quality of evidence*).

XXI. Should cleaning adequacy be evaluated?

Recommendation

- Incorporate measures of cleaning effectiveness to ensure quality of environmental cleaning (*good practice recommendation*).

XXII. What is the role of automated terminal disinfection using a method that is sporicidal against *C. difficile*?

Recommendation

- There are limited data at this time to recommend use of automated, terminal disinfection using a sporicidal method for CDI prevention (*no recommendation*).

XXIII. What is the role of daily sporicidal disinfection?

Recommendation

- Daily cleaning with a sporicidal agent should be considered in conjunction with other measures to prevent CDI during outbreaks or in hyperendemic (sustained high rates) settings, or if there is evidence of repeated cases of CDI in the same room (*weak recommendation, low quality of evidence*).

XXIV. Should asymptomatic carriers of *C. difficile* be identified and isolated if positive?

Recommendation

- There are insufficient data to recommend screening for asymptomatic carriage and placing asymptomatic carriers on contact precautions (*no recommendation*).

XXV. What is the role of antibiotic stewardship in controlling CDI rates?

Recommendations

- Minimize the frequency and duration of high-risk antibiotic therapy and the number of antibiotic agents prescribed, to reduce CDI risk (*strong recommendation, moderate quality of evidence*).
- Implement an antibiotic stewardship program (*good practice recommendation*).
- Antibiotics to be targeted should be based on the local epidemiology and the *C. difficile* strains present. Restriction of fluoroquinolones, clindamycin, and cephalosporins (except for surgical antibiotic prophylaxis) should be considered (*strong recommendation, moderate quality of evidence*).

XXVI. What is the role of proton pump inhibitor restriction in controlling CDI rates?

Recommendation

- Although there is an epidemiologic association between proton pump inhibitor (PPI) use and CDI, and unnecessary PPIs should always be discontinued, there is insufficient evidence for discontinuation of PPIs as a measure for preventing CDI (*no recommendation*).

XXVII. What is the role of probiotics in primary prevention of CDI?

Recommendation

- There are insufficient data at this time to recommend administration of probiotics for primary prevention of CDI outside of clinical trials (*no recommendation*).

TREATMENT

XXVIII. What are important ancillary treatment strategies for CDI?

Recommendations

1. Discontinue therapy with the inciting antibiotic agent(s) as soon as possible, as this may influence the risk of CDI recurrence (*strong recommendation, moderate quality of evidence*).
2. Antibiotic therapy for CDI should be started empirically for situations where a substantial delay in laboratory confirmation is expected, or for fulminant CDI (described in section XXX) (*weak recommendation, low quality of evidence*).

XXIX. What are the best treatments of an initial CDI episode to ensure resolution of symptoms and sustained resolution 1 month after treatment?

Recommendations

1. Either vancomycin or fidaxomicin is recommended over metronidazole for an initial episode of CDI. The dosage is vancomycin 125 mg orally 4 times per day or fidaxomicin

200 mg twice daily for 10 days (*strong recommendation, high quality of evidence*) (Table 1).

2. In settings where access to vancomycin or fidaxomicin is limited, we suggest using metronidazole for an initial episode of nonsevere CDI only (*weak recommendation, high quality of evidence*). The suggested dosage is metronidazole 500 mg orally 3 times per day for 10 days. Avoid repeated or prolonged courses due to risk of cumulative and potentially irreversible neurotoxicity (*strong recommendation, moderate quality of evidence*). (See Treatment section for definition of CDI severity.)

XXX. What are the best treatments of fulminant CDI?

Recommendations

1. For fulminant CDI*, vancomycin administered orally is the regimen of choice (*strong recommendation, moderate quality of evidence*). If ileus is present, vancomycin can also be administered per rectum (*weak recommendation, low quality of evidence*). The vancomycin dosage is 500 mg orally 4 times per day and 500 mg in approximately 100 mL normal saline per rectum every 6 hours as a retention enema. Intravenously administered metronidazole should be administered together

Table 1. Recommendations for the Treatment of *Clostridium difficile* Infection in Adults

| Clinical Definition | Supportive Clinical Data | Recommended Treatment ^a | Strength of Recommendation/ Quality of Evidence |
|--------------------------------------|--|--|--|
| Initial episode, non-severe | Leukocytosis with a white blood cell count of ≤ 15000 cells/mL and a serum creatinine level < 1.5 mg/dL | <ul style="list-style-type: none"> • VAN 125 mg given 4 times daily for 10 days, OR • FDX 200 mg given twice daily for 10 days • Alternate if above agents are unavailable: metronidazole, 500 mg 3 times per day by mouth for 10 days | Strong/High Strong/High Weak/High |
| Initial episode, severe ^b | Leukocytosis with a white blood cell count of ≥ 15000 cells/mL or a serum creatinine level > 1.5 mg/dL | <ul style="list-style-type: none"> • VAN, 125 mg 4 times per day by mouth for 10 days, OR • FDX 200 mg given twice daily for 10 days | Strong/High Strong/High |
| Initial episode, fulminant | Hypotension or shock, ileus, megacolon | <ul style="list-style-type: none"> • VAN, 500 mg 4 times per day by mouth or by nasogastric tube. If ileus, consider adding rectal instillation of VAN. Intravenously administered metronidazole (500 mg every 8 hours) should be administered together with oral or rectal VAN, particularly if ileus is present. | Strong/Moderate (oral VAN); Weak/Low (rectal VAN); Strong/Moderate (intravenous metronidazole) |
| First recurrence | ... | <ul style="list-style-type: none"> • VAN 125 mg given 4 times daily for 10 days if metronidazole was used for the initial episode, OR • Use a prolonged tapered and pulsed VAN regimen if a standard regimen was used for the initial episode (eg, 125 mg 4 times per day for 10–14 days, 2 times per day for a week, once per day for a week, and then every 2 or 3 days for 2–8 weeks), OR • FDX 200 mg given twice daily for 10 days if VAN was used for the initial episode | Weak/Low Weak/Low Weak/Moderate |
| Second or subsequent recurrence | ... | <ul style="list-style-type: none"> • VAN in a tapered and pulsed regimen, OR • VAN, 125 mg 4 times per day by mouth for 10 days followed by rifaximin 400 mg 3 times daily for 20 days, OR • FDX 200 mg given twice daily for 10 days, OR • Fecal microbiota transplantation^c | Weak/Low Weak/Low Weak/Low Strong/Moderate |

Abbreviations: FDX, fidaxomicin; VAN, vancomycin.

^aAll randomized trials have compared 10-day treatment courses, but some patients (particularly those treated with metronidazole) may have delayed response to treatment and clinicians should consider extending treatment duration to 14 days in those circumstances.

^bThe criteria proposed for defining severe or fulminant *Clostridium difficile* infection (CDI) are based on expert opinion. These may need to be reviewed in the future upon publication of prospectively validated severity scores for patients with CDI.

^cThe opinion of the panel is that appropriate antibiotic treatments for at least 2 recurrences (ie, 3 CDI episodes) should be tried prior to offering fecal microbiota transplantation.

with oral or rectal vancomycin, particularly if ileus is present (*strong recommendation, moderate quality of evidence*). The metronidazole dosage is 500 mg intravenously every 8 hours.*

*Fulminant CDI, previously referred to as severe, complicated CDI, may be characterized by hypotension or shock, ileus, or megacolon.

- If surgical management is necessary for severely ill patients, perform subtotal colectomy with preservation of the rectum (*strong recommendation, moderate quality of evidence*). Diverting loop ileostomy with colonic lavage followed by antegrade vancomycin flushes is an alternative approach that may lead to improved outcomes (*weak recommendation, low quality of evidence*).

XXXI. What are the best treatments for recurrent CDI?

Recommendations

- Treat a first recurrence of CDI with oral vancomycin as a tapered and pulsed regimen rather than a second standard 10-day course of vancomycin (*weak recommendation, low quality of evidence*), OR
- Treat a first recurrence of CDI with a 10-day course of fidaxomicin rather than a standard 10-day course of vancomycin (*weak recommendation, moderate quality of evidence*), OR
- Treat a first recurrence of CDI with a standard 10-day course of vancomycin rather than a second course of metronidazole if metronidazole was used for the primary episode (*weak recommendation, low quality of evidence*).

- Antibiotic treatment options for patients with >1 recurrence of CDI include oral vancomycin therapy using a tapered and pulsed regimen (*weak recommendation, low quality of evidence*), a standard course of oral vancomycin followed by rifaximin (*weak recommendation, low quality of evidence*), or fidaxomicin (*weak recommendation, low quality of evidence*).

- Fecal microbiota transplantation is recommended for patients with multiple recurrences of CDI who have failed appropriate antibiotic treatments (*strong recommendation, moderate quality of evidence*).
- There are insufficient data at this time to recommend extending the length of anti-*C. difficile* treatment beyond the recommended treatment course or restarting an anti-*C. difficile* agent empirically for patients who require continued antibiotic therapy directed against the underlying infection or who require retreatment with antibiotics shortly after completion of CDI treatment, respectively (*no recommendation*).

TREATMENT (PEDIATRIC CONSIDERATIONS)

XXXII. What is the best treatment of an initial episode or first recurrence of nonsevere CDI in children?

Recommendation

- Either metronidazole or vancomycin is recommended for the treatment of children with an initial episode or first recurrence of nonsevere CDI (see Pediatric treatment section for dosing) (*weak recommendation, low quality of evidence*) (Table 2).

Table 2. Recommendations for the Treatment of *Clostridium difficile* Infection in Children

| Clinical Definition | Recommended Treatment | Pediatric Dose | Maximum Dose | Strength of Recommendation/ Quality of Evidence |
|---------------------------------------|--|---|--|--|
| Initial episode, non-severe | <ul style="list-style-type: none"> Metronidazole × 10 days (PO), OR Vancomycin × 10 days (PO) | <ul style="list-style-type: none"> 7.5 mg/kg/dose tid or qid 10 mg/kg/dose qid | <ul style="list-style-type: none"> 500 mg tid or qid 125 mg qid | Weak/Low Weak/Low |
| Initial episode, severe/ fulminant | <ul style="list-style-type: none"> Vancomycin × 10 days (PO or PR) with or without metronidazole × 10 days (IV)^a | <ul style="list-style-type: none"> 10 mg/kg/dose qid 10 mg/kg/dose tid | <ul style="list-style-type: none"> 500 mg qid 500 mg tid | Strong/Moderate Weak/Low |
| First recurrence, non-severe | <ul style="list-style-type: none"> Metronidazole × 10 days (PO), OR Vancomycin × 10 days (PO) | <ul style="list-style-type: none"> 7.5 mg/kg/dose tid or qid 10 mg/kg/dose qid | <ul style="list-style-type: none"> 500 mg tid or qid 125 mg qid | Weak/Low |
| Second or subsequent recurrence | <ul style="list-style-type: none"> Vancomycin in a tapered and pulsed regimen^b, OR Vancomycin for 10 days followed by rifaximin^c for 20 days, OR Fecal microbiota transplantation | <ul style="list-style-type: none"> 10 mg/kg/dose qid Vancomycin: 10 mg/kg/dose qid; rifaximin: no pediatric dosing ... | <ul style="list-style-type: none"> 125 mg qid Vancomycin: 500 mg qid; rifaximin: 400 mg tid ... | Weak/Low Weak/Low Weak/Very low |

Abbreviations: IV, intravenous; PO, oral; PR, rectal; qid, 4 times daily; tid, 3 times daily.

^aIn cases of severe or fulminant *Clostridium difficile* infection associated with critical illness, consider addition of intravenous metronidazole to oral vancomycin.

^bTapered and pulsed regimen: vancomycin 10 mg/kg with max of 125 mg 4 times per day for 10–14 days, then 10 mg/kg with max of 125 mg 2 times per day for a week, then 10 mg/kg with max of 125 mg once per day for a week, and then 10 mg/kg with max of 125 mg every 2 or 3 days for 2–8 weeks.

^cNo pediatric dosing for rifaximin; not approved by the US Food and Drug Administration for use in children <12 years of age.

XXXIII. What is the best treatment of an initial episode of severe CDI in children?

Recommendation

1. For children with an initial episode of severe CDI, oral vancomycin is recommended over metronidazole (*strong recommendation, moderate quality of evidence*).

XXXIV. What are the best treatments for a second or greater episode of recurrent CDI in children?

Recommendation

1. For children with a second or greater episode of recurrent CDI, oral vancomycin is recommended over metronidazole (*weak recommendation, low quality of evidence*).

XXXV. Is there a role for fecal microbiota transplantation in children with recurrent CDI?

Recommendation

1. Consider fecal microbiota transplantation for pediatric patients with multiple recurrences of CDI following standard antibiotic treatments (*weak recommendation, very low quality of evidence*).

INTRODUCTION

Since publication of the 2010 Infectious Diseases Society of America (IDSA)/Society for Healthcare Epidemiology of America (SHEA) *Clostridium difficile* infection (CDI) clinical practice guideline, there has been continued expanding interest in the epidemiology, prevention, diagnosis, and treatment of CDI. This reflects the ongoing magnitude of these infections impacting all aspects of healthcare delivery and reaching out into the community. Also new since the previous guidelines, quality of evidence and strength of recommendations was evaluated using GRADE methodology [1–4]. While there is evidence that CDI rates have declined remarkably in England and other parts of Europe since their peak before 2010, rates have plateaued at historic highs in the United States since about 2010 [5]. Recent estimates suggest the US burden of CDI is close to 500 000 infections annually, although the exact magnitude of burden is highly dependent upon the type of diagnostic tests used [6]. Depending upon the degree and method of attribution, CDI is associated with 15 000–30 000 US deaths [6, 7] and excess acute care inpatient costs alone exceed \$4.8 billion [5]. Due to this US burden of CDI, national efforts to control and prevent CDI have been put in place including incentives for public reporting of hospital rates [8] and hospital “pay for performance” [9]. It is in this context of CDI remaining a major public health problem, undermining both patient safety and the efficiency and value of healthcare delivery, that the 2010 recommendations are now

revised and updated. There are no updates in the clinical definition of CDI or the clinical manifestations of CDI. The reader is referred to the 2010 guideline for the definition, background information, and clinical manifestations of CDI.

Since completion of this guideline, a new therapeutic agent and a molecular diagnostic test platform have become available for CDI. Bezlotoxumab, a monoclonal antibody directed against toxin B produced by *C. difficile*, has been approved as adjunctive therapy for patients who are receiving antibiotic treatment for CDI and who are at high risk for recurrence [10]. Multiplex polymerase chain reaction (PCR) platforms that detect *C. difficile* as part of a panel of >20 different enteric pathogens have also become available [11]. These most recent innovations and other innovations that may become available in the near future will be covered in subsequent guideline updates.

METHODOLOGY

Practice Guidelines

“Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options” [12].

Panel Composition

A panel of 14 multidisciplinary experts in the epidemiology, diagnosis, infection control, and clinical management of adult and pediatric patients with CDI was convened to develop these practice guidelines. A systematic evidence-based approach was adopted for the guideline questions and population, intervention, comparator, outcome (PICO) formulations, the selection of patient-important outcomes, as well as the literature searches and screening of the uncovered citations and articles. The rating of the quality of evidence and strength of recommendation was supported by a Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodologist. In addition to members of both IDSA and SHEA, representatives from the American Society for Health-Systems Pharmacists (ASHP), the Society of Infectious Diseases Pharmacists (SIDP), and the Pediatric Infectious Diseases Society (PIDS) were included.

Literature Review and Analysis

For this 2017 guideline update, search strategies, in collaboration with the guideline panel members, were developed and built by independent health sciences librarians from National Jewish Health (Denver, Colorado). Each strategy incorporated medical subject headings and text words for “*Clostridium difficile*,” limited to human studies or nonindexed citations. In addition, the strategies focused on articles published in English or in any language with available English abstracts. The Ovid platform was used to search 5 electronic evidence databases: Medline, Embase, Cochrane Central Registry of Controlled

Trials, Health Technology Assessment, and the Database of Abstracts of Reviews of Effects.

To supplement the electronic search, reviewers also hand-searched relevant journals, conference proceedings, reference lists from manuscripts retained from electronic searches, and regulatory agency web sites for relevant articles. Literature searches were originally implemented on 4 December 2012, updated on 3 March 2014, and further extended to 31 December 2016. The 2010 guideline used a search cutoff of 2009 and thus for this guideline, the literature review included a defined search period of 2009–2016. Separate, nondiscrete evidence libraries were created for adults and pediatrics. The result of the searching was 14 479 citations being eligible at title and abstract phase of screening for the adult literature. As the 2010 guideline did not address pediatrics as part of any searching, a decision was made to reexamine the evidence landscape for pediatric-related studies that could inform the guideline. For this, the period of 1977–2016 was searched, yielding 3572 citations eligible at title and abstract phase. Those retained at the title and abstract phase of screening were then examined at the full-text phase.

Process Overview

To evaluate the initial search evidence for eligibility, the panel followed a process consistent with other IDSA guidelines. The process for evaluating the evidence was based on the IDSA Handbook on Clinical Practice Guideline Development and involved a systematic weighting of the quality of the evidence and the grade of recommendation using the GRADE system (Figure 1) [1–4].

Each author was asked to review the literature (based on screening examination of titles and abstracts and manuscript full-text examination, as well as abstraction of relevant variables/data from eligible studies/reports), evaluate the evidence, and determine the strength of the recommendations along with an evidence summary supporting each recommendation. The panel reviewed all recommendations, their strength, and quality of evidence. For recommendations in the category of good practice statements that should not be graded, we followed published principles by the GRADE working group on how to identify such recommendations and use appropriate wording choices [13]. Accordingly, a formal GRADE rating was not pursued for those statements as these statements would make it clear that they would do greater good than harm or greater harm than good, and thus a study would not be warranted to address such a question. Discrepancies were discussed and resolved, and all panel members are in agreement with the final recommendations.

Consensus Development Based on Evidence

The panel met face-to-face on 3 occasions and conducted numerous monthly subgroup and full panel conference calls to complete the work of the guideline. The panel as a whole

reviewed all individual sections. The guideline was reviewed and approved by the IDSA Standards and Practice Guidelines Committee (SPGC) and SHEA Guidelines Committee as well as both organizations' respective Board of Directors (BOD). The guideline was endorsed by ASHP, SIDP, and PIDS.

Guidelines and Conflicts of Interest

All members of the expert panel complied with the IDSA policy on conflicts of interest, which requires disclosure of any financial, intellectual, or other interest that might be construed as constituting an actual, potential, or apparent conflict. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic [14]. Evaluation of such relationships as potential conflicts of interest (COI) is determined by a review process that includes assessment by the SPGC chair, the SPGC liaison to the development panel, and the BOD liaison to the SPGC, and, if necessary, the COI Task Force of the Board. This assessment of disclosed relationships for possible COI is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). See Acknowledgments section for disclosures reported to IDSA.

Revision Dates

At annual intervals and more frequently if needed, IDSA and SHEA will determine the need for revisions to the guideline on the basis of an examination of the current literature and the likelihood that any new data will have an impact on the recommendations. If necessary, the entire expert panel will be reconvened to discuss potential changes. Any revision to the guideline will be submitted for review and approval to the appropriate Committees and Boards of IDSA and SHEA.

GUIDELINE RECOMMENDATIONS FOR *CLOSTRIDIUM DIFFICILE* INFECTION

EPIDEMIOLOGY

I. How are CDI cases best defined?

Recommendation

1. To increase comparability between clinical settings, use available standardized case definitions for surveillance of (1) healthcare facility-onset (HO) CDI; (2) community-onset, healthcare facility-associated (CO-HCFA) CDI; and (3) community-associated (CA) CDI (*good practice recommendation*).

II. What is the minimal surveillance recommendation for institutions with limited resources?

Recommendation

1. At a minimum, conduct surveillance for HO-CDI in all inpatient healthcare facilities to detect elevated rates or outbreaks of CDI within the facility (*weak recommendation, low quality of evidence*).

III. What is the best way to express CDI incidence and rates?

Recommendation

1. Express the rate of HO-CDI as the number of cases per 10 000 patient-days. Express the CO-HCFA prevalence rate as the number of cases per 1000 patient admissions (*good practice recommendation*).

IV. How should CDI surveillance be approached in settings of high endemic rates or outbreaks?

Recommendation

1. Stratify data by patient location to target control measures when CDI incidence is above national and/or facility reduction goals or if an outbreak is noted (*weak recommendation, low quality of evidence*).

SUMMARY OF THE EVIDENCE

Surveillance

A recommended case definition for surveillance requires (1) the presence of diarrhea or evidence of megacolon or severe ileus and (2) either a positive laboratory diagnostic test result or evidence of pseudomembranes demonstrated by endoscopy or histopathology. An incident case is defined as a new primary episode of symptom onset (ie, no episode of symptom onset with positive result within the previous 8 weeks) and positive assay result (eg, toxin enzyme immunoassay [EIA] or nucleic acid amplification test [NAAT]). A recurrent case is defined as an episode of symptom onset and positive assay result following an episode with positive assay result in the previous 2–8 weeks. The minimum surveillance that should be performed by all healthcare facilities is tracking of healthcare facility-onset (HO) cases, which will allow for detection of elevated rates or an outbreak within the facility [15]. HO-CDI cases are defined by the Centers for Disease Control and Prevention (CDC)'s National Healthcare Safety Network (NHSN) as Laboratory-Identified (LabID) Events collected >3 days after admission to the facility (ie, on or after day 4) [16]. Facilities may also monitor cases of CDI occurring within 28 days after discharge from a healthcare facility, which are considered community-onset, healthcare facility-associated (CO-HCFA) cases (ie, postdischarge cases).

Because the risk of CDI increases with the length of stay, the most appropriate denominator for HO-CDI rates is the number of patient-days. If a facility notes an increase in the incidence of CDI from the baseline rate, or if the incidence is higher than in comparable institutions or above national and/or facility reduction goals, surveillance data should be stratified by hospital location or clinical service to identify particular patient populations where infection prevention measures may be targeted. In addition, measures should be considered for tracking severe outcomes, such as colectomy, intensive care unit (ICU) admission, or death, attributable to CDI.

In the United States, CDI surveillance in healthcare facilities is conducted via the CDC's NHSN Multidrug-Resistant Organism and *C. difficile* Infection Module LabID Event Reporting [16]. To allow for risk-adjusted reporting of healthcare-associated infections (HAIs), CDC calculates the standardized infection ratio (SIR) by dividing the number of observed events by the number of predicted events. The number of predicted events is calculated using LabID probabilities estimated from models constructed from NHSN data during a baseline time period, which represents a standard population [16]. These have been recently updated using a 2015 baseline period with specific models developed for each of 4 facility types: acute care hospitals, long-term acute care hospitals, critical access hospitals (rural hospitals with ≤25 acute care inpatient beds), and inpatient rehabilitation facilities [17]. Use of more sensitive tests (eg, NAATs) for *C. difficile* have been demonstrated to result in substantial increases in reported CDI incidence rates compared with those derived from toxin detection by enzyme immunoassay [18, 19]. Consistent with this, the impact of test type on facilities' reported rates is an independent predictor in each of the aforementioned NHSN risk adjustment models except that for critical access hospitals [17]. The prevalence of CO cases not associated with the facility (ie, defined in NHSN as present-on-admission with no discharge from the same facility within the previous 4 weeks) is also associated with HO-CDI [20, 21]. This likely reflects colonization pressure in the admitted patient population, and is an independent predictor in each of the NHSN risk adjustment models except for inpatient rehabilitation facilities [17].

Despite these attempts to risk-adjust based upon data that hospitals are already reporting to NHSN, there are limitations. For example, adjustment by test type accounts for only the pooled mean impact on rates resulting from differences in sensitivity between major test categories (eg, NAAT, toxin EIA) and does not account for differences in sensitivity between individual test manufacturers, nor potential interaction of *C. difficile* strain types on relative test sensitivity [22, 23]. Similarly, there are inherent limitations in all surveillance adjusting for the disease risk in the surveyed population. For example, Thompson et al demonstrated how the Medicare

Case Mix Index, a summary metric calculated at the hospital level and reflecting clinical complexity and resource consumption of patients within a hospital, could further explain variation across hospital CDI rates over and above the existing model [24]. However, any potential benefit to hospital performance improvement from additional risk adjustment strategies must be balanced by any increased data-reporting burden or impact on timeliness.

Prevalence, Incidence, Morbidity, and Mortality

Clostridium difficile is the most commonly recognized cause of infectious diarrhea in healthcare settings. Among 711 acute care hospitals in 28 states conducting facility-wide inpatient LabID-CDI event reporting to NHSN in 2010, the pooled rate of HO-CDI was 7.4 (median, 5.4) per 10 000 patient-days [25]. As these data were reported prior to development of the SIR, they were unadjusted; at that time, 35% of NHSN hospitals reported using NAATs. Based on data from the CDC's Emerging Infections Program (EIP) [26] population-based surveillance system in 2011, the estimated number of incident CDI cases in the United States was 453 000 (95% confidence interval [CI], 397 100–508 500), with an incidence of 147.2 (95% CI, 129.1–165.3) cases/100 000 persons [6]. The incidence was highest among those aged ≥ 65 years (627.7) and was greater among females and whites. Of the total estimated 453 000 incident cases, 293 300 (64.7%) were considered to be healthcare-associated, of which 37% were HO, 36% had their onset in long-term care facilities (LTCFs), and 28% were CO healthcare-associated (ie, specimen collected in an outpatient setting or ≤ 3 calendar days after hospital admission and documented overnight stay in a healthcare facility in the prior 12 weeks). Of the estimated 159 700 community-associated CDI cases (ie, no documented overnight stay in a healthcare facility in the prior 12 weeks), 82% were associated with outpatient healthcare exposure; therefore, the overwhelming majority (94%) of all cases of CDI had a recent healthcare exposure [6, 27].

A multistate prevalence survey of HAIs conducted by EIP in 2011 found that *C. difficile* was the most common causative pathogen, accounting for 61 of 504 (12.1%) HAIs identified in 183 hospitals [28]. The increasing burden of CDI was also noted in a network of community hospitals in the southeastern United States, where *C. difficile* surpassed methicillin-resistant *Staphylococcus aureus* (MRSA) as the most common cause of HAIs [29].

Recent hospital discharge data [30] indicate that the total number of hospital discharges with a diagnosis of CDI in the United States plateaued at historic highs between 2011 and 2013. During this apparent plateau in hospital discharges, there has been an 8% decline in the risk-adjusted HO-CDI SIR of NHSN [31].

As most LTCFs do not report CDI data, limited data are available about the burden of CDI in these settings. LTCF residents

are often elderly, have numerous comorbid conditions, and have been exposed to antibiotics, which are important risk factors for *C. difficile* colonization and infection [32, 33]. Data from the CDC EIP and other sources suggest that the burden is high; $>20\%$ of all CDIs identified in 2011 had onset in LTCFs [6]. Furthermore, in 2012 there were an estimated 112 800 cases of CDI with onset in LTCFs [34]; 57% of these patients were discharged from a hospital within 1 month. Conversely, 20% of HO-CDI cases were found to occur in patients who had been LTCF residents any time in the previous 12 weeks [5]. Using a multilevel longitudinal nested case-control study of Veterans Affairs LTCFs, all but 25% of the variability in LTCF rates could be explained by 2 factors: the importation of active or convalescing cases with hospital-onset CDI in the previous 8 weeks, and LTCF antibiotic use as measured by antibiotic days per 10 000 resident-days [35].

Severity of CDI has been reported to have increased coincident with the increasing incidence during the outbreaks and emergence of the PCR ribotype 027 epidemic strain (also known as the North American pulsed field type 1 [NAP1] or restriction endonuclease analysis pattern "BI") in the 2000s [36, 37]. Severity of CDI has been variably defined based on laboratory data, physical examination findings, ICU stay, colectomy, and/or mortality. Reported colectomy rates in hospitalized patients with CDI during endemic periods range from 0.3% to 1.3%, whereas during epidemic periods, colectomy rates range from 1.8% to 6.2% [38]. Other indicators of CDI morbidity include recurrent CDI, readmissions to the hospital, and discharge to LTCFs. Overall, 0.8% of patients develop candidemia in the 120 days after CDI and both more severe CDI and treatment with the combination of vancomycin and metronidazole are associated with increased candidemia risk [39]. After a first diagnosis of CDI, 10%–30% of patients develop at least 1 recurrent CDI episode, and the risk of recurrence increases with each successive recurrence [40, 41]. A national estimate of first CDI recurrences in 2011 was 83 000 (95% CI, 57 100–108 900) [6]. Prior to 2000, the attributable mortality of CDI was low, with death as a direct or indirect result of infection occurring in $<2\%$ of cases [42–45]. Since 2000, CDI-attributable mortality has been reported to be higher, both during endemic periods, where mortality ranges from 4.5% to 5.7%, and during epidemic periods, where mortality ranges from 6.9% to 16.7% [38]. However, a recent study in 6 Canadian hospitals evaluating CDI cases in 2006–2007 found an attributable mortality of 1.7%, similar to historic data [46]. Based on 2011 EIP data, the estimated number of deaths within 30 days of the initial diagnosis of CDI in the United States was 29 300 (95% CI, 16 500 to 42 100) [6]. After controlling for demographics, underlying severity of illness, and medications during an index hospitalization, recurrent CDI is associated with a 33% increased risk of mortality at 180 days relative to patients who do not suffer a recurrence [47].

The attributable excess costs of CDI suggest a substantial burden on the healthcare system. Studies adjusting for cost by propensity score matching have found that the CDI-attributable cost for acute care hospitals is \$3427–\$9960 per episode (adjusted for 2012 US dollars) [38]. Extrapolating these estimates to the nation using 2012 Healthcare Cost Utilization Project data, the total annual US acute care cost attributable to CDI is estimated to be \$1.2–\$5.9 billion [38].

Strain Types and Changing Epidemiology

The emergence of the virulent, epidemic ribotype 027 strain was associated with increased incidence, severity, and mortality during the mid-2000s and resulted in outbreaks across North America [36, 48, 49], England [50, 51], parts of continental Europe [52, 53], and Asia [54]. The recent isolates of the 027 strain are more highly resistant to fluoroquinolones compared to historic strains of the same type [48]. This, coupled with increasing use of the fluoroquinolones worldwide likely promoted dissemination of a once uncommon strain [48].

Consistent with the presence of one or more molecular markers responsible for increased virulence, patients infected with the 027 epidemic strain in Montreal were shown to have more-severe disease than patients infected with other strains [36]. In a later Canadian multicenter study of hospitalized patients, the 027 strain was predominant among patients with CDI, whereas other strains were more common among asymptotically colonized patients [46]. Similarly, in a sample of isolates and patient information collected from 10 CDC EIP sites between 2009 and 2011, ribotype 027 was the most prevalent strain (28.4%) and was associated with more severe disease, severe outcomes, and death than other strains, controlling for patient risk factors, healthcare exposure, and antibiotic use [55].

Since the emergence and spread of 027, recent data from Europe suggest that the prevalence of this strain is decreasing. England has seen a dramatic decrease in 027 prevalence since the establishment of a nationwide ribotyping network in 2007 [56]. Ribotype 027 decreased significantly between 2007 and 2010, dropping from 55% prevalence to 21%, coincident with significant decreases in reported CDI incidence and related mortality. The decrease in 027 prevalence was likely driven by significant reductions in fluoroquinolone use during this time period [56], although increase in awareness and improved infection control may also have impacted CDI incidence.

Continued molecular typing will enable detection of emerging *C. difficile* strains with novel virulence factors, risk factors, and antibiotic resistance patterns. For example, evidence of emergence of a virulent strain, ribotype 078, has been reported from the Netherlands [57]. The prevalence of ribotype 078 increased between 2005 and 2008 and was associated with similar severity compared to CDI cases due to ribotype 027, but was associated with a younger population and more CA CDI. There was also a high degree of genetic relatedness between 078

isolates found in humans and pigs, an association also noted in the United States [58].

CDI in the Community and Special Populations at Increased Risk

In the context of the changing epidemiology of CDI in hospitals in the mid-2000s, evidence suggested increasing incidence of CDI in the community, even in healthy people previously at low risk, including peripartum women [59–64]. The sources of and risk factors for CA CDI (ie, occurring in patients with no inpatient stay in the previous 12 weeks) are not well defined. An analysis of CA CDI cases identified during 2009–2011 in the CDC EIP surveillance found that the majority of cases (82%) had some kind of healthcare exposure in the 12 weeks prior to CDI diagnosis. A relatively large percentage (36%) of CA CDI cases did not report antibiotic exposure in the 12 weeks prior to infection, although medication exposures were self-reported and may have been subject to limitations in recall. Among patients without reported antibiotic exposure, 31% received proton pump inhibitors (PPIs) [27]. In another recent study, a predictive risk scoring system developed in one cohort in a capitated-payment healthcare system and validated in another cohort in the same system proved useful for differentiating CDI risk in patients following an outpatient healthcare visit [65]. Major components of the scoring system included age, recent inpatient stay, chronic conditions (eg, liver and kidney disease, inflammatory bowel disease [IBD], cancer), and antibiotics; the role of PPIs was not examined or otherwise not included.

Patients with IBD, especially ulcerative colitis, are at increased risk of not only primary CDI but also recurrent disease, as well as increased morbidity and mortality from CDI. The risk of CDI within 5 years of a diagnosis of ulcerative colitis may be >3% and worsens prognosis by increasing risk of colectomy, postoperative complications, and death [66]. Patients with IBD are 33% more likely to suffer recurrent CDI [67]. There is an increased colectomy risk from CDI occurrence in patients with IBD overall, especially patients with ulcerative colitis [68].

Other patient populations at increased risk include solid organ transplant recipients: With an overall prevalence of 7.4%, rates in this population are 5-fold greater than among general medicine patients, and cases are associated with remarkable increases in hospital days and costs [69, 70]. Risks are highest in multiple solid organ transplants, followed by lung, liver, intestine, kidney, and pancreas with an overall prevalence of severe disease of 5.3% and risk of recurrence approximately 20% [70]. Patients with chronic kidney disease and end-stage renal disease have an approximately 2- to 2.5-fold increased risk of CDI and recurrence, a 1.5-fold increased risk of severe disease, and similarly increased mortality [71, 72]. Finally, hematopoietic stem cell transplant patients have a rate of CDI that is approximately 9 times greater than that in hospitalized patients overall; within this population, rates are about twice as high in allogeneic (vs autologous) transplants, where CDI occurs in about 1

in 10 transplants [73]. Most of this risk is during the peritransplantation period (ie, first 100 days posttransplant).

Epidemiology of Colonization and Infection

Clostridium difficile transmission resulting in disease in the healthcare setting is most likely a result of person-to-person spread through the fecal–oral route or, alternatively, direct exposure to the contaminated environment. Studies have found that the prevalence of asymptomatic colonization with *C. difficile* is 3%–26% among adult inpatients in acute care hospitals [46, 74, 75] and is 5%–7% among elderly patients in LTCFs [33, 76]. In contrast, the prevalence of *C. difficile* in the stool among asymptomatic adults without recent healthcare facility exposure is <2% [77, 78]. A recent meta-analysis found that the pooled colonization rate upon hospital admission across 19 studies (mostly since 2005 and through 2014) was 8.1% with the main risk factor for such colonization being a previous hospitalization [79]. Notably, neither antibiotic use nor previous CDI was associated with colonization on hospital admission.

The period between initial colonization with *C. difficile* and the occurrence of CDI (ie, incubation period) was estimated in 3 earlier studies to be a median of 2–3 days [66, 68]. However, recent evidence suggests a longer incubation period, even >1 week; Curry et al, in a study of asymptomatic *C. difficile* carriers, found 7 of 100 patients with CDI that tested positive for highly related *C. difficile* isolates 8–28 days prior to infection diagnosis [75]. Other early studies suggested that persons who remain asymptomatically colonized with *C. difficile* over longer periods of time are at decreased, rather than increased, risk for development of CDI [74, 80–82]. In contrast, the aforementioned recent meta-analysis found that preceding colonization increased the risk of subsequent CDI 6-fold; however, neither the time course from first detection of colonization to symptom onset nor the impact of diagnostic methods on this risk were examined [79].

Thus it is likely that the daily risk of progression from colonization to infection is not static but decreases over time; if so, the protection afforded by more long-standing colonization may be mediated in part by the boosting of serum antibody levels against *C. difficile* toxins A and B [46, 80, 81]. It is also likely that as long as an individual is colonized by one strain they are protected from infection caused by another strain; there is evidence of protection from CDI in both humans and in animal models following colonization with nontoxigenic strains, suggesting competition for nutrients or access to the mucosal surface [82, 83].

Routes of Transmission

The hands of healthcare personnel, transiently contaminated with *C. difficile* spores [84], and environmental contamination [75, 85–88] are probably the main means by which the organism is spread within healthcare. Although occupying a room where a prior occupant had CDI is a significant risk factor for

CDI acquisition, this accounts for approximately 10% of CDI cases, indicating other vectors are more common [89]. There have also been outbreaks in which particular high-risk fomites, such as electronic rectal thermometers or inadequately cleaned commodes or bedpans, were shared between patients and were found to contribute to transmission [90].

The potential role of asymptomatically colonized patients in transmission has recently been highlighted. Using multilocus variable number of tandem repeats analysis, Curry et al found that 29% of CDI cases in a hospital were associated with asymptomatic carriers, compared to 30% that were associated with CDI patients [75]. Similarly, 2 studies of hospitalized patients in the United Kingdom found that only 25%–35% of CDI cases were genetically linked to previous CDI cases [91, 92], suggesting a role for other sources of transmission such as asymptomatic carriers and the environment. In the Curry et al study, environmental transmission may have occurred in 4 of 61 incident healthcare-associated CDI cases [75].

Two recent studies highlight how antibiotics may affect CDI risk in hospitalized patients through impacting the contagiousness of asymptomatically colonized patients. Through use of a multilevel model, ward-level antibiotic prescribing (ie, among both CDI and non-CDI patients, therefore including potential asymptomatic carriers) was found to be a risk factor for CDI that was independent of the risk from antibiotics and other factors in individual patients [93]. Meanwhile, the individual risk of symptomatic CDI was found to be higher in patients admitted to a room where a previous patient without CDI was administered antibiotics, suggesting induced shedding of *C. difficile* from asymptomatic carriers [94].

Shedding of *C. difficile* spores is particularly high among patients recently treated for CDI, even after resolution of diarrhea [84, 95], suggesting a population of asymptomatic carriers who might be more likely to transmit the organism. In one study, the frequency of skin contamination and environmental shedding remained high at the time of resolution of diarrhea (60% and 37%, respectively), decreased at the end of treatment, and increased again 1–4 weeks after treatment (58% and 50%, respectively) [95].

Risk Factors for Disease

Advanced age, potentially as a surrogate for severity of illness and comorbidities, is one of the most important risk factors for CDI [46, 96, 97], as is duration of hospitalization. The daily increase in the risk of *C. difficile* acquisition during hospitalization suggests that duration of hospitalization may be a proxy for the duration and degree of exposure to the organism, likelihood of exposure to antibiotics, and severity of underlying illness [46, 74, 98]. The most important modifiable risk factor for the development of CDI is exposure to antibiotic agents. Virtually every antibiotic has been associated with CDI through the years, but

certain classes—third-/fourth-generation cephalosporins [99], fluoroquinolones [36, 37, 100], carbapenems [99], and clindamycin [101, 102]—have been found to be high risk. Receipt of antibiotics increases the risk of CDI because it suppresses the normal bowel microbiota, thereby providing a “niche” for *C. difficile* to flourish [103]. The relative risk of therapy with a given antibiotic agent and its association with CDI depends on the local prevalence of strains that are highly resistant to that particular antibiotic agent [101].

The disruption of the intestinal microbiota by antibiotics is long-lasting, and risk of CDI increases both during therapy and in the 3-month period following cessation of therapy. The highest risk of CDI (7- to 10-fold increase) appears to be during and in the first month after antibiotic exposure [99]. Both longer exposure to antibiotics [100] and exposure to multiple antibiotics increase the risk for CDI [100]. Nonetheless, even very limited exposure, such as single-dose surgical antibiotic prophylaxis, increases a patient’s risk of *C. difficile* colonization and symptomatic disease [104]. However, as previously noted, asymptomatic colonization, at least as detected among patients commonly admitted to the hospital, may not be associated with prior antibiotics [79].

Cancer chemotherapy is another risk factor for CDI that is, at least in part, mediated by the antibiotic activity of several chemotherapeutic agents [105, 106] but could also be related to the immunosuppressive effects of neutropenia [107, 108]. Evidence suggests that *C. difficile* is an important pathogen causing bacterial diarrhea in US patients infected with human immunodeficiency virus, which suggests that these patients are at specific increased risk because of their underlying immunosuppression, exposure to antibiotics, exposure to healthcare settings, or some combination of those factors [109]. Other risk factors for CDI include gastrointestinal surgery [102] or manipulation of the gastrointestinal tract, including tube feeding [110]. Meta-analyses of risk factors for recurrence identified many of those described above for initial CDI including advanced age, antibiotics during follow-up, PPIs, and strain type, as well previous exposure to fluoroquinolones [111, 112]. Meanwhile, risk factors for complicated disease include older age, leukocytosis, renal failure and comorbidities, while risk factors for mortality from CDI alone include age, comorbidities, hypoalbuminemia, leukocytosis, acute renal failure, and infection with ribotype 027 [112]. Recent data confirm the role of humoral immunity, primarily directed against toxin B, at least for protecting against recurrent disease [113]. There may be an important role for vitamin D in protecting against CDI, with low levels being an independent risk factor among both general patients with community-associated disease, older patients, and those with underlying inflammatory bowel disease [114, 115].

Breaches in the protective effect of stomach acid or the antibiotic activity of acid-suppressing medications, such as histamine-2 blockers and PPIs, while a potential risk factor, remain

controversial. Although a number of studies have suggested an epidemiologic association between use of stomach acid-suppressing medications, primarily PPIs, and CDI [37, 60, 116–119], results of other well-controlled studies suggest this association is the result of confounding with the underlying severity of illness, non-CDI diarrhea, and duration of hospital stay [36, 120, 121].

In a retrospective study of 754 patients with healthcare-associated CDI, continuous use of PPIs was independently associated with a 50% increased risk for recurrence, whereas reexposure to antibiotics was associated with only a 30% increased risk [122]. Moreover, long-term use of PPIs has been shown to decrease lower gastrointestinal microbial diversity [123]. However, whether as a risk factor for primary or recurrent disease, the choice of control group in such epidemiologic studies is important. PPIs and histamine-2 blockers may be associated with CDI when comparing cases to nontested controls but not when comparing cases to tested-negative controls [120]. This reflects why understanding the role of these drugs in the pathogenesis of CDI remains elusive; PPIs induce diarrhea on their own, making it more likely patients are tested for CDI. More careful assessment of confounding factors, symptoms, and criteria for testing for recurrence, as is typical in a prospective clinical trial, may then explain why PPIs were not associated with recurrence in clinical trials of fidaxomicin [121].

EPIDEMIOLOGY (PEDIATRIC CONSIDERATIONS)

V. What is the recommended CDI surveillance strategy for pediatric institutions?

Recommendations

1. Use the same standardized case definitions (HO, CO-HCFA, CA) and rate expression (cases per 10 000 patient-days for HO, cases per 1000 patient admissions for CO-HCFA) in pediatric patients as for adults (*good practice recommendation*).
2. Conduct surveillance for HO-CDI for inpatient pediatric facilities but do not include cases <2 years of age (*weak recommendation, low quality of evidence*).
3. Consider surveillance for CA-CDI to detect trends in the community (*weak recommendation, low quality of evidence*).

Summary of the Evidence

Similar to the findings in adults, the incidence of CDI has risen in children since 2000 [124–129]. The majority of pediatric studies have evaluated the incidence of CDI-related hospitalizations among multicenter cohorts of hospitalized children [126–128]. More recently, a population-based study of children residing in Olmsted County, Minnesota, between 1991 and 2009 identified an increase in incidence of CDI among pediatric residents from 2.6 to 32.6 per 100 000 using standard surveillance definitions [125].

The incidence of CDI has increased overall, including increases in CDI among children in community and outpatient settings [124, 125, 130]. Using data from active population- and laboratory-based surveillance by the EIP, Wendt et al showed that 71% of pediatric CDI identified by positive *C. difficile* stool testing arose from the community [131]. These estimates are limited by reliance on laboratory surveillance methods, where differences in testing practices may undermine the accuracy of some longitudinal and interinstitutional comparisons of rates of CDI in children [132, 133]. Nonetheless, these data indicate an epidemiologic shift with increased disease in nonhospitalized children.

One important feature of the epidemiology of *C. difficile* in children is the presence of asymptomatic colonization with either toxigenic or nontoxigenic strains among many infants and young children, with the highest rates (which can exceed 40%) in infants <12 months of age [134–141]. Nontoxigenic strains are more common than toxigenic strains among colonized infants, but colonization is transient and different strains are found to colonize the same infant at different times [135, 139, 142–144]. Colonization is less frequent among breastfed as compared with bottle-fed infants [140, 145–147]. Some evidence implicates the hospital environment as a source of acquisition of colonizing strains [134, 135, 138, 143, 148–150].

Colonization rates decrease with increasing age [140, 147, 151, 152]. The prevalence of asymptomatic colonization with *C. difficile* is still elevated in the second year of life, although to a lesser degree than in infants [139, 153, 154]. Therefore, testing in this population should also be avoided unless other infectious and noninfectious causes of diarrhea have been excluded. Consistent with the epidemiology of CDI in infants and young children, the NHSN does not permit reporting of CDI from newborn nurseries and neonatal ICU locations. Additionally, public reporting of cases in children <2 years of age is strongly discouraged. By 2–3 years of age, approximately 1%–3% of children are asymptomatic carriers of *C. difficile* (a rate similar to that observed in healthy adults). While young children are unlikely to have *C. difficile* infection, asymptotically colonized infants and children may serve as a source of transmission of the organism to adults, leading to *C. difficile* infection among adult contacts [27, 139, 155, 156].

Many of the risk factors for *C. difficile* infection in children mirror those for adults, including recent antibiotic exposure, hospitalization, and underlying complex chronic conditions such as malignancy, solid organ transplant, and inflammatory bowel disease [126, 127, 157–160]. In children, the presence of a gastrostomy or jejunostomy tube has been found to be an additional independent risk factor [158]. Recent studies suggest that acid-suppressing medications may also be an independent risk factor for CDI in children, although the association has been more consistently observed in children who receive histamine-2 receptor antagonists than PPIs [161, 162].

Severe disease and complications due to CDI are less common in children [126, 158, 163] but have been described [164, 165]. Among hospitalized children who are otherwise similar in important demographic and clinical characteristics, CDI has been associated with worse outcomes, including prolonged hospital stay, increased total hospital costs, and higher mortality rates [127, 166].

DIAGNOSIS

VI. What is the preferred population for *C. difficile* testing, and should efforts be made to achieve this target?

Recommendation

1. Patients with unexplained and new-onset ≥ 3 unformed stools in 24 hours are the preferred target population for testing for CDI (*weak recommendation, very low quality of evidence*).

Summary of the Evidence

Determining the optimal number of episodes of diarrhea that justifies the need for CDI testing depends on the likelihood of infection (high vs low CDI rates), potential confounders (underlying diseases and/or medical or surgical interventions that increase the chance of iatrogenic diarrhea), risk factors for CDI, and the chosen testing methods (high vs low specificity/predictive value methods).

If a patient has diarrheal symptoms *not* clearly attributable to underlying conditions (IBD, and therapies such as enteral tube feeding, intensive cancer chemotherapy, or laxatives), then testing to determine if diarrhea is due to *C. difficile* is indicated. Alternatively, testing may be indicated if symptoms persist after stopping therapies to which diarrhea may be otherwise attributed (eg, laxatives). However, some of these conditions and interventions associated with diarrhea in their own right, such as IBD and enteral tube feeding, have been shown to have increased risk of CDI when compared with a matched cohort [110]. So, in practice it is difficult to exclude the possibility of CDI on clinical grounds alone in a patient with new-onset or worsened diarrhea.

The evidence base to optimize CDI testing is weak. Clinical criteria for the diagnosis of CDI have altered as awareness of CDI has increased. Notably, the number and frequency of diarrheal stools required to justify CDI testing have declined over the past 40 years. Tedesco et al defined diarrhea as >5 loose stools per day in 1974 [167]; Teasley et al as >6 loose stools over a period of 36 hours in 1983 [168]; Fekety et al as liquid stools or >4 bowel movements per day for at least 3 days in 1989 [169]; and Johnson et al as ≥ 3 loose or watery bowel movements in 24 hours in 2013 [170]. Using the latter definition of diarrhea, Dubberke et al and Peterson et al (also using additional clinical criteria) have examined the frequency of these symptoms in patients whose stool is submitted for CDI testing [171, 172]. Peterson et al that found 39% of patients did

not meet the minimal diarrhea definition and were dropped from further analysis [172].

Dubberke et al used a clinical definition of ≥ 3 diarrheal bowel movements (type 6 or 7 stool on the Bristol Stool Chart) [173] in the 24 hours preceding stool collection, or diarrhea plus patient-reported abdominal pain or cramping. They found that 36% of patients failed to meet the clinical definition but were retained in the study [171]. The authors caution that even in the presence of clinical diarrheal symptoms, there may be confounding clinical issues such as laxative use, which was found in 19% within the previous 48 hours [171].

Clinicians can improve laboratory test relevance by only testing patients likely to have *C. difficile* disease. This includes not routinely performing testing on stool from a patient who has received a laxative within the previous 48 hours. Laboratories can improve specificity by rejecting specimens that are not liquid or soft (ie, take the shape of the container). In addition, laboratories may wish to collaborate with available quality improvement teams such as infection prevention and control and antibiotic stewardship, to assess appropriateness of testing in the population from which samples are submitted. This may involve periodic chart review in a series of patients to assess for clinical risk factors, signs, and symptoms suggestive of CDI.

Laboratory Testing

Two diagnostic testing recommendations based on institutional and laboratory preagreed criteria for patient stool submission are prefaced by questions VII and VIII (Figure 2).

VII. What is the best-performing method (ie, in use positive and negative predictive value) for detecting patients at increased risk for clinically significant *C. difficile* infection in commonly submitted stool specimens?

Recommendation

1. Use a stool toxin test as part of a multistep algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no preagreed institutional criteria for patient stool submission (Figure 2) (*weak recommendation, low quality of evidence*).

Summary of the Evidence

There is a variety of available options for laboratory testing to support the diagnosis of CDI, and these are well described in several recent reviews [174, 175]. In brief, these methods detect either the organism or one or both of its major toxins (A and B) directly in stool. Table 3 lists these methods in decreasing order of analytical sensitivity. Toxigenic culture (TC) uses a prerduced selective agar, cycloserine-cefoxitin-fructose agar or a variant of it, followed by anaerobic incubation for several

days. Once there is growth, the organism is identified by several methods including matrix-assisted laser desorption/ionization–time of flight mass spectrometry, although the characteristic “horse barn odor” often heralds its presence. To enhance the recovery of the organism, a spore selection step, whether heat or alcohol shock, is applied to the stool prior to inoculating media. Once an organism is identified, a toxin test must be performed on the isolate to confirm its toxigenic potential. TC, although not standardized, has been one of the reference methods against which other methods are compared.

The other reference method is the cell cytotoxicity neutralization assay (CCNA), which detects toxin directly in stool. This assay begins with preparation of a stool filtrate, which is applied to a monolayer of an appropriate cell line, such as Vero cells, or human fibroblasts, among others. Following incubation, the cells are observed for cytopathic effect (CPE); duplicate testing is usually carried out simultaneously with neutralizing antibodies to *Clostridium sordellii* or *C. difficile* toxin, to ensure that the observed CPE is truly caused by *C. difficile* toxins and not by other substances in the stool. Incubation continues for up to 48 hours, but the majority of positives are detected after overnight incubation. This method is cumbersome, time-consuming, and lacks standardization, although if optimized, it is one of the most sensitive and specific methods available for *C. difficile* toxin detection. As laboratories abandoned their viral cell culture facilities in favor of antigen and molecular tests, CCNA became less popular. Enzyme immunoassays, initially for toxin A detection alone, and later both toxins, became available and replaced the above reference methods for routine clinical testing in the late 1980s and early 1990s. EIAs use monoclonal or polyclonal antibodies to detect *C. difficile* toxins and there are numerous commercial assays available. Performance is variable and their overall poor performance sparked development of other methods such as GDH immunoassays and molecular tests for toxin gene detection [174, 176, 177]. While toxin EIAs remain insensitive in the detection of toxigenic *C. difficile* when compared with these successive technologies, sensitivities vary among available toxin EIA tests. Results across both sponsored and nonsponsored studies should be considered to select a relatively more sensitive EIA for general use [174]. Also, there is some evidence that newer EIAs have improved sensitivity compared with those examined in older studies [178].

Glutamate dehydrogenase immunoassays detect the highly conserved metabolic enzyme (common antigen) present in high levels in all isolates of *C. difficile*. Since this antigen is present in both toxigenic and nontoxigenic strains, GDH immunoassays lack specificity and must be combined with another (usually toxin) test. GDH testing is the initial screening step in 2- and 3-step algorithms that combine it with a toxin test and/or a molecular test for toxin gene detection. The combination

Table 3. Summary of Available Tests for *Clostridium difficile* Infection, in Decreasing Order of Sensitivity

| Test | Sensitivity | Specificity | Substance Detected |
|--|-------------|------------------|---|
| Toxigenic culture | High | Low ^a | <i>Clostridium difficile</i> vegetative cells or spores |
| Nucleic acid amplification tests | High | Low/moderate | <i>C. difficile</i> nucleic acid (toxin genes) |
| Glutamate dehydrogenase | High | Low ^a | <i>C. difficile</i> common antigen |
| Cell culture cytotoxicity neutralization assay | High | High | Free toxins |
| Toxin A and B enzyme immunoassays | Low | Moderate | Free toxins |

^aMust be combined with a toxin test.

has allowed for rapid results and improved sensitivity compared with toxin EIA testing alone, and can be economical [174, 176, 177].

Although NAATs for *C. difficile* detection in stool began to appear in the literature in the early 1990s, the first US Food and Drug Administration (FDA)–cleared platform was not available in the United States until 2009 [174]. There are at least 12 available commercial platforms that detect a variety of gene targets including *tcdA*, *tcdB*, and 16S ribosomal RNA (rRNA). These assays are more sensitive for *C. difficile* detection than toxin EIAs (and possibly than GDH EIAs) but less sensitive than TC. However, the positive predictive value of NAATs for CDI is low to moderate depending upon disease prevalence and the limit of detection of the assay.

The optimum method for laboratory diagnosis of CDI remains elusive as patients may harbor toxigenic strains and not have clinical disease, an observation that was made in early studies soon after the discovery of *C. difficile* [78, 179]. In addition, diarrhea in hospitalized patients is common and *C. difficile* is the culprit in <30% and often in as little as 5%–10% of patients [179–181]. Consensus regarding the best laboratory testing method is lacking. Much of the literature on diagnostic testing comparing laboratory methods is limited by use of an inappropriate comparative standard (ie, standards other than clinical disease) or a reference method that has never been standardized (ie, CCNA or the toxigenic component of TC) [182]. Furthermore, use of an inappropriate comparative reference method is a recurring issue (eg, using TC to assess the accuracy of a toxin test when the correct comparator is CCNA). In addition, comparative methods are often performed without knowledge of the prevalence of true disease in the population based on clinical presentation. There are very few studies that incorporate clinical assessment into analyses of test performance. These are discussed below. Finally, much of the literature is derived from single centers and/or is underpowered to achieve definitive conclusions upon which to base recommendations; thus, current GRADE methodology is not well adapted to gauging the strength of a recommendation using the type of evidence currently available for diagnostic tests.

Given these various conundrums and the paucity of large prospective studies, the recommendations, while strong in some instances, are based upon a very low to low quality of evidence (Table 4).

In 2011, Dubberke and colleagues performed an observational study of 150 patients to assess the impact of clinical symptoms (>3 diarrheal bowel movements in the 24 hours preceding stool collection, or diarrhea plus patient-reported abdominal pain or cramping) on interpretation of diagnostic assays for CDI [171]. While the study is too small to draw definitive conclusions, it illustrates some important caveats about diagnostic evaluations. The authors evaluated 8 diagnostic assays including 2 toxin EIAs, a test for GDH, a commercial CCNA assay, and 3 NAATs [171]. TC was also performed for all specimens. Two reference standards were assessed, each with and without consideration of patient symptoms. The prevalence of true CDI based upon a gold standard of clinically significant diarrhea and a positive TC was 11% [171]. However, this rate was determined only for the first 100 samples, and given the use of a relatively nonspecific (TC) testing method, it is likely to be an overestimation of the true CDI rate. As expected, given the choice of reference method (TC), the toxin tests detected fewer positive samples. Conversely, the GDH and NAATs detected the most positive samples. Compared with this TC gold standard, the least sensitive assays were the CCNA (62.9% sensitive, 95% CI, 46.3%–76.8%) and one of the toxin A/B EIA tests (80.0% sensitive; 95% CI, 64.1%–90.0%) [171]. The most sensitive methods (all >90%) were the GDH assay, all NAATs, and one of the EIAs performed on frozen stools. While all assays had a negative predictive value of > 95%, the positive predictive values (PPVs) for the GDH and NAATs were <50%, suggesting that they were positive in many patients who did not meet the clinical criteria for diarrhea [171]. By contrast, the TechLab toxin EIA PPV (notably when testing freeze-thawed stools) was 59%. Other important observations from this study were that 19% of patients had received a laxative in the 48 hours prior to testing, and another 36% of patients who were tested did not have clinically significant diarrhea, indicating that improvements in validated criteria for deciding when to test patients are needed [171].

Kaltsas et al attempted to understand the clinical and epidemiological impact of transitioning from a 2-step algorithm, which involved screening with GDH followed by a CCNA, to NAAT for the diagnosis of CDI in a major cancer hospital [183]. Test performance for 128 samples was assessed in the context of symptoms, severity of illness, and patient outcomes.

Table 4. Evidence for Recommendations of Diagnostic Test Methods for *Clostridium difficile*

| Use a stool toxin test as part of a multistep algorithm vs a NAAT alone for all specimens received in the clinical laboratory when there are no preagreed institutional criteria for patient stool submission | | | | | |
|--|--|-----------------|--|---|-------------------------|
| Evidence Supporting Diagnostic Tests | Design | No. of Subjects | Methodologic Limitations | Quality of Evidence (GRADE ^a) | Reference, First Author |
| GDH and NAATs had the highest sensitivity but poor PPV in patients with no symptoms; all tests had high NPV regardless of symptoms | Observational study, patient interviews, and ID physician assessment | 150 | Small sample size; only standard of care assay was tested in real time; others frozen | | Dubberke [171] |
| Toxin-negative, NAAT-positive patients who were not treated did not have adverse outcomes. Recurrence of CDI was more common when both NAAT and toxin assays were positive than when NAAT alone was positive (31% vs 14%; $P = .03$) | Observational retrospective study | 128 | Small sample size | | Kaltsas [183] |
| No difference in toxin EIA positivity between patients with mild vs severe disease (49% vs 58%; $P = .31$) | Observational study, prospective testing, retrospective chart review | 299 | Single-center study | | Humphries [187] |
| Complications were more common among patients positive by both NAAT and GDH/EIA/CCNA compared to NAAT alone (39% vs 3%; $P < .001$) | Prospective cohort study, observational | 1321 | Only some of the samples were tested using a gold standard | | Longtin [184] |
| Patients who were CCNA positive or GDH/EIA positive had higher all-cause mortality than patients who were NAAT or TC positive alone ($P = .022$) | Prospective, multicenter, observational study | 12 420 | Limited clinical data | | Planche [185] |
| Patients who were EIA toxin positive had longer median duration of diarrhea, more CDI-related complications, higher CDI-related mortality than toxin negative/PCR positive patients (8.4% vs 0.6%; $P = .001$) | Prospective, single-center observational cohort study | 1416 | Single-center study; differences in empiric treatment and risk allocation between groups | | Polage [389] |
| Quality of evidence for diagnosis when the pretest probability is unknown or low | | | | ⊕ ⊕ ⊕ ⊕ (Low) | |
| Use a NAAT alone or multiple-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin; NAAT, or NAAT plus toxin) vs a toxin test alone when there are preagreed institutional criteria for patient stool submission | | | | | |
| Evidence Supporting Diagnostic Tests | Design | No. of Subjects | Methodologic Limitations | Quality of Evidence (GRADE ^a) | Reference, First Author |
| PCR was more sensitive (93.3%) than toxin EIA (73.3%; $P < .05$) and direct cytotoxin testing (76.7%) when applied to patients who met clinical criteria for <i>C. difficile</i> disease | Observational; prospective patient interviews | 350 | Small number of positive patients | | Peterson [172] |
| Using clinical diagnosis as the reference standard, PCR was more sensitive than CCNA and GDH (99.1% vs 51% vs 83.8%). Close to double the number of patients were positive by PCR compared to CCNA and 91.5% of those were clinically confirmed. | Prospective performed at 2 centers | 1051 | Specimens were not consecutive; limited statistical analysis; limited patient follow-up | | Berry [190] |
| Quality of evidence for diagnosis when there is a high likelihood of CDI | | | | ⊕ ⊕ ⊕ ⊕ (Low) | |

Abbreviations: CCNA, cell cytotoxicity neutralization assay; CDI, *Clostridium difficile* infection; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; ID, infectious disease; NAAT, nucleic acid amplification test; NPV, negative predictive value; PCR, polymerase chain reaction; PPV, positive predictive value; TC, toxigenic culture.

^aFor GRADE interpretation, see Figure 1.

Two time periods were evaluated: May to August 2008 and March to May 2010 [183]. For both time periods, CDI cases were defined as having clinical symptoms including diarrhea (84%), fever and abdominal pain (4%), nausea and vomiting (2%), abdominal pain, leukocytosis, or sepsis (2% each), and fever alone (1%) with a positive NAAT or a positive CCNA [183]. Different NAATs were used in the first compared with the second time period and no information was provided on overall test positivity or other indicators of the prevalence of CDI in the tested population. Testing for CDI was performed on diarrheal (84%) and nondiarrheal (16%) stool samples in patients in whom it may be very difficult to interpret the true clinical significance of diarrhea, namely cancer patients undergoing intensive chemotherapy [183]. There was no statistically significant difference in the clinical presentations at the onset of infection and severity of disease between patients positive by NAAT alone compared with those concordant for both NAAT and 2-step algorithm assays [183]. Among 23 toxin-negative, NAAT-positive patients who were not treated, the only possible adverse outcome was recurrence in 3 patients; however, only 15 (65%) had diarrhea on the day of testing [183]. Recurrence of CDI was more common in patients when both assays were positive than when NAAT alone was positive (31% vs 14%; $P = .03$). In summary, it is not clear what the results mean from this modestly sized cohort of difficult-to-interpret cases (patients with high frequency of multifactorial diarrhea), other than the impact of a 2-fold increase in reported *C. difficile* rates when transitioning to the more sensitive, but probably less specific NAAT method [183].

Longtin et al assessed the impact of diagnostic test methods on CDI rates and the occurrence of complications based upon the tests used to diagnose CDI [184]. This was a prospective cohort study in Quebec over a 1-year period [184]. CDI was defined by documented diarrhea of ≥ 3 loose or liquid stools in < 24 hours and symptoms lasting ≥ 24 hours in combination with a positive test for toxin-producing *C. difficile* or clinical diagnosis based upon histopathology or presence of pseudomembranes on colonoscopy [184]. Structured data collection forms were used to collect information prospectively regarding complications and whether patients with positive tests met the case definition. All samples submitted to the laboratory were tested by a NAAT that detected the toxin B gene and a 3-step algorithm that began with screening for GDH followed by toxin A/B EIA testing [184]. Samples positive by both methods (NAAT and 3-step algorithm) were considered positive for *C. difficile*. GDH-positive, toxin EIA-negative samples were retested using a CCNA [184]. Only NAAT results were reported to clinicians and infection control. A total of 1321 stool specimens from 888 patients were assessed over the 1-year period, of which 17% were positive by NAAT and 12.3% were positive by the 3-step algorithm [184]. There were 85 cases of healthcare-associated CDI detected by

NAAT whereas only 56 of these cases were diagnosed by EIA/CCNA ($P = .01$). Complications (ie, 30-day mortality, colectomy, ICU admission, or readmission for recurrence) were more common among patients positive by both test methods (NAAT and 3-step algorithm) compared with cases detected by NAAT alone (39% vs 3%, $P < .001$). The major limitation of this study was that it was performed at a single center and only some of the specimens were tested by a recognized gold standard method (ie, CCNA). That said, the results support the findings by Planche and colleagues discussed below [185].

Planche et al sought to validate the reference methods for *C. difficile* diagnosis, namely TC and CCNA testing according to clinical outcomes in an attempt to derive the optimal diagnostic laboratory method [185]. This was a large observational, multicenter study of 12 420 routinely submitted fecal samples. The authors examined the results of the 2 reference assays (TC and CCNA) along with 4 commercial methods—2 toxin A/B enzyme EIAs, GDH, and a NAAT [185]. Limited clinical data were collected (all patients had diarrhea but stool frequency was not known) and outcomes were assessed for 6522 inpatients who were stratified into 3 groups as follows: CCNA positive (group 1; $n = 435$), TC positive but CCNA negative (group 2; $n = 207$), and negative by both methods (group 3; $n = 5880$). On univariate analysis, leukocytosis was greater in group 1 than group 2 or 3, and white blood cell (WBC) counts were similar in groups 2 and 3. However, both groups 1 and 2 had similarly low serum albumin levels compared with group 3; group 2, but not group 1, had a higher mean rise in creatinine than group 3. Both groups 1 and 2 had similarly longer mean lengths of stay (before and after testing) than group 3. All-cause 30-day mortality was markedly higher in group 1 (16.6%) than group 2 (9.7%) ($P = .022$). The mortality in group 2 was not significantly different from the control group (8.6%) [185]. When the analysis was performed using NAAT in place of TC, the findings were similar, with the absolute difference in mortality between patients who were CCNA positive vs those with NAAT positive but CCNA negative of 6.9% ($P = .004$). The combination of GDH immunoassay plus toxin EIA (TechLab assay) was almost identical in performance to CCNA. In a multivariate logistic regression model, group 1 patients were older and had greater leukocytosis, serum creatinine rise, depressed albumin, and 30-day mortality compared with group 3 [185]. Lengths of stay were not independently associated with group 1, and all other group multivariate comparisons, including mortality in group 1 vs 2, were not significant. The failure to find a mortality difference in groups 1 vs 2 on multivariate analysis may be due to the much smaller number of patients in group 2 than in group 3. Another limitation was the relatively low prevalence of true disease in the tested population based upon the positivity rate of either the CCNA (5.9%) or TC (8.3%); this reflected national endemic rates of CDI at that time.

Clinical outcome data were available for 69% (143/206) of inpatients with discordant reference method results. Of these

patients, 75 (52%) who were TC positive but CCNA negative received no CDI treatment. Among the 4 of 75 cases that were TC positive and CCNA negative who died and did not receive CDI treatment, none had a diagnosis of this infection on their death certificate. Also, 64 of 143 (45%) patients with a discordant reference method result did not have diarrhea recorded on their stool chart; for the remainder of the patients, the median duration of diarrhea was 2 days.

The authors concluded that patients with a positive toxin test should be treated and those who are positive by TC and/or NAAT alone could be considered “excretors” who may present an infection control risk but do not require treatment.

In the Planche et al study, based upon the assay comparison validation, the authors recommended using a multistep algorithm such as screening with GDH and confirming positives with a “sensitive” toxin A/B enzyme immunoassay [185], and this has been national UK policy since 2012. The 2 toxin EIAs used in the study, the Meridian Tox A/B test and the TechLab assay, had significantly differing sensitivities of 69.2% (95% CI, 64.3%–73.8%) and 82.3% (95% CI, 78.1%–85.9%), respectively [185].

Support for using the Meridian Tox A/B toxin testing alone instead of a NAAT alone to diagnose CDI is provided in a more recent study by Polage et al. In a large ($n = 1416$) prospective, observational cohort study performed at a single academic medical center, the authors assessed the natural history and need for treatment of patients who were toxin EIA positive (assay in clinical use) compared with toxin negative/PCR positive (blindly tested) [186]. The toxin-positive/PCR-positive arm had 131 patients (9.3%), 162 patients were toxin negative/PCR positive (11.4%), and 1123 patients were toxin negative/PCR negative. Patient demographics were similar among all 3 arms as were the proportions with leukopenia, renal insufficiency, and hypoalbuminemia. The toxin-positive/PCR-positive group had more diarrhea and longer duration of diarrhea, more prior antibiotic exposure, and more patients with leukocytosis. In the multivariable model, the frequency of CDI-related complications was highest in the toxin-positive/PCR-positive group compared with the toxin-negative/PCR-positive and toxin-negative/PCR-negative patients (7.6% vs 0% vs 0.3%; $P < .001$). The rate of CDI-related complications was similar between the PCR-positive/toxin-negative patients and patients who were negative by both tests (0% vs 0.3%; $P > .99$). In terms of mortality, similar observations were noted. There were 11 CDI-related deaths among the toxin-positive/PCR-positive patients, one death among the PCR alone cohort, and no deaths among the group with negative tests ($P < .001$). The authors also assessed repeat testing and treatment within 14 days of onset of symptoms as surrogates of ongoing clinical suspicion or empiric treatment for CDI in the toxin-negative/PCR-positive group, and again during the 15- to 30-day period following symptom onset to assess recurrent or prolonged CDI during the latter time period. Sixty-one toxin-negative/PCR-positive patients were retested

(37.7%) and 8% had toxins detected. While none of the patients had CDI-related complications, one patient had CDI as a contributing factor to death.

During the early period, only 21 patients (13%) received a full course of treatment and close to 60% received no treatment [186]. Likewise, in the later period (15–30 days after onset), most (78%) toxin-negative/PCR-positive patients received no treatment. During that period, patients who were toxin positive were twice as likely to have repeat testing and 3 times more likely to be positive compared with toxin-negative/PCR-positive patients. The authors conclude that toxin EIA positivity was a better predictor of CDI-related complications and deaths, and outcomes in patients who were PCR positive alone were comparable with those in patients who were negative by both tests. The use of molecular tests alone is likely to lead to overdiagnosis and overtreatment. There are several strengths of this study including the large number of patients assessed, the prospective study design, and assessment of patient outcomes. The weaknesses include that fact it was a single-center study and risk allocation between the 2 groups was not equivalent. In addition, empiric treatment may have affected outcomes in some patients in the toxin-negative/PCR-positive group.

Absence of toxin in stool may not be predictive of CDI severity. Investigators at the University of California, Los Angeles attempted to assess the significance of detecting *C. difficile* in patient samples in the absence of toxins, for example, in NAAT-positive, EIA-negative situations [187]. The goal was to determine if patients who tested negative for *C. difficile* toxins by EIA but were positive by NAAT were more likely to have mild disease [187]. Retrospective chart review was performed following completion of laboratory testing. Patients were selected on the basis of initial NAAT result, selecting one NAAT-negative patient for every NAAT-positive patient until a predicted necessary sample size to test the above goal was reached. Thus, 296 patients were enrolled in the study with 143 classified as true CDIs (48% of the cohort) based on multiple different results, some of which likely lacked specificity for CDI [187]. Among the 143 with CDI, there was no difference in toxin EIA positivity between patients with mild vs severe disease (49% vs 58%; $P = .31$) according to the criteria of Zar et al; however, patients with mild disease had a 2.7-fold lower all-cause mortality [187, 188]. Although the toxin EIA-positive patients did have significantly longer overall hospital stays, the authors concluded that, because of similarly low toxin EIA positivity in both less- and more-severe disease, NAAT-positive, EIA-negative results are clinically meaningful and therefore a NAAT should be used for the diagnosis of CDI [187]. This study is likely underpowered and may suffer from bias based upon its retrospective design and suboptimal choice of the toxin EIA; also, the reference method used (toxigenic culture) for assessment of the toxin EIA results was not ideal as this would have underestimated the sensitivity of the latter test.

In summary, if laboratories have no clinical data and accept all unformed stools for testing, it is most appropriate to use a diagnostic approach that includes a test that is more specific for CDI, such as a relatively sensitive toxin test as part of a multistep algorithm.

VIII. What is the most sensitive method of diagnosis of CDI in stool specimens from patients likely to have CDI based on clinical symptoms?

Recommendation

1. Use a NAAT alone or a multistep algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are preagreed institutional criteria for patient stool submission (Figure 2) (*weak recommendation, low quality of evidence*).

Summary of the Evidence

One of the first studies to incorporate clinical information in the validation of a molecular test was by Peterson et al [172]. This study was performed prior to the availability of the first FDA-cleared molecular assay using an in-house developed assay that detected the toxin B gene (*tcdB*). This real-time PCR test was compared with TC, a toxin EIA, and an in-house CCNA [172]. The authors performed 2 clinical evaluations. A checklist of validated clinical criteria for diagnosis of *C. difficile* disease was used for both the retrospective and prospective investigations [189]. Toxigenic culture was used as the reference method for other assay comparisons for the retrospective study and the reference method for the prospective study was diarrhea defined as ≥ 3 loose stools for at least 1 day and ≥ 2 positive test results [172]. For the initial investigation (retrospective clinical assessment), the authors observed that documentation was so poor that clinical criteria could not be used for correlation with test performance [172]. Compared with toxigenic culture, the toxin EIA had a sensitivity of 66.7% and specificity of 91.8% and the values for the PCR assay were 94.4% and 96.8%, respectively [172]. For the second investigation, patients were interviewed prospectively and among the 350 patients with 365 unique episodes of potential CDI, 39% did not have sufficient diarrhea to warrant testing and were not further analyzed [172]. There were 30 true-positive results in this analysis [172]. The PCR was more sensitive (93.3%) than toxin EIA (73.3%; $P < .05$) and direct cytotoxin testing (76.7%). The authors concluded that PCR outperformed the other diagnostic test methods when applied to patients who meet clinical criteria for *C. difficile* disease. Overall, the design of this study was quite complex with varying reference methods for the 2 study arms, and despite the prospective design for the second investigation, limitations were the very small numbers of positive patients and the fact that it was a single-center study.

In a later publication, Berry et al assessed prospectively whether a rapid PCR assay correlated well and reliably with clinical CDI diagnosis [190]. The GeneXpert *C. difficile* assay was compared with CCNA and a GDH/Toxin A/B EIA algorithm. Clinical diagnosis, adjudicated by an unblinded team of multidisciplinary experts, served as the reference for evaluation of the different test performances (>1000 PCR and CCNA tests were performed). Sixty-two patients were both PCR and CCNA positive and an additional 59 specimens were PCR positive alone, among which 54 (91.5%) were in patients clinically diagnosed as having CDI. When the GDH screen was evaluated, 16.2% of patients with clinical CDI would not have been detected. Combining GDH and EIA testing, 59.7% of patients with CDI would have been missed (GDH positive, toxin EIA negative). Patients who were CCNA positive/PCR positive had higher all-cause 30-day mortality compared with CCNA-negative/PCR-positive patients. This study only presented results obtained after repeat testing of indeterminate results. The claimed PPV of 91.9%, using clinical diagnosis as the reference, is much higher than found elsewhere [186]. Patients were not followed long term to assess other clinical outcomes.

In summary, if patients are screened carefully for clinical symptoms likely associated with CDI (at least 3 loose or unformed stools in ≤ 24 hours with history of antibiotic exposure), then a highly sensitive test such as a NAAT alone or multistep algorithm (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) may be best. A 2- or 3-stage approach increases the PPV vs one-stage testing.

IX. What is the role of repeat testing, if any? Are there asymptomatic patients in whom repeat testing should be allowed, including test of cure?

Recommendation

1. Do not perform repeat testing (within 7 days) during the same episode of diarrhea and do not test stool from asymptomatic patients, except for epidemiological studies (*strong recommendation, moderate quality of evidence*).

Summary of the Evidence

The issue of if or when to retest for CDI is inherently linked to the accuracy of the employed routine testing method. Methods with suboptimal sensitivity for *C. difficile* (eg, stand-alone toxin EIAs) led to frequent retesting in some settings. Ironically, use of tests with suboptimal specificity means that multiple repeat testing runs a high risk that false-positive results could eventually be generated. Ideally, in the absence of clear changes to the clinical presentation of suspected CDI (ie, change in character of diarrhea or new supporting clinical evidence), repeat testing should not be performed. This advice is based on the above-mentioned issues and also on studies that have shown that the diagnostic yield of

repeat testing within a 7-day period (with either toxin A/B EIA or NAAT) is approximately 2% [191, 192]. Furthermore, use of highly sensitive testing strategies (eg, 2-stage algorithms or stand-alone NAATs) means that the single tests have very high negative predictive value (typically >99%) for CDI.

There may be more value of repeat testing in epidemic settings where CDI acquisition is more frequent [193, 194]. For symptomatic patients with a high clinical suspicion of CDI but a negative CDI test, particularly those in whom symptoms worsen, repeat testing should be considered; this does not equate to routine retesting, given that the great majority of patients with suspected CDI do not have the disease.

Given that recurrent CDI occurs commonly, a recurrence of symptoms following successful treatment and diarrhea cessation should be assessed by repeat testing. Testing for recurrent CDI should ideally include toxin detection, as persistence of toxigenic *C. difficile* can occur commonly after infection. Patients can have reduced health scores for months after CDI, and may experience altered bowel habits for prolonged periods. In one study in which all CDI patients with recurrent diarrhea were tested for toxin in stool, 35% were negative [195]. Empiric treatment, that is without confirmatory testing of suspected recurrence, is discouraged, as this may be unnecessary and indeed possibly harmful to microbiome restoration.

Last, there is no clinical value in repeat CDI testing to establish cure; >60% of patients may remain *C. difficile* positive even after successful treatment [196, 197].

X. Does detection of fecal lactoferrin or another biologic marker improve the diagnosis of CDI over and above the detection of toxigenic *C. difficile*? Can such a subset predict a more ill cohort?

Recommendation

1. There are insufficient data to recommend use of biologic markers as an adjunct to diagnosis (*no recommendation*).

Summary of the Evidence

A variety of fecal biomarkers to distinguish inflammatory causes of diarrhea from noninflammatory conditions, such as irritable bowel syndrome, have evolved over the last few decades. Lactoferrin is an iron binding glycoprotein found in neutrophils and its concentration in stool is proportional to the number of neutrophils present [198]. Calprotectin is a calcium binding protein found in the cytosol of neutrophils [198]. Secretion of cytokines in the intestines such as interleukin 8 and interleukin 1 β has also been evaluated [199–201]. While they have utility in diagnosing IBD, their usefulness in the diagnosis of CDI has not been established. Most of the published studies include small or moderate numbers of patients. There are few prospective studies. Interpretation of the literature is further complicated by the use of different methods of testing (latex agglutination vs EIA in

the case of fecal lactoferrin), deviation from the manufacturers' cutoffs for interpretation, and other confounding factors. Some of these biomarkers may be helpful in identifying patients at risk for severe disease. Given these limitations, no recommendations for their routine use can be made.

DIAGNOSIS (PEDIATRIC CONSIDERATIONS)

XI. When should a neonate or infant be tested for *C. difficile*?

Recommendations

1. Because of the high prevalence of asymptomatic carriage of toxigenic *C. difficile* in infants, testing for CDI should never be routinely recommended for neonates or infants ≤ 12 months of age with diarrhea (*strong recommendation, moderate quality of evidence*).

Summary of the Evidence

The rate of *C. difficile* colonization among asymptomatic infants can exceed 40% [136, 143, 154]. Colonization rates among hospitalized neonates are greater than observed for healthy infants [136]. Although the rate of colonization declines over the first year of life, intermittent detection of *C. difficile* toxin can persist throughout infancy [202]. *Clostridium difficile* toxin can still be detected in approximately 15% of 12-month-old infants [153]. Thus, there is a substantial risk of a biologic false positive when *C. difficile* diagnostic testing is performed in neonates and infants. Another challenge to defining when an infant with diarrhea should be tested for *C. difficile* is the absence of a validated definition of clinically significant diarrhea in this age group, where passage of frequent loose stools is common. Children <12 months of age should only be tested for *C. difficile* if they have evidence of pseudomembranous colitis or toxic megacolon, or if they have clinically significant diarrhea and other causes of diarrhea have been excluded.

XII. When should a toddler or older child be tested for *C. difficile*?

Recommendations

1. *Clostridium difficile* testing should not be routinely performed in children with diarrhea who are 1–2 years of age unless other infectious or noninfectious causes have been excluded (*weak recommendation, low quality of evidence*).
2. In children ≥ 2 years of age, *C. difficile* testing is recommended for patients with prolonged or worsening diarrhea and risk factors (eg, underlying inflammatory bowel disease or immunocompromising conditions) or relevant exposures (eg, contact with the healthcare system or recent antibiotics) (*weak recommendation, moderate quality of evidence*).

Summary of the Evidence

The prevalence of asymptomatic colonization with *C. difficile* is elevated in the second year of life, although to a lesser degree than in infants [139, 153, 154]. Therefore, testing in this population should also be avoided unless other infectious and noninfectious causes of diarrhea have been excluded. However, by 2–3 years of age, approximately 1%–3% of children are asymptomatic carriers of *C. difficile* (a rate similar to that observed in healthy adults). Rarely, some conditions such as Hirschsprung disease may predispose young children to CDI, and testing should be considered in this population [203, 204]. The role of *C. difficile* in community-onset diarrhea in otherwise healthy young children remains controversial. Studies of children hospitalized with acute gastroenteritis have documented that *C. difficile* can be isolated in >50% of children in whom an alternate gastrointestinal pathogen has been identified [205]. Additionally, one recently published study found that among 100 children <2 years of age who were hospitalized with diarrhea and had *C. difficile* toxin detected; all had resolution of diarrhea regardless of whether *C. difficile*-specific therapy was administered [206]. Limited data suggest that identification of multiple enteric pathogens (including *C. difficile*) may predict more severe symptoms [205].

INFECTION PREVENTION AND CONTROL

Isolation Measures for Patients With CDI

XIII. Should private rooms and/or dedicated toilet facilities be used for isolated patients with CDI?

Recommendations

1. Accommodate patients with CDI in a private room with a dedicated toilet to decrease transmission to other patients. If there is a limited number of private single rooms, prioritize patients with stool incontinence for placement in private rooms (*strong recommendation, moderate quality of evidence*).
2. If cohorting is required, it is recommended to cohort patients infected or colonized with the same organism(s)—that is, do not cohort patients with CDI who are discordant for other multidrug-resistant organisms such as methicillin-resistant *Staphylococcus aureus* or vancomycin-resistant *Enterococcus* (*strong recommendation, moderate quality of evidence*).

Summary of the Evidence

Isolation of patients with CDI or suspected CDI is a prevention measure used by most healthcare facilities regardless of local epidemiology; however, additional measures are often implemented, particularly when CDI rates are high. An infection control “bundle” strategy has been used to successfully control major CDI outbreaks [207–211]. The “bundle” approach involves multifaceted interventions and includes hand hygiene, isolation measures, environmental disinfection, and antibiotic

stewardship. However, it is often difficult to determine which interventions were the most effective in controlling the outbreak as they are implemented simultaneously.

Hospital room design and handwashing accessibility are essential elements in the prevention and control of CDI. Private rooms may facilitate better infection control practices. In a cohort study of healthcare-associated CDI acquisition, higher rates of CDI were demonstrated among patients housed in double rooms than in single rooms (17% vs 7%; $P = .08$) and there was a significantly higher risk of acquisition after exposure to a roommate with a positive culture result [74]. The effect of private rooms on CDI and other bacterial acquisition rates was studied when an ICU was renovated to only private rooms with accessible handwashing facilities [212]. There was a significant reduction in CDI rates by 43%, although other potential confounders, such as antibiotic utilization, were not examined [212]. Private rooms may not be available and cohorting patients with CDI in a multibed room may be required. The risk of recurrence was examined among patients with CDI admitted to a cohort ward while adjusted for potential risk factors such as age, comorbidities, and continued antibiotic use [213]. Admission to a *C. difficile* cohort ward was shown to be an independent predictor for recurrence [213]. If cohorting is required, dedicated commodes should be provided to the patients to reduce further cross-transmission.

In conclusion, patients with CDI should be placed in a private room to decrease transmission to other patients. If there is a limited number of private single rooms, CDI patients with stool incontinence should be prioritized for placement in private rooms. If cohorting is required, it is recommended to cohort patients infected or colonized with the same organism(s) ie, do not cohort patients with CDI who are discordant for other multidrug-resistant organisms such as MRSA or vancomycin-resistant *Enterococcus* (VRE).

XIV. Should gloves and gowns be worn while caring for isolated CDI patients?

Recommendation

1. Healthcare personnel must use gloves (*strong recommendation, high quality of evidence*) and gowns (*strong recommendation, moderate quality of evidence*) on entry to a room of a patient with CDI and while caring for patients with CDI.

Summary of the Evidence

Additional isolation techniques (contact precautions, private rooms, and cohorting of patients with active CDI) have been used for control of outbreaks, with variable success [207, 214, 215]. Contact precautions include the donning of gowns and gloves when caring for patients with CDI. The hands of personnel can become contaminated with *C. difficile* spores, particularly when

gloves are not used and when exposed to fecal soiling [74, 216]. Wearing gloves in conjunction with hand hygiene should decrease the concentration of *C. difficile* organisms on the hands of health-care personnel. A prospective controlled trial of vinyl glove use for handling body substances showed a significant decrease in CDI rates, from 7.7 cases per 1000 discharges before institution of glove use to 1.5 cases per 1000 discharges after institution of glove use ($P=.015$), but not on control wards that did not institute the glove intervention [217]. Care should also be taken to prevent contamination of hands when removing gloves.

Clostridium difficile has been detected on nursing uniforms, but there is no evidence that uniforms are a source of transmission to patients [218]. The use of gowns has been recommended because of potential soiling and contamination of the uniforms of health-care personnel with *C. difficile* and high quality of evidence for reducing transmission of other enteric multidrug-resistant organisms (ie, VRE) [219, 220]. In addition, the fact that gloves reduce transmission provides further indirect evidence for gowns.

XV. When should isolation be implemented?

Recommendation

1. Patients with suspected CDI should be placed on preemptive contact precautions pending the *C. difficile* test results if test results cannot be obtained on the same day (*strong recommendation, moderate quality of evidence*).

Summary of the Evidence

It is important to place patients suspected of having CDI on contact precautions before diagnostic laboratory test confirmation if there will be a lag before test results are available. In a prospective study of 100 patients suspected of CDI, skin contamination was evaluated as well as the average time for test results to become available [221]. The potential for healthcare personnel hand contamination was assessed by applying sterile gloved hands to frequently examined patient skin sites and then imprinting the gloves onto agar for *C. difficile* culture. Twenty of these 100 patients (20%) were diagnosed with CDI but the test results were not available for 2.07 days. The frequency of *C. difficile* acquisition on gloved hands of healthcare personnel after skin contact with these patients was 69%. This study supports that patients with suspected CDI should be placed on preemptive contact precautions pending the *C. difficile* test results if the results cannot be obtained the same day as when the specimen was collected.

XVI. How long should isolation be continued?

Recommendations

1. Continue contact precautions for at least 48 hours after diarrhea has resolved (*weak recommendation, low quality of evidence*).

2. Prolong contact precautions until discharge if CDI rates remain high despite implementation of standard infection control measures against CDI (*weak recommendation, low quality of evidence*).

Summary of the Evidence

The CDC currently recommends that contact precautions be continued for the duration of the illness [222]. The UK guidelines recommend continuing contact precautions for at least 48 hours after diarrhea resolves [223]. *Clostridium difficile* was suppressed to undetectable levels in stool samples from most patients by the time diarrhea resolved (mean, 4.2 days) in a prospective study of 52 patients [95]. However, at the time of resolution of diarrhea, skin and environmental contamination was high at 60% and 37%, respectively. In addition, stool detection of *C. difficile* was 56% at 1–4 weeks posttreatment. Continue contact precautions for at least 48 hours after diarrhea has ceased. There are no studies that demonstrate further extending contact precautions results in reductions in CDI incidence. Prolonging contact precautions until discharge remains a special control measure if CDI rates remain high despite implementation of standard infection control measures against CDI [222].

XVII. What is the recommended hand hygiene method (assuming glove use) when caring for patients in isolation for CDI?

Recommendations

1. In routine or endemic settings, perform hand hygiene before and after contact of a patient with CDI and after removing gloves with either soap and water or an alcohol-based hand hygiene product (*strong recommendation, moderate quality of evidence*).
2. In CDI outbreaks or hyperendemic (sustained high rates) settings, perform hand hygiene with soap and water preferentially instead of alcohol-based hand hygiene products before and after caring for a patient with CDI given the increased efficacy of spore removal with soap and water (*weak recommendation, low quality of evidence*).
3. Handwashing with soap and water is preferred if there is direct contact with feces or an area where fecal contamination is likely (eg, the perineal region) (*good practice recommendation*).

Summary of the Evidence

Transmission of *C. difficile* strains commonly occurs via the hands of healthcare personnel. After caring for patients with CDI, the proportion of healthcare personnel with hand contamination when gloves are not worn ranges from 14% to 59% [74, 87, 216, 224]. Hand hygiene is considered to be one of the cornerstones of prevention of transmission of *C. difficile*, as it is for

most other healthcare-associated infections. Many studies have documented low rates of handwashing by healthcare personnel, particularly when sinks are not readily accessible [225–228]. The introduction of alcohol-based hand antiseptics has been considered transformative for increasing hand hygiene compliance. Hand hygiene guidelines recommend the use of alcohol-based products, unless the hands have come into contact with body fluids or are visibly soiled, in which case handwashing with soap and water is recommended. These alcohol-based antiseptics are popular because of their ease of use at the point of care and their effectiveness in rapid killing of most vegetative bacteria and many viruses that contaminate hands. However, *C. difficile* spores are highly resistant to killing by alcohol. Indeed, the addition of ethanol to stool samples in the laboratory facilitates the culture of *C. difficile* from these specimens [229]. Therefore, healthcare personnel who do not wear gloves or whose hands become contaminated when doffing gloves may be merely redistributing spores over the hand surface when using alcohol-based products. This could potentially increase the risk of transferring *C. difficile* to patients under their care, but numerous studies have not shown an association between the use of alcohol-based hand hygiene products and an increased incidence of CDI. The impact of using an alcohol-based hand hygiene product on rates of infection with MRSA, VRE, and CDI 3 years before and after its implementation was studied [230]. After implementation, the rates of MRSA and VRE infections decreased by 21% and 41%, respectively, whereas the incidence of CDI was unchanged. This finding is consistent and has been reproduced in other studies [231–234]. A large prospective, ecological interrupted time series study was conducted from July 2004 to June 2008 in England and Wales to evaluate the impact of the “cleanyourhands” campaign on the rates of hospital procurement of alcohol hand rub and soap and to investigate the association between the rates of MRSA bacteremia and CDI [235]. Procurement of these products was used as a proxy for hand hygiene compliance. This study demonstrated that increased soap procurement was significantly associated with a decline in CDI rates whereas increased alcohol hand rub procurement was significantly associated with a reduction in MRSA bacteremia rates.

The use of alcohol-based products has been compared with other methods of hand hygiene in removal of *C. difficile* spores [236, 237]. These studies evaluated the efficacy of different handwashing methods among volunteers for removal of spores of a nontoxigenic strain of *C. difficile*. Handwashing with soap and water, or with an antimicrobial soap and water, was found to be more effective at removing *C. difficile* spores than alcohol-based hand hygiene products. McFarland et al showed that chlorhexidine-containing antiseptic was more effective than plain soap for eliminating *C. difficile* from the hands of healthcare personnel [74]. *Clostridium difficile* was recovered from the hands of 88% of personnel (14 of 16) who had washed with plain soap. Washing with 4% chlorhexidine gluconate reduced

the rate to 14% (1 of 7 personnel) [74]; in contrast, another study that conducted experimental hand seeding with *C. difficile* spores showed no difference between plain soap and chlorhexidine gluconate in removing *C. difficile* from hands [238].

In summary, there is a theoretical possibility for alcohol-based hand hygiene products to increase the incidence of CDI because of their inability to eliminate *C. difficile* spores from the hands. However, there have not been any clinical studies to support that the use of alcohol-based hand hygiene products results in an increased incidence of CDI. Therefore, before and after providing care for a patient with CDI, it is recommended to preferentially use soap and water over alcohol-based products alone for hand hygiene in CDI-hyperendemic (sustained high rates) or outbreak settings. It is important to confirm compliance with glove use and to use alcohol-based products in nonoutbreak or endemic settings.

XVIII. Should patient bathing interventions be implemented to prevent CDI?

Recommendation

1. Encourage patients to wash hands and shower to reduce the burden of spores on the skin (*good practice recommendation*).

Summary of the Evidence

The hands of patients can also become contaminated with *C. difficile* at a rate of 32% [239]. Potentially, these patients can transmit *C. difficile* to surfaces. In addition, this could be a factor in CDI recurrence when the spores are ingested from their contaminated hands. Patient bathing can also decrease skin contamination of *C. difficile*. Among 37 patients with CDI, showering was more effective than bed bathing in decreasing the rate of positive skin cultures [240]. Encouraging patients to wash hands and shower could be a useful strategy to reduce the burden of spores on the skin.

XIX. Should noncritical devices or equipment be dedicated to or specially cleaned after being used on the isolated patient with CDI?

Recommendation

1. Use disposable patient equipment when possible and ensure that reusable equipment is thoroughly cleaned and disinfected, preferentially with a sporicidal disinfectant that is equipment compatible (*strong recommendation, moderate quality of evidence*).

Summary of the Evidence

Single-use disposable equipment should be used to prevent CDI transmission. Nondisposable medical equipment should be dedicated to the patient's room, and other equipment should be thoroughly cleaned after use in a patient with CDI.

Environmental contamination has been associated with the spread of *C. difficile* via contaminated commodes, blood pressure cuffs, and oral and rectal electronic thermometers [74, 241, 242]. Replacement of electronic thermometers with single-use disposable thermometers has been associated with significant decreases in CDI incidence [243]. During simulated routine physical examinations on patients with CDI, stethoscopes were found to acquire and transfer *C. difficile* spores as often as gloved hands [244]. These results support the recommendation to use disposable patient equipment when possible and to ensure that reusable equipment is cleaned and disinfected with a US Environmental Protection Agency–registered, sporicidal disinfectant, when possible. It is important to ensure that the responsibility and methods for cleaning and disinfection are clearly defined in standard operating procedures.

XX. What is the role of manual, terminal disinfection using a *C. difficile* sporicidal agent for patients in isolation for CDI?

Recommendation

1. Terminal room cleaning with a sporicidal agent should be considered in conjunction with other measures to prevent CDI during endemic high rates or outbreaks, or if there is evidence of repeated cases of CDI in the same room (*weak recommendation, low quality of evidence*).

Summary of the Evidence

Clostridium difficile produces spores that are resistant to most standard hospital environmental disinfectants and can survive for months in the hospital environment [245]. Patients who are colonized with *C. difficile* shed spores and contaminate their local environment. These spores can serve as a source of transmission to other patients. Surfaces from which *C. difficile* spores have been cultured include toilets, commodes, floors, bed rails, call buttons, sinks, and over bed tables [87, 246]. Although some studies demonstrated that epidemic strains have increased capacity for sporulation, other studies have not [247]. Environmental contamination is lowest in rooms of culture-negative patients (<8% of rooms), intermediate in rooms of patients with asymptomatic *C. difficile* colonization (8%–30% of rooms), and highest in rooms of patients with CDI (9%–50% of rooms) [74, 87, 245, 248]. Samore et al found the degree of environmental contamination to correlate with the degree of healthcare personnel hand contamination [87]. Hand contamination was 0%, 8%, and 26% when environmental contamination was 0–25%, 26%–50%, and >50%, respectively. Of note, this study was conducted prior to the routine use of contact precautions for patients with CDI, so regular use of gloves may decrease hand contamination if implemented.

Measuring the effect of environmental agents with sporicidal activity on the incidence of CDI is complicated by data that indicate

that most patients with CDI do not directly acquire *C. difficile* from the environment, the existence of different methods to apply these agents, and the record of inconsistent impact of sporicidal agents on reducing CDI incidence in nonoutbreak settings. Several recent studies provide insight as to why this may be. Shaughnessy et al found admission to an ICU room that previously housed a patient with CDI to be a risk factor for CDI, but only 11% of patients who developed CDI had this risk factor [89]. Consistent with this finding, a modeling study found that environmental contamination with *C. difficile* spores likely contributes to only 10% of new CDI cases [249]. In addition, studies using sequencing to characterize isolates found only 2%–7% of new CDI cases could be attributed to environmental contamination [75, 250]. Studies that have found a reduction in CDI after implementation of a sporicidal agent have mostly occurred in outbreak settings, with implementation of the sporicidal agent occurring concurrently with other interventions to prevent CDI [251–253]. However, sporicidal agents have not been associated with reductions in CDI in nonoutbreak settings [86, 88]. This is likely because in an endemic setting, in the absence of consecutive patients admitted to a room developing CDI, the degree of environmental contamination is not sufficient to cause transmission. In addition, *C. difficile* spores are physically removed when surfaces are wiped down. Other confounding variables in studies include the following: Several different products have been used including various dilutions of sodium hypochlorite, phenol-based agents, peroxide-based agents, and ultraviolet irradiation; applied by people or by automated systems; and with daily cleaning alone, daily cleaning and terminal cleaning, terminal cleaning alone, and periodic “deep cleaning.”

In outbreak settings, terminal disinfection with a sporicidal agent in conjunction with other interventions to prevent CDI has been associated with reductions in CDI. However, terminal disinfection with a sporicidal agent has not been associated with consistent reductions in CDI in nonoutbreak settings. Therefore this remains most appropriate as a supplemental intervention for outbreaks, hyperendemic settings, and evidence of repeated cases of CDI in the same room.

If a sporicidal agent is implemented, compliance with thoroughness of cleaning has been associated with reductions in viable *C. difficile* spores from the environment.

XXI. Should cleaning adequacy be evaluated?

Recommendation

1. Incorporate measures of cleaning effectiveness to ensure quality of environmental cleaning (*good practice recommendation*).

Summary of the Evidence

To decrease *C. difficile* spore contamination, one hospital found, over the course of several interventions that included terminal

disinfection with bleach, use of fluorescent markers to assess cleaning adequacy, use of an automated ultraviolet radiation device, and a dedicated team focused on daily cleaning of rooms housing patients with CDI, that the latter intervention was clearly the most effective at removing viable *C. difficile* spores from the environment [254]. Several methods have been used to assess thoroughness of cleaning, including fluorescent markers and adenosine triphosphate bioluminescence [254, 255]. These measures of cleaning adequacy are most effective when feedback is given in real time. Barriers to effective cleaning may be due to insufficient time for cleaning, inadequate cleaning supplies, inadequate education, and poor communication [222]. Just as, if not more, important than using markers and providing feedback is having environmental services staff dedicated to thorough cleaning [254].

XXII. What is the role of automated terminal disinfection using a method that is sporicidal against *C. difficile*?

Recommendation

1. There are limited data at this time to recommend use of automated, terminal disinfection using a sporicidal method for CDI prevention (*no recommendation*).

Summary of the Evidence

“No-touch” disinfection technologies have garnered much interest of late. In general, these products use ultraviolet radiation or hydrogen peroxide vapor to disinfect the environment, and several studies have found that these products are effective at reducing viable *C. difficile* spores from patient rooms [254, 256, 257]. No single methodology (“no-touch” or otherwise) appears to be superior in regard to reductions in CDI incidence. Automated, terminal disinfection using a sporicidal method has been associated with reductions in viable *C. difficile* spores from the environment. There have been several reports associating use of no-touch disinfection technologies and reductions in CDI, but all of these have at least one significant limitation. These include before–after study designs, inappropriate statistical methods to analyze the data, other concurrent interventions, high baseline incidence of CDI prior to implementation, reduction of CDI back to baseline prior to no-touch technology implementation, and reductions driven by results from single units without apparent impact on other units [256, 258–264]. Data are currently too limited to draw any conclusions as to whether/when these devices should be a component of a CDI prevention program.

XXIII. What is the role of daily sporicidal disinfection?

Recommendation

1. Daily cleaning with a sporicidal agent should be considered in conjunction with other measures to prevent CDI during outbreaks or in hyperendemic (sustained high rates) settings,

or if there is evidence of repeated cases of CDI in the same room (*weak recommendation, low quality of evidence*).

Summary of the Evidence

Daily sporicidal disinfection can be effective at reducing *C. difficile* environmental contamination and has been associated with reductions in CDI in outbreak settings in conjunction with other interventions to prevent CDI. Mayfield et al reported that the introduction of disinfection with a hypochlorite-based solution (5000 ppm available chlorine) was associated with reduced incidence of CDI in a bone marrow transplant unit where there was a relatively high incidence of CDI [86]. Notably, the incidence of CDI increased almost to the baseline level after the reintroduction of the original quaternary ammonium compound as the principal cleaning agent. However, the environmental contamination of *C. difficile* was not measured in this study, and the results were not reproducible on other units with low CDI incidence. Orenstein et al evaluated the use of daily disinfection with bleach wipes containing 0.55% active chlorine on the incidence of HA-CDI in 2 units with hyperendemic rates [253]. The intervention successfully decreased the incidence by 85%. Daily disinfection of high-touch surfaces using a peracetic acid-based disinfectant was also shown to reduce contamination of health-care workers’ hands [265]. In contrast to daily disinfection, Hacek et al conducted a study to examine the impact of only terminal room cleaning with hypochlorite containing solution and no change to the daily room cleaning with quaternary ammonium [266]. With this intervention, there was a statistically significant decrease of 48% in the incidence of CDI.

There have not been any head-to-head comparisons of daily vs terminal cleaning using only sporicidal disinfection.

XXIV. Should asymptomatic carriers of *C. difficile* be identified and isolated if positive?

Recommendation

1. There are insufficient data to recommend screening for asymptomatic carriage and placing asymptomatic carriers on contact precautions (*no recommendation*).

Summary of the Evidence

In institutions with higher rates of CDI (7.8–22.5 cases per 1000 discharges), the number of asymptomatic carriers has been found to be considerably higher than the number with CDI [74, 87]. These asymptomatic carriers admitted to a ward could represent an important source of healthcare-associated spread of infection [92, 267, 268]. Results from mathematical modeling studies have suggested that reductions in CDI incidence by 10%–25% could be achieved by identifying and isolating carriers upon hospital admission [269, 270]. This novel approach was implemented by Longtin et al in an acute care hospital in Quebec that had high

endemic rates of CDI [271]. Using a quasi-experimental design and time series analysis, the effect of detecting and isolating asymptomatic carriers was evaluated. Potential confounders such as antibiotic and PPI utilization, hand hygiene compliance, and intensity of CDI testing were taken into consideration. The incidence of CDI decreased significantly after this intervention compared with the preintervention period and the lower incidence was sustained for at least 1 year after the study terminated. This study provides the most compelling evidence to date for the significant effect of isolating carriers. However, several potential confounders were not assessed including compliance with isolation precautions, effect of environmental cleaning, and knowledge of *C. difficile* carrier status on the management of a patient. Ultimately, these promising results need to be reproduced in multiple centers prior to being considered for widespread adoption. If these findings are confirmed in various different hospital settings, implementation of screening and isolation of asymptomatic carriers may be an important strategy to decrease CDI rates.

XXV. What is the role of antibiotic stewardship in controlling CDI rates?

Recommendations

1. Minimize the frequency and duration of high-risk antibiotic therapy and the number of antibiotic agents prescribed, to reduce CDI risk (*strong recommendation, moderate quality of evidence*).
2. Implement an antibiotic stewardship program (*good practice recommendation*).
3. Antibiotics to be targeted should be based on the local epidemiology and the *C. difficile* strains present. Restriction of fluoroquinolones, clindamycin, and cephalosporins (except for surgical antibiotic prophylaxis) should be considered (*strong recommendation, moderate quality of evidence*).

Summary of the Evidence

Antibiotic restriction may be one of the most useful control measures for a CDI outbreak. Fifteen quasi-experimental studies published between 1994 and 2013 were identified that evaluated the effectiveness of interventions to decrease antibiotic usage and changes in CDI rates [272–286]. Most studies were considered moderate (n = 13) or low (n = 2) quality. No randomized controlled trials (RCTs) were identified. A summary of the published studies is shown in Table 5. Studies published during 1994–2014 from hospitals (n = 13) or long-term care facilities (n = 2) were based in North America (n = 7) or the United Kingdom (n = 8). All studies but one were associated with an ongoing CDI epidemic (defined by most studies as a dramatic increase in rate of CDI) of which 7 studies demonstrated a clonal, epidemic strain. All studies used either a formulary restriction strategy (n = 11) or prospective audit and feedback (n = 4) as their predominant stewardship strategy. Targeted antibiotics included

fluoroquinolones (n = 7 studies), cephalosporins (n = 10), clindamycin (n = 5), amoxicillin or amoxicillin-clavulanate (n = 3), other β -lactamase inhibitors, carbapenems, vancomycin, or aztreonam (n = 1 each). Many studies targeted more than one antibiotic (n = 6). Second- and third-generation cephalosporins were more likely targets of intervention from studies published in the 1990s to early 2000s with fluoroquinolones targeted more frequently in studies published after 2000. Antibiotics within the same class (eg, cephalosporins) may not have the same risk for CDI and studies usually targeted the antibiotic most likely causing the current epidemic (generally considered the most widely used antibiotic in the hospital). All interventions were highly effective at decreasing usage of the targeted antibiotic(s) with percentage reduction that ranged from 50% to >90%, indicative of a successful process implementation. When reported, a global decrease for all antibiotics was shown in 5 of 9 studies. Change of CDI incidence was recorded as number per 10 000 patient-days (10 studies), CDI cases per month (3 studies), or CDI cases per 1000 discharges (2 studies). Three studies evaluated the change in incidence rate of CDI as a result of antibiotic change. Reduction in CDI incidence rates ranged from 33% to >90%, indicative of a successful outcome measure. After the intervention, rates of CDI ranged from 0.3–1.2 cases per 10 000 patient days.

The number and duration of antibiotics can also influence the development of CDI. Use of multiple antibiotics (mean number used, 4.2 vs 1.4 antibiotics) was found to be an important risk factor for developing CDI and the incidence of CDI increases with the number of antibiotics prescribed (relative risk, 1.49; 95% CI, 1.23–1.81) [102, 287]. A retrospective cohort of 241 patients examined the risk of development of CDI and cumulative antibiotic exposures. The risk of CDI was associated with increasing cumulative dose, number of antibiotics, and days of antibiotic exposure. For example, compared to patients who received only 1 antibiotic, the adjusted hazard ratios (HRs) for those who received 2, 3 or 4, or ≥ 5 antibiotics were 2.5 (95% CI, 1.6–4.0), 3.3 (95% CI, 2.2–5.2), and 9.6 (95% CI, 6.1–15.1), respectively [288]. Therefore, it is critical to avoid unnecessary antibiotics and to minimize the duration of use to reduce the risk of CDI.

Although many hospitals have implemented an antibiotic stewardship program (ASP), it is important to sustain the program with the required resources. The benefits of ASP include improved patient outcomes, reduced adverse events (including CDI), improvement in rates of antibiotic susceptibilities, and optimization of resource utilization [289].

XXVI. What is the role of proton pump inhibitor restriction in controlling CDI rates?

Recommendation

1. Although there is an epidemiologic association between PPI use and CDI, and unnecessary PPIs should always be

Table 5. Quasi-experimental Studies on the Association Between Antibiotic Stewardship Interventions and *Clostridium difficile* Infection

| Year [Reference] | Area | Time Frame | Setting (Bed Size) | Dominant Strain | Stewardship Method | Target | Targeted Antibiotics Decrease | Global Change in Hospital Antibiotic Use | CDI Rate Method | Pre- intervention | Post- intervention | Reduction in CDI Rates |
|---------------------|---------|------------|----------------------------|--------------------|-----------------------------------|--|-------------------------------------|--|--------------------|----------------------|-----------------------|------------------------------|
| 1994 [272] | US | 1990–1992 | Hospital (168) | J7 | Restrictive use | Clindamycin | >90% | NR | ^a | 15.8 | 1.9 | 88% |
| 1997 [273] | UK | 1994–1995 | Hospital (NR) | NR | Restrictive use | Cefuroxime | >90% | NR | ^b | 5.3 | 2.3 | 57% |
| 1998 [274] | US | 1992–1996 | Hospital (703) | Clonal strain A | Restrictive use | Clindamycin | >90% | No change | ^b | 11.5 | 3.3 | 71% |
| 2003 [275] | UK | 1995–2000 | Hospital (800) | NR | Restrictive use | Ceftriaxone | >90% | NR | ^c | 14.6 | 3.4 | 77% |
| 2003 [276] | US | 1991–1998 | Hospital (159) | NR | Prospective audit and feedback | Third-generation cephalosporins and aztreonam | 75% | Decreased | ^c | 2.2 | 0.3 | 86% |
| 2004 [277] | UK | 1997–2002 | Hospital (24 ward beds) | NR | Restrictive use | Cefotaxime | 83% | No change | ^a | 46 | 22 | 52% |
| 2004 [278] | US | 2001–2003 | LTCF (100) | A | Restrictive use | Gatifloxacin | >90% | No change | ^c | 1.32 | 0.51 | 61% |
| 2007 [279] | Canada | 2003–2006 | Hospital (683) | 027 | Restrictive use | High-risk antibiotics | 80% | Decreased | ^c | 2.03 | 0.82 | 60% |
| 2007 [280] | UK | 1999–2003 | Hospital (78 ward beds) | NR | Prospective audit and feedback | Cephalosporins and amoxicillin-clavulanate | 50%–75% | No change | ^b | NR | NR | 65% |
| 2011 [281] | UK | 2005–2007 | Hospital (495) | 027 | Restrictive use | High-risk antibiotics | 50%–75% | No change | ^c | 2.22 | 0.45 | 80% |
| 2012 [282] | Canada | 2008–2010 | Hospital (48 ICU beds) | NR | Prospective audit and feedback | High-risk antibiotics | 20% | Decreased | ^c | 1.12 | 0.71 | 37% |
| 2013 [283] | UK | 2008–2011 | Hospital (215) | NR | Restrictive use | Ceftriaxone and ciprofloxacin | 70%–90% | NR | ^c | 2.398 | 1.2 | 50% |
| 2011 [284] | Ireland | 2004–2009 | Hospital (665) | 027 | Restrictive use | Quinolones | >90% | NR | ^c | 0.8 | 0.746 | ^d |
| 2012 [285] | Ireland | 2004–2010 | Hospital (233) | NR | Restrictive use | High-risk antibiotics | 70%–90% | Decreased | ^c | 0.8 | 0.7 | ^e |
| 2012 [286] | US | 2007–2010 | LTCF (160) | NR | Prospective audit and feedback | High-risk antibiotics | 25%–50% | Decreased | ^c | NR | NR | ^f |

Abbreviations: CDI, *Clostridium difficile* infection; ICU, intensive care unit; LTCF, long-term care facility; NR, not reported; UK, United Kingdom; US, United States.

^aCDI cases per 1000 hospital discharges.

^bCDI cases per month.

^cCDI cases per 10000 patient-days.

^dEach defined daily dose reduction in quinolone per 100 bed-days resulted in reduced incidence of CDI by 0.054 cases per 100 bed-days.

^eCDI incidence rate decreased by 0.0047/100 bed-days per month. 8

^fCDI rates reduced by 0.2 cases per 1000 patient-days.

discontinued, there is insufficient evidence for discontinuation of PPIs as a measure for preventing CDI (*no recommendation*).

Summary of the Evidence

There is a clinical association between PPI use and CDI [290–293]. Three recent meta-analyses assessed the association between PPI use and the risk for CDI using data from >47 studies containing >300 000 patients. All studies demonstrated significant heterogeneity in the dataset, and 2 of 3 noted publication bias (the third did not perform this analysis due to underlying heterogeneity of data). Kwok et al assessed 42 total studies (30 case-control; 12 cohort) totaling 313 000 patients [290]. Summary odds ratios (ORs) were presented for incident cases of CDI (OR, 1.74; 95% CI, 1.47–2.85) as well as recurrent CDI (OR, 2.51; 95% CI, 1.16–5.44). Concomitant use of non-*C. difficile* antibiotics increased the risk of CDI with PPI usage (OR, 1.96; 95% CI, 1.03–3.70). Histamine type 2 receptor antagonists had decreased risk of CDI compared to PPI use. Janarthan et al assessed 23 total studies (17 case-control and 6 cohort) totaling 288 620 patients [293]. Incidence of CDI increased with exposure to PPIs (OR, 1.69; 95% CI, 1.34–1.97). There was no difference in the summary OR if the analysis was limited to cohort (OR, 1.66; 95% CI, 1.23–2.24) or case-control studies (OR, 1.65; 95% CI, 1.38–1.98). Finally, Tleyjeh assessed 47 total studies (37 case control and 14 cohort) [291]. Incidence of CDI increased with exposure to PPIs (OR, 1.69; 95% CI, 1.34–1.97). Two studies assessed the number of cases likely to occur with the addition of PPI therapy. Number needed to harm was higher for the general population (range, 899–3925) compared with hospitalized patients not on concomitant antibiotics (range, 202–367), or hospitalized patients receiving concomitant antibiotics (range, 28–50). Despite clinical data showing consistently increased risk, heterogeneity of the data, role of unknown confounders, lack of dose–response relationships, and other methodologic considerations are considerable limitations to the practical application of these data.

A number of further observational studies have investigated the association between PPI use and CDI after publication of these meta-analyses [27, 294–297]. A large, population surveillance study of 984 patients with community-associated CDI showed that 31% of patients with CDI who did not receive antibiotics did receive a PPI [27]. Three studies investigated the association between PPI usage and recurrent CDI in 1627 patients [294, 295, 297]. Two of the 3 studies did not show an association between PPI use and recurrent CDI. Finally, a study of 483 patients colonized with *C. difficile* showed that exposure to PPI increased the risk of developing CDI [296]. Thus, there appears to be a clinical association between PPI use and CDI, but the true causal relationship is unclear. No RCTs or quasi-experimental studies have studied the relationship between discontinuing or avoiding PPI use and risk of CDI. Thus, a recommendation to globally discontinue PPIs in patients at high

risk for CDI or recurrent CDI regardless of need for PPI will require further causal proof. However, stewardship activities to discontinue unneeded PPIs are warranted.

XXVII. What is the role of probiotics in primary prevention of CDI?

Recommendation

1. There are insufficient data at this time to recommend administration of probiotics for primary prevention of CDI outside of clinical trials (*no recommendation*).

Summary of the Evidence

Several meta-analyses indicate probiotics may be effective at preventing CDI when given to patients on antibiotics who do not have a history of CDI [298–300]. The typical CDI incidence among hospitalized people >65 years of age on antibiotics with a length of stay >2 days is ≤3%, even during outbreaks of CDI [21, 36, 248]. The studies with the greatest influence on the results of the meta-analyses had a CDI incidence 7–20 times higher in the placebo arms than would otherwise be expected based on the patient population studied, potentially biasing the results to benefit of the probiotic [301, 302]. When these studies are excluded, a trend toward a reduction in CDI remains, but it is not as great as when these studies are included. Many limitations remain when the studies with extremely high CDI incidence are excluded, including differences in probiotic formulations studied, duration of probiotic administration, definitions of CDI, duration of study follow-up, and inclusion of patients not typically considered at high risk for CDI. There is also the potential for organisms in probiotic formulations to cause infections in hospitalized patients [303–305]. Due to these issues, there are insufficient data to recommend administration of probiotics for primary prevention of CDI.

TREATMENT

XXVIII. What are important ancillary treatment strategies for CDI?

Recommendations

1. Discontinue therapy with the inciting antibiotic agent(s) as soon as possible, as this may influence the risk of CDI recurrence (*strong recommendation, moderate quality of evidence*).
2. Antibiotic therapy for CDI should be started empirically for situations where a substantial delay in laboratory confirmation is expected, or for fulminant CDI (described in section XXX) (*weak recommendation, low quality of evidence*).

Summary of the Evidence

Discontinuation of inciting antibiotic agent(s) as soon as possible should always be considered as their continued use has been shown

to decrease clinical response and increase recurrence rates [292, 306]. Antibiotic therapy should be started empirically if a substantial delay in laboratory confirmation is expected (eg, >48 hours) or if a patient presents with fulminant CDI. For other patients, antibiotic therapy should be started after diagnosis to limit overuse of antibiotics and associated toxicities including overgrowth of multidrug-resistant pathogens [307]. Historically, administering antimotility agents to patients with diarrhea without consideration or specific therapy for CDI has led to bad outcomes. Addition of an antimotility agent such as loperamide as an adjunct to specific antibacterial therapy for CDI may be safe, although no prospective or randomized studies are available [308, 309].

XXIX. What are the best treatments of an initial CDI episode to ensure resolution of symptoms and sustained resolution 1 month after treatment?

Recommendations

1. Either vancomycin or fidaxomicin is recommended over metronidazole for an initial episode of CDI. The dosage is vancomycin 125 mg orally 4 times per day or fidaxomicin 200 mg twice daily for 10 days (*strong recommendation, high quality of evidence*) (Table 1).
2. In settings where access to vancomycin or fidaxomicin is limited, we suggest using metronidazole for an initial episode of nonsevere CDI only (*weak recommendation, high quality of evidence*). The suggested dosage is metronidazole 500 mg orally 3 times per day for 10 days. Avoid repeated or prolonged courses due to risk of cumulative and potentially irreversible neurotoxicity (*strong recommendation, moderate quality of evidence*). (See Treatment section for definition of CDI severity.)

Summary of the Evidence

For 30 years, metronidazole and oral vancomycin have been the main antibiotic agents used in the treatment of CDI. Consensus on optimal treatment of CDI is evolving with the availability of new data on established agents and introduction of a new, FDA-approved drug, fidaxomicin. Two RCTs conducted in the 1980s and 1990s that compared metronidazole therapy and vancomycin therapy found no difference in outcomes but included <50 patients per study arm [168, 310]. However, since 2000, additional randomized, placebo-controlled trials have shown that oral vancomycin was superior to metronidazole (Table 6) [170, 188]. The first study assessed clinical cure rates of 150 patients with CDI given oral metronidazole 250 mg 4 times daily (n = 79) compared to oral vancomycin 125 mg 4 times daily (n = 71) [188]. Cure was superior for all patients given oral vancomycin (97%) compared to metronidazole (84%; $P < .006$). Clinical cure superiority was also observed in 69 patients with

severe disease given vancomycin (97%) compared to metronidazole (76%; $P = .02$). The second publication was a combined analysis of 2 multinational studies that compared the efficacy of tolevamer (n = 563), a toxin-binding polymer, with oral vancomycin 125 mg 4 times daily (n = 266) and oral metronidazole 250 mg 4 times daily (n = 289) [170]. Tolevamer was inferior to both metronidazole and vancomycin ($P < .001$). Metronidazole clinical response rates (72.7%) were also inferior to vancomycin (81.1%) response rates ($P = .02$). Combined, these RCTs published since 2000 demonstrated that metronidazole was inferior to oral vancomycin for clinical cure in patients with CDI ($P = .002$). These studies also demonstrated that metronidazole was inferior to oral vancomycin for resolution of diarrhea at end of treatment without CDI recurrence 21–30 days after treatment ($P = .002$). A recent retrospective study of hospitalized patients with mild-to-moderate CDI found that metronidazole was inferior to vancomycin for treatment response in this population as well [311].

Nearly all randomized trials have compared 10-day regimens of CDI treatment agents, and 10 days should be sufficient to resolve symptoms in most patients. However, some patients may have delayed response to treatment, particularly those treated with metronidazole [309]. The recent randomized trial data (Table 6) [170, 188] have confirmed prior observational studies that demonstrated decreased effectiveness of oral metronidazole [312, 313]. If patients have improved, but have not had symptom resolution by 10 days, extension of the treatment duration to 14 days should be considered [314]. Use of oral metronidazole, however, should be restricted to an initial episode of nonsevere CDI in cases where other therapies are contraindicated or not available (Tables 4 and 5), and treatment should be limited to one course due to case reports of neurotoxicity with prolonged or repeated use [315, 316]. Although cost and utilization analyses were not specifically addressed in these guidelines, compounding of the intravenous formulation of vancomycin for oral administration has been used as a less expensive alternative when barriers to use of the capsular form of vancomycin exist (Table 7).

The previous IDSA/SHEA guidelines used severity criteria to guide treatment decisions, and use of vancomycin in particular. The criteria used were based on expert opinion and had not been validated at the time. Subsequently, other severity criteria [188] have been used to document improved clinical response rates for patients with severe CDI who received vancomycin as opposed to metronidazole [317].

Several recent studies have evaluated potential factors for correlation with disease severity [318] or treatment outcome [319, 320]. The data base of the recent phase 3 fidaxomicin vs vancomycin treatment trials has been used to develop [319, 320] and validate [321] factors that might predict treatment failure [319] or cure [320]. Bauer et al found that fever

Table 6. Evidence for Resolution of Symptoms and Sustained Resolution ~1 Month (21–30 Days) After Treatment for Specific *Clostridium difficile* Treatment Agents

| Outcomes | No. of Participants (No. of Studies) | Percentage Resolution | Relative Effect ^a (95% CI) | P Value | Quality of Evidence (GRADE) ^b | Reference, First Author |
|--|--|------------------------------------|--|---------|---|--------------------------------|
| Direct comparisons of metronidazole and vancomycin | | | | | | |
| Resolution of diarrhea at end of (10 days) treatment | RCTs prior to 2000: 156 (2) | 95 (MTR) 98 (VAN) | RR, 0.97 (.91–1.03) | .4 | | Teasley [168] Wenisch [310] |
| | RCTs since 2000: 687 ^c (3) | 75 (MTR) 85 (VAN) | RR, 0.89 (.82–.96) | .002 | | Zar [188] Johnson [170] |
| | All RCTs: 843 (5) | 78 (MTR) 87 (VAN) | RR, 0.89 (.85–.96) | .0008 | ⊕⊕⊕⊕ High | |
| Resolution of diarrhea at end of treatment without CDI recur- rence ~1 month after treatment | RCTs prior to 2000: 156 (2) | 85 (MTR) 84 (VAN) | RR, 1.0 (.90–1.2) | 1.0 | | Teasley [168] Wenisch [310] |
| | RCTs since 2000: 687 ^c (3) | 59 (MTR) 70 (VAN) | RR, 0.84 (.74–.94) | .002 | | Zar [188] Johnson [170] |
| | All RCTs: 843 (5) | 63 (MTR) 73 (VAN) | RR, 0.87 (.79–.96) | .003 | ⊕⊕⊕⊕ High | |
| Direct comparisons of fidaxomicin and vancomycin | | | | | | |
| Resolution of diarrhea at end of (10 days) treatment | 1105 ^d (2) | 88 (FDX) 86 (VAN) | RR, 1.0 (.98–1.1) | .36 | ⊕⊕⊕⊕ High | Louie [321] Cornely [324] |
| Resolution of diarrhea at end of treatment without CDI recur- rence ~1 month after treatment | 1105 ^d (2) | 71 (FDX) 57 (VAN) | RR, 1.2 (1.1–1.4) | <.0001 | ⊕⊕⊕⊕ High | Louie [321] Cornely [324] |
| Direct comparisons of FMT and vancomycin | | | | | | |
| Resolution of diarrhea at end of treatment without CDI recur- rence 56 days after treatment | 29 (1) | 81 (FMT) 31 (VAN ^e) | RR, 2.6 (1.1, 6.2) | .01 | ⊕⊕⊕⊖ Moderate | van Nood [367] |

Abbreviations: CDI, *Clostridium difficile* infection; CI, confidence interval; FDX, fidaxomicin; FMT, fecal microbiota transplantation; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; MTR, metronidazole; RCT, randomized controlled trial; RR, relative risk; VAN, vancomycin.

^aAll relative risks calculated using vancomycin as the comparator agent. An RR <1.0 represents results favoring the use of vancomycin; an RR >1.0 represents results favoring the comparator.

^bFor GRADE interpretation, see Figure 1.

^cFull analysis set. Population in the 2 phase 3 tolevamer trials published in the same journal article [170].

^dModified intention-to-treat population (combined analysis of both phase 3 fidaxomicin trials [390]).

^eA second control group of 13 patients who received a bowel lavage in addition to vancomycin was included in this study. The RR for this comparison (FMT vs VAN + lavage) was 3.5 (95% CI, 1.1–9.8).

(>38.5°C), WBC count >15 × 10⁹/L, and creatinine >1.5 mg/dL correlated with treatment failure and that timing of measurement with respect to the positive stool *C. difficile* assay influenced the values of the variables [319]. Miller et al [320] measured 6 different factors individually and in various combinations to look for correlation with cure following treatment. WBC count was the only single factor that correlated with cure and a score based on a combination of age, treatment with non-CDI systemic antibiotics, leukocyte (WBC) count, albumin, and serum creatinine (ATLAS) was the most discriminatory. The ATLAS score showed excellent predictive value in the validation cohort, although it was designed as a continuous variable and the optimal cutoff score was not clear. In addition, severely ill patients were not included and metronidazole treatment response was not evaluated.

As a practical measure, we continue to recommend WBC count and serum creatinine as supportive clinical data for the

diagnosis of severe CDI, but have changed the creatinine value to an absolute value as opposed to the previous comparison to baseline values, which are not always available [322] (Table 1). Further validation of these criteria is still needed, and these criteria do not perform well for patients with underlying hematologic malignancies [323] or renal insufficiency [322].

Two RCTs compared oral vancomycin to oral fidaxomicin for the treatment of CDI [321, 324]. Primary and secondary endpoints were resolution of diarrhea at the end of the 10-day treatment course and resolution of diarrhea at the end of treatment without CDI recurrence 25 days after treatment, respectively. In total, 1105 patients were enrolled and eligible for the intention-to-treat analysis. Resolution of diarrhea was similar in patients given fidaxomicin (88%) or vancomycin (86%) (RR, 1.0; 95% CI, .98–1.1). Resolution of diarrhea at end of treatment without recurrence 25 days after treatment (sustained clinical response) was superior for fidaxomicin (71%) compared to vancomycin

Table 7. Potential Treatment Agents for Treatment of the Primary *Clostridium difficile* Infection Episode

| Agent | Adult Dose | Cost ^a | Initial Treatment Response ^b | Recurrence Risk ^b | Resistance in Clinical Isolates | Adverse Events | Evidence Supporting Efficacy |
|--|-------------------------------|----------------------|---|------------------------------|---|--------------------------------|---|
| Proven efficacy | | | | | | | |
| Vancomycin | 125 mg PO qid × 10 days | \$\$\$\$ \$ (Liq) | +++ | ++ | Not reported | Minimally absorbed | Multiple RCTs; US FDA approved |
| Fidaxomicin | 200 mg PO bid × 10 days | \$\$\$\$ | +++ | + | One clinical isolate with increased MIC | Minimally absorbed | Two phase 3 RCT comparisons to vancomycin; US FDA approved |
| Metronidazole | 500 mg PO tid × 10 days | \$ | ++ | ++ | Increased MIC reported in some studies; hetero-resistance also reported | Neuropathy, nausea | Multiple RCTs |
| Probable efficacy | | | | | | | |
| Nitazoxanide | 500 mg PO bid × 10 days | \$ | +++ | ++ | Not reported | GI symptoms | Small RCT comparison to vancomycin and a modest-sized RCT comparison to metronidazole |
| Fusidic acid | 250 mg PO tid × 10 days | NA in United States | ++ | ++ | Reported to develop in vivo resistance | GI symptoms | Modest-sized RCT comparison to metronidazole and a small RCT comparison to vancomycin |
| Inadequate data to support efficacy | | | | | | | |
| Rifaximin | 400 mg PO tid × 10 days | \$\$\$ | ++ | + | Potential for development of high-level resistance | Minimally absorbed | 1 small RCT comparison to vancomycin for primary treatment; case series and 1 RCT pilot study show promise for use as a post-vancomycin, "chaser" strategy in management of recurrent CDI |
| Tigecycline | 50 mg IV every bid × 10 days | \$\$\$\$ | ++? | ? | Not reported | GI symptoms | Case reports and small case series |
| Bacitracin | 25 000 units PO qid × 10 days | \$\$ | + | + | Increasing resistance noted | Minimally absorbed, poor taste | Two small RCT comparisons to vancomycin |

Abbreviations: bid, twice daily; CDI, *Clostridium difficile* infection; FDA, Food and Drug Administration; GI, gastrointestinal; IV, intravenous; Liq, liquid formulation of vancomycin compounded from powder intended for intravenous administration; MIC, minimum inhibitory concentration; NA, not available; PO, oral; qid, 4 times daily; RCT, randomized controlled trial; tid, 3 times daily.

^aAll prices are estimated in US dollars as quoted from Red Book Online Search, Micromedex Solutions, last accessed on 10 March 2015 or approximated hospital pharmacy pricing (tigecycline, bacitracin). \$, \$0–100; \$\$, \$101–500; \$\$\$, \$501–1000; \$\$\$\$\$, >\$1000.

^b+, lowest; ++, intermediate; +++, highest; ?, unknown.

(57%) (RR, 1.2; 95% CI, 1.1–1.4). A post hoc exploratory time to event meta-analyses from the 2 studies investigated a composite endpoint of persistent diarrhea or CDI recurrence or death over 40 days in patients given fidaxomicin or vancomycin [325]. Fidaxomicin reduced the incidence of the composite endpoint by 40% compared to vancomycin (95% CI, 26%–51%; $P < .001$), primarily due to decreased recurrence in patients given fidaxomicin. Deaths within the first 12 days of therapy occurred in 7 of 572 patients given fidaxomicin and 17 of 592 given vancomycin ($P = .06$). The effect of fidaxomicin compared to vancomycin was reduced in patients infected with the epidemic BI strain (HR, 0.78; 95% CI, .51–1.19) compared to non-BI strains (HR, 0.30; 95% CI, .19–.46). Finally, a subanalysis from the North American study demonstrated that patients treated with fidaxomicin were less likely to have acquisition and overgrowth of vancomycin-resistant *Enterococcus* and *Candida* species [326]. However, subpopulations of VRE with elevated fidaxomicin minimum inhibitory concentrations (MICs) were common, suggesting that this effect may change over time if enterococci resistance to fidaxomicin becomes common.

Although these data were derived from 2 separate studies and patients with fulminant CDI were not included, both studies included the same treatment protocols and >1000 patients were randomized in a double-blinded manner. Based on these 2 large clinical trials and meta-analyses, fidaxomicin should be considered along with vancomycin as the drug of choice for an initial episode of CDI.

Additional treatment agents that are probably effective, but have less supportive evidence and which have not received FDA approval, include nitazoxanide and fusidic acid (Table 7). Additional agents with inadequate evidence to recommend treatment of an initial CDI episode include rifaximin, tigecycline, and bacitracin (Table 7). Rifaximin, however, has been more extensively studied as an adjunctive postvancomycin treatment regimen in patients with recurrent CDI (see section XXXI). One potential concern for use of rifaximin is the potential for resistance. Isolates with high MICs (>256 µg/mL) and development of high MICs during treatment with rifaximin are well documented [327].

XXX. What are the best treatments of fulminant CDI?

Recommendations

1. For fulminant CDI*, vancomycin administered orally is the regimen of choice (*strong recommendation, moderate quality of evidence*). If ileus is present, vancomycin can also be administered per rectum (*weak recommendation, low quality of evidence*). The vancomycin dosage is 500 mg orally 4 times per day and 500 mg in approximately 100 mL normal saline per rectum every 6 hours as a retention enema. Intravenously administered metronidazole should be administered together with oral or rectal vancomycin, particularly if ileus is present (*strong recommendation, moderate quality of evidence*). The metronidazole dosage is 500 mg intravenously every 8 hours.*

*Fulminant CDI, previously referred to as severe, complicated CDI, may be characterized by hypotension or shock, ileus, or megacolon.

2. If surgical management is necessary for severely ill patients, perform subtotal colectomy with preservation of the rectum (*strong recommendation, moderate quality of evidence*). Diverting loop ileostomy with colonic lavage followed by antegrade vancomycin flushes is an alternative approach that may lead to improved outcomes (*weak recommendation, low quality of evidence*).

Summary of the Evidence

Vancomycin, administered orally at high dosage, has been the historical recommendation for fulminant CDI and there remains a lack of high-quality evidence to support this recommendation. If an ileus is present, then vancomycin can also be administered per rectum even though it is unclear whether a sufficient quantity of the drug reaches beyond the left colon [44, 328, 329]. Despite the lack of data, it seems prudent to administer vancomycin by oral and/or rectal routes at higher dosages for patients with fulminant CDI (500 mg 6 hourly by mouth and 500 mg in approximately 100 mL of normal saline by retention enema). Use of high doses of vancomycin is safe, but serum concentrations have been noted with high doses, prolonged exposure, renal failure, and disrupted intestinal epithelial integrity [330]. Hence, it may be appropriate to monitor trough serum concentration in such circumstances to rule out drug accumulation.

In fulminant CDI, intravenously administered metronidazole (500 mg every 8 hours) should be used in addition to vancomycin [331]. This is especially important if ileus is present as this may impair the delivery of orally administered vancomycin to the colon, but intravenously administered metronidazole is likely to achieve therapeutic concentrations in an inflamed colon. In patients not responding to vancomycin and metronidazole, intravenously administered tigecycline (loading dose of 100 mg followed by 50 mg 2 times per day) or passive immunotherapy

with intravenous immunoglobulins (150–400 mg/kg) has been used, but no controlled trials have been performed [332–337]. Surgical intervention can be life-saving for selected patients [338]. A rising WBC count (≥ 25000) or a rising lactate level (≥ 5 mmol/L) is associated with high mortality and may be helpful in identifying patients whose best hope for survival lies with early surgery [338]. Subtotal colectomy is the established surgical procedure for patients with megacolon, colonic perforation, an acute abdomen, or for patients with septic shock and associated organ failure (renal, respiratory, hepatic, or hemodynamic compromise) [338, 339]. More recently, an alternative procedure has been proposed (loop ileostomy with antegrade vancomycin lavage) as a colon-preserving, less invasive (usually laparoscopic), and less morbid approach that warrants further investigation as it may lead to improved outcomes as well as colon salvage [340].

XXXI. What are the best treatments for recurrent CDI?

Recommendations

1. Treat a first recurrence of CDI with oral vancomycin as a tapered and pulsed regimen rather than a second standard 10-day course of vancomycin (*weak recommendation, low quality of evidence*), or
2. Treat a first recurrence of CDI with a 10-day course of fidaxomicin rather than a standard 10-day course of vancomycin (*weak recommendation, moderate quality of evidence*), or
3. Treat a first recurrence of CDI with a standard 10-day course of vancomycin rather than a second course of metronidazole if metronidazole was used for the primary episode (*weak recommendation, low quality of evidence*).
4. Antibiotic treatment options for patients with >1 recurrence of CDI include oral vancomycin therapy using a tapered and pulsed regimen (*weak recommendation, low quality of evidence*), a standard course of oral vancomycin followed by rifaximin (*weak recommendation, low quality of evidence*), or fidaxomicin (*weak recommendation, low quality of evidence*).
5. Fecal microbiota transplantation is recommended for patients with multiple recurrences of CDI who have failed appropriate antibiotic treatments (*strong recommendation, moderate quality of evidence*).
6. There are insufficient data at this time to recommend extending the length of anti-*C. difficile* treatment beyond the recommended treatment course or restarting an anti-*C. difficile* agent empirically for patients who require continued antibiotic therapy directed against the underlying infection or who require retreatment with antibiotics shortly after completion of CDI treatment, respectively (*no recommendation*).

Summary of the Evidence

The frequency of further episodes of CDI necessitating retreatment remains a major concern. Approximately 25% of patients

treated for CDI with vancomycin can be expected to experience at least 1 additional episode [321, 324]. Recurrent CDI results from the same or a different *C. difficile* strain but, in clinical practice, it is impossible to distinguish these 2 mechanisms [341, 342]. Diagnosis and management do not differ between the former (relapse) or the latter (new infection). Recurrence rates are significantly lower following treatment of an initial CDI episode with fidaxomicin as compared to vancomycin [321, 322, 324]. Risk factors for CDI recurrence are the administration of other antibiotics during or after initial treatment of CDI, a defective humoral immune response against *C. difficile* toxins, advancing age, and increasingly severe underlying disease [81, 343]. Continued use of PPIs has also been associated with an increased risk of recurrence [344, 345].

A first recurrence of CDI may be treated with oral vancomycin (particularly if metronidazole was used for the first episode), vancomycin followed by a tapered and pulsed regimen, or fidaxomicin. In a randomized, stratified substudy of patients with a first CDI recurrence, a subsequent, second recurrence was less common following therapy with fidaxomicin compared to a standard 10-day course of vancomycin (19.7% vs 35.5%; $P = .045$) [346]. Uncontrolled, postapproval experience with fidaxomicin suggests less efficacious responses in terms of cure and subsequent recurrence after treatment of patients with recurrent CDI, particularly ≥ 2 recurrences [347]. Oral vancomycin should be used as a tapered and pulsed-dose regimen if a standard 10-day course of vancomycin was used for the initial episode. Various regimens have been used and are similar to this one: After the usual dosage of 125 mg 4 times per day for 10–14 days, vancomycin is administered at 125 mg 2 times per day for a week, 125 mg once per day for a week, and then 125 mg every 2 or 3 days for 2–8 weeks, in the hope that *C. difficile* vegetative forms will be kept in check while allowing restoration of the normal microbiota. Metronidazole is not recommended for treatment of recurrent CDI as initial and sustained response rates are lower than for vancomycin (Table 7). Furthermore, metronidazole should not be used for long-term therapy because of the potential for cumulative neurotoxicity [348, 349].

Second or subsequent CDI recurrences may be treated with oral vancomycin as a tapered and pulsed-dose regimen as described above [350]. In a small RCT, patients received rifaximin 400 mg 3 times daily or placebo for 20 days immediately after completing standard therapy for CDI [195]. CDI recurrences occurred in 5 of 33 (15%) patients given rifaximin and in 11 of 35 (31%) patients given placebo ($P = .11$). Experience using fidaxomicin to treat multiply recurrent CDI is limited. There is little evidence that adding cholestyramine, colestipol, or rifampin to the treatment regimen decreases the risk of a further recurrence [351].

Several probiotics including *Saccharomyces boulardii* and *Lactobacillus* species have shown promise for the prevention of

CDI recurrence [352–354]. However, as yet, none has demonstrated significant and reproducible efficacy in controlled clinical trials.

Some patients need to receive other antibiotics during or shortly after the end of CDI therapy. These patients are at a higher risk of a recurrence and its attendant complications [81, 306, 343]. Many clinicians prolong the duration of treatment of CDI in such cases, until after the other antibiotic regimens have been stopped. Lower doses may be sufficient to prevent recurrence (eg, vancomycin 125 mg once daily). Whether this approach reduces the risk of CDI recurrence is unknown, but one retrospective study suggested no benefit for extension of CDI treatment beyond 10–14 days [355]. A similar concern is encountered among patients who have successfully completed treatment for CDI but subsequently are administered systemic antibiotics. Two retrospective cohort studies have been published looking at the risk of recurrent CDI in patients who received subsequent antibiotic exposure between those who were empirically treated with vancomycin during that exposure and those who were not [356, 357]. One of these studies looked at patients who received antibiotics within 90 days of the prior episode and one looked at patients who were rehospitalized (1–22 months later) and given systemic antibiotics. The vancomycin dose and regimen varied considerably, but both studies showed a decreased risk of subsequent CDI for some patients treated empirically with vancomycin. One study showed a decreased risk for those whose previous CDI episode was itself a recurrent CDI episode, but not for those following a primary CDI episode [356]. The obvious bias in these studies was the unknown factors that dictated prescribing oral vancomycin prophylaxis. In addition, the long-term benefit is unknown. To date there are no prospective, randomized studies of secondary prophylaxis of CDI to guide recommendations, but if the decision is to institute CDI prevention agents, it may be prudent to administer low doses of vancomycin or fidaxomicin (eg, 125 mg or 200 mg, respectively, once daily) while systemic antibiotics are administered. Factors that might influence the decision to administer secondary prophylaxis include length of time from previous CDI treatment, and patient characteristics (number of previous CDI episodes, severity of previous episodes, and underlying frailty of the patient).

Patients who have failed to resolve recurrent CDI despite repeated antibiotic treatment attempts present a particularly difficult challenge. Clinical investigations of patients with recurrent CDI have shown significant disruption of the intestinal microbiome diversity as well as relative bacterial population numbers. Instillation of processed stool collected from a healthy donor into the intestinal tract of patients with recurrent CDI has been used with a high degree of success to correct the intestinal dysbiosis brought about by repeated courses of antibiotic administration [358–361]. Anecdotal treatment success rates of fecal microbiota transplantation (FMT) for recurrent

CDI have been high regardless of route of instillation of feces, and have ranged between 77% and 94% with administration via the proximal small bowel [358, 362]; the highest success rates (80%–100%) have been associated with instillation of feces via the colon [360, 363–366]. By March 2016, >1945 patients (reported as single case reports and larger case series) with recurrent CDI had been described in the peer-reviewed literature (J. S. Bakken, unpublished data).

Despite the large number of anecdotal reports that have consistently demonstrated high efficacy of FMT, the first prospective randomized clinical trial that compared the outcome of standard antibiotic therapy to FMT was published in 2013 [367]. In this unblinded trial, van Nood and collaborators randomly assigned 43 patients with ≥ 2 recurrent episodes of CDI to receive either a standard 14-day course of oral vancomycin (13 patients), vancomycin with bowel lavage (13 patients), or a 4-day course of vancomycin followed by bowel lavage and subsequent FMT infusion administered through a nasoduodenal tube (17 patients) [367]. The primary endpoint was initial response without relapse for 10 weeks after completion of therapy. The investigation was terminated early after interim analysis, due to the marked difference in treatment outcomes. Thirteen of the 16 (81%) patients in the FMT arm had a sustained resolution of diarrhea after the first fecal infusion; only 7 of the 26 (27%) patients who were treated with vancomycin resolved their CDI ($P < .001$). Four additional randomized trials of FMT have been published through 2016 [368–371]. One of these trials compared FMT to antibiotic treatment [368] and the other 3 compared various refinements of the FMT product [370], delivery of the product [369], or FMT to autologous FMT [371]. In general, the reported efficacy of FMT is lower in most randomized trials than in nonrandomized reports. The largest of these randomized trials reported an efficacy of approximately 50% for one FMT delivered by enema, which increased to 75% for 2 FMT administrations and approximately 90% for >2 FMT administrations. Patient selection, proximity to recurrent CDI episode, and antibiotic treatment prior to FMT all likely influence response to FMT.

FMT has been well accepted by patients and represents a viable alternative treatment approach to an increasing clinical problem. Judged by the published literature, FMT appears to be safe in the short term [359, 367, 372, 373] and mild to moderate posttreatment adverse events are for the most part self-limited [374]. A recent retrospective multicenter case series report of 80 immunocompromised patients concluded that FMT was safe and well tolerated, although they included a heterogeneous group of conditions [375]. Reported infectious complications directly attributed to the instillation of donor feces has so far been limited to 2 patients who developed norovirus gastroenteritis after FMT for treatment of CDI despite use of asymptomatic donors and lack of sick contacts [376]. Physical complications from the FMT instillation procedure (upper gastrointestinal bleed after

nasogastric tube insertion, colon perforation during colonoscopy) has been occasionally reported and may occur with the same frequency as when these procedures are performed for gastrointestinal illnesses other than recurrent CDI. Potential unintended long-term infectious and noninfectious consequences of FMT are still unknown in the absence of large-scale controlled trials with sufficient follow-up.

Potential candidates for FMT include patients with multiple recurrences of CDI who have failed to resolve their infection despite treatment attempts with antibiotic agents targeting CDI. Although there are no data to indicate how many antibiotic treatments should be attempted before referral for FMT, the opinion of the panel is that appropriate antibiotic treatments for at least 2 recurrences (ie, 3 CDI episodes) should be tried. There are limited data on FMT administration in patients with severe, refractory CDI [377, 378]. FMT has also been used for treating recurrent CDI in patients with underlying IBD, although it appears to be less effective for this population compared to those without IBD [379], and flares of underlying disease activity have been reported following FMT for recurrent CDI in patients with IBD [379–381]. Once a patient has been found to be a candidate for FMT, an appropriate stool donor must be identified. Occult contagious pathogens may be present in the stool of a candidate FMT donor, which could potentially place the recipient at risk for a transmissible infection. Careful evaluation and selection of all candidate stool donors is therefore important to minimize the risk for an iatrogenic infection and to maximize the likelihood for a successful treatment outcome. The designated stool donor should undergo screening of blood and feces prior to the stool donation in accordance with recommendations recently published [372]. Detection of any transmissible microbial pathogen should disqualify the individual from donating stool. Individuals who have been treated with an antibiotic agent during the preceding 3 months of donating stool, and those with preexisting chronic medical conditions, such as IBD, malignant diseases, chronic infections, active autoimmune illnesses, or individuals who are receiving active treatment with immunosuppressive medication should also be disqualified from donating stool [372].

Most investigators have recommended that patients who are not receiving active antibiotic treatment prior to planned FMT should be placed on a brief “induction course” of oral vancomycin for 3–4 days prior to FMT administration to reduce the burden of vegetative *C. difficile*. The patient and the treating physician must also decide the route of FMT instillation, taking into consideration individual preferences and recognizing that the rate of success varies with the route of instillation [373].

TREATMENT (PEDIATRIC CONSIDERATIONS)

XXXII. What is the best treatment of an initial episode or first recurrence of nonsevere CDI in children?

Recommendation

1. Either metronidazole or vancomycin is recommended for the treatment of children with an initial episode or first recurrence of nonsevere CDI (see Pediatric treatment section for dosing) (*weak recommendation, low quality of evidence*) (Table 2).

Summary of the Evidence

Robust data assessing the optimal approach for treating an initial episode of CDI in children are limited, and evidence of the comparative effectiveness of metronidazole and vancomycin for treating pediatric CDI is lacking. There are no RCTs comparing the use of these agents in children. A few recent studies suggest that failure rates with metronidazole may be higher than traditionally reported, but these data have limitations. Kim et al [165] prospectively studied 82 children with CDI, of whom 56 received metronidazole; 6 (11%) of them had treatment failure, but half of these were children with severe disease. Khanna et al [125] performed a population-based cohort study of CDI epidemiology in children 0–18 years of age. Among 69 patients with community-acquired CDI, treatment failure rate was 18% for metronidazole and 0% for vancomycin, but these rates were not statistically different. In a survey of pediatric infectious diseases physicians by Sammons et al [382], 100% of respondents reported using metronidazole for initial therapy in healthy children with mild CDI, but the proportion fell to 41%–79% for treating mild CDI in children with underlying comorbidities. Schwenk et al [383] used a national administrative database to study vancomycin use for pediatric CDI and found that vancomycin use for initial therapy increased significantly between 2006 and 2011, with substantial variability between children's hospitals. Complications and mortality from CDI in children are uncommon, regardless of severity of disease or choice of antibiotic for treatment [125, 126, 158, 345].

Treatment recommendations for pediatric CDI should balance the accumulated experience of good outcomes with metronidazole for initial mild disease and emerging data in both adults and children, suggesting a possible difference in favor of vancomycin. At the current time there are insufficient pediatric data to recommend vancomycin over metronidazole as preferred treatment, so either metronidazole or vancomycin should be used for an initial episode or first recurrence of nonsevere CDI in children (Table 2). However, because oral vancomycin is not absorbed, the risk of side effects is lower than for metronidazole. Nonetheless, studies have demonstrated that vancomycin exposure promotes carriage of vancomycin-resistant enterococci in the intestinal flora of treated patients, although available data suggest that metronidazole use is also associated with this outcome [307, 384].

XXXIII. What is the best treatment of an initial episode of severe CDI in children?

Recommendation

1. For children with an initial episode of severe CDI, oral vancomycin is recommended over metronidazole (*strong recommendation, moderate quality of evidence*).

Summary of the Evidence

There are no well-designed trials that examine the comparative effectiveness of metronidazole and oral vancomycin for the initial treatment of children with severe CDI. As noted above, observational studies of hospitalized children with CDI suggest that the rate of treatment failure may be greater among children with severe disease as compared to those with nonsevere disease [345]. Although pediatric studies have not demonstrated conclusively that the therapeutic agent used to treat a child with severe CDI is associated with different outcomes, evidence from adult RCTs has demonstrated improved outcomes in adult patients with severe CDI who are treated with oral vancomycin compared with those treated with oral metronidazole. Therefore, clinicians should use vancomycin in children who present with severe or fulminant CDI (Table 2). Because fidaxomicin was not approved for use in patients <18 years of age, at the time of this writing, it is not recommended for routine use in the treatment of children with severe CDI, although a recent survey of pediatric infectious disease physicians revealed that it had been used or recommended by 12% of respondents [382]. Of note, neither vancomycin nor fidaxomicin is significantly absorbed when orally administered; thus, there are few systemic adverse events associated with these drugs.

XXXIV. What are the best treatments for a second or greater episode of recurrent CDI in children?

Recommendation

1. For children with a second or greater episode of recurrent CDI, oral vancomycin is recommended over metronidazole (*weak recommendation, low quality of evidence*).

Summary of the Evidence

There are no well-designed trials that examine the effectiveness of various treatment regimens in children with multiply recurrent CDI. In addition, pediatric studies have not demonstrated conclusively that there is a difference in the risk of recurrence related to the therapeutic agent used to treat an initial episode [125, 165]. Thus, recommendations about the therapeutic approach to children with multiply recurrent CDI must be guided by evidence drawn from the studies performed in adults

and an assessment of the theoretical benefits and harms associated with various treatment regimens. As described above, evidence from adult studies supports the use of an extended course of oral vancomycin (tapered or pulse regimen), oral vancomycin followed by rifaximin, or fidaxomicin in patients with multiply recurrent CDI. For children with a second recurrence of CDI who have been treated exclusively with metronidazole, a conventional course of oral vancomycin should be considered. For children with multiple recurrences of CDI despite conventional courses of metronidazole and oral vancomycin, an alternate therapeutic regimen should be used (Table 2).

Vancomycin, fidaxomicin, and rifaximin are not absorbed when orally administered; thus, there are few systemic adverse events associated with these drugs. Rifaximin has been approved by the FDA for the treatment of traveler's diarrhea in children ≥ 12 years of age but has been used in younger children with refractory IBDs [385] and small intestinal bacterial overgrowth [386] with few reports of adverse events. As noted above, fidaxomicin was not approved for use in patients < 18 years of age at the time of this writing. In contrast to vancomycin and fidaxomicin, repeated or prolonged exposure to metronidazole has been associated with neuropathies. Additional concerns have been voiced about the risk of resistance associated with the use of rifaximin.

XXXV. Is there a role for fecal microbiota transplantation in children with recurrent CDI?

Recommendation

1. Consider fecal microbiota transplantation for pediatric patients with multiple recurrences of CDI following standard antibiotic treatments (*weak recommendation, very low quality of evidence*).

Summary of the Evidence

Management of multiply recurrent CDI can be challenging. As detailed above, FMT restores gut microbiota diversity through instillation of donor stool into the gastrointestinal tract of patients with CDI. Good clinical response has been shown in adults with refractory or recurrent CDI with few reports of adverse events. At present, robust data examining the effectiveness of FMT for pediatric patients are lacking. Thus, recommendations regarding the therapeutic approach to multiply recurrent CDI in children should be guided primarily by evidence from adult studies. Limited evidence from case reports and case series in pediatric patients suggests that FMT via nasogastric tube or colonoscopy can be effective in children with multiply recurrent CDI who have failed standard antibiotic therapy, with follow-up periods up to 16 months [387, 388]. In most reported cases, fecal sample donation was from the child's mother or father [388]. Despite limited pediatric data, a survey of pediatric infectious diseases physicians revealed that 18% of respondents

who reported using alternative therapies for CDI had recommended FMT, most commonly for the treatment of a third or later recurrence [382]. Finally, the potential benefits of FMT must be balanced against theoretical risks.

As described above, instillation of donor stool typically requires use of nasogastric tube or colonoscopy, which may carry procedure-related risks. In addition, use of donor stool introduces the potential for transmission of resistant organisms and blood-borne pathogens, necessitating donor-screening protocols. There is a general concern that FMT might ultimately lead to unexpected adverse events such as metabolic or immune-based disorders [359].

RESEARCH GAPS

The initial step in developing a rational clinical research agenda is the identification of gaps in information. The process of guideline development, as practiced by SHEA and the IDSA, serves as a natural means by which such gaps are identified. Clinical questions identified by the IDSA/SHEA Expert Panel and by members of the IDSA Research Committee that could inform a *C. difficile* research agenda are listed below.

Epidemiology

What is the epidemiology of CDI? What is the incubation period of *C. difficile*? What is the infectious dose of *C. difficile*? How should hospital rates be risk-adjusted for appropriate interhospital comparisons? Does administration of PPIs increase the risk of CDI and, if so, what is the magnitude of risk? What are the sources for *C. difficile* transmission in the community? Is exposure to antibiotics (or equivalent agents, such as chemotherapy drugs) required for susceptibility to CDI? If not, what are the antibiotic surrogates or other factors that place patients at risk for CDI, particularly in the community? What is the role of asymptomatic carriers in transmission of *C. difficile* in the healthcare setting? What are the validated clinical predictors of severe CDI? Can clinical predictors of severe CDI in children be identified? At what age and to what degree is *C. difficile* pathogenic among infants and young children? How should clinically significant diarrhea be defined in infants and children who are not continent of stool? How should pediatric healthcare facilities conduct surveillance and report rates of *C. difficile* infection? Should data from infants < 12 months of age be included in laboratory-based surveillance and reporting?

Diagnostics

What is the role and optimal sequence for multistep testing for CDI? Is GDH detection in stool sufficiently sensitive as a screening test for *C. difficile* colitis? How well does GDH correlate with culture for toxigenic *C. difficile*? Which of the "gold standard" assays (culture for toxigenic *C. difficile* or cell culture cytotoxicity assay) is optimal as a reference test for diagnosis of CDI? Does screening by GDH test, coupled with confirmatory

testing for toxigenic *C. difficile* by cell culture cytotoxicity assay or NAAT for toxin genes, better identify patients with CDI than using NAAT alone? What should be done with patients who are positive by NAAT but toxin negative? What is the best diagnostic method for hospital laboratories that do not have molecular technology available?

What is the role for NAAT in the diagnosis of CDI? Is molecular testing for toxin genes too sensitive for clinical utility? Are there patient populations in whom a NAAT is method of choice?

Additional diagnostic research questions: Should infants and young children with diarrhea be tested for *C. difficile*? Which children in the ambulatory setting who present with diarrhea should be tested for *C. difficile*? Can new diagnostic tests be developed that will accurately distinguish colonization from infection? When should multiplex PCR test platforms for enteric pathogens be used for diagnosis of CDI? Should these platforms exclude *C. difficile* or should the *C. difficile* result be hidden given the availability of specific *C. difficile* diagnostics and the consideration of the different indications for testing (eg, traveler's diarrhea, hospital onset, antibiotic-associated diarrhea)? Should testing for *C. difficile* be performed on patients with ileostomy/colostomy?

Treatment

What is the best treatment for recurrent CDI? What is the best method to prevent recurrent CDI? What is the best way to restore colonization resistance of intestinal microbiota? When should fecal transplant be considered? Should specific commensal bacteria be administered in place of minimally screened fecal specimens from donors? What is the role of adjunctive therapy as new agents become available (eg, monoclonal antibodies [bezlotoxumab, a monoclonal antibody that binds to toxin B, received FDA approval at the time this guideline was being finalized], nontoxigenic *C. difficile*, toxin-binding agents). What is the role for new anti-*C. difficile* antibiotics that are being developed? Does the in vitro spectrum of activity of new CDI treatment agents against gut commensal bacteria predict clinical outcome with respect to CDI recurrence in clinical trials with these agents? Assuming an effective vaccine is developed, what population should be targeted? What is the best approach to treatment of fulminant CDI? What are the criteria for colectomy in a patient with fulminant CDI? Should diverting loop ileostomy be the preferred procedure over colectomy in this setting? What is the role of treatment with vancomycin or other antibiotics alone or in combination, or FMT in fulminant infection? What is the role of treatment with passive antibodies (immunoglobulin or monoclonal antibody therapy) in fulminant infection?

Additional treatment research questions: When should vancomycin be used to treat children with CDI? Is fidaxomicin safe and effective in children? How is a CDI episode best

distinguished from an IBD flare in patient with ulcerative colitis or Crohn's disease? What role does *C. difficile* play in IBD flares? How is CDI best managed in this population? Can postinfectious irritable bowel syndrome be distinguished from recurrent CDI?

Prevention

What preventive measures can be taken to reduce the incidence of CDI? What is the best method to identify patients at risk of primary or recurrent CDI? Can administration of probiotics or biotherapeutic agents effectively prevent CDI? What are the most effective antibiotic stewardship strategies to prevent CDI? What are the most effective transmission prevention strategies (ie, environmental management and isolation) to prevent CDI in inpatient settings? What is the incremental impact of each? Is there a core "bundle" infection control strategy that can be used by a wide-range of healthcare facilities? Can vaccination effectively prevent CDI, and what would be the composition of the vaccine and the route of administration? What are systemic or mucosal serologic markers that predict protection against CDI? What is the role of anti-CDI agents in secondary CDI prevention of CDI (patients successfully treated for CDI but who receive subsequent oral, intravenous, or intramuscular antibiotics)? What drugs, dosages, and duration? What patient characteristics should be considered for initiating secondary prophylaxis (eg, age, number of previous CDI episodes, and time since previous CDI episode)? What is the effect of screening patients on admission for *C. difficile* carriage and isolating positive *C. difficile* carriers on the incidence of hospital-acquired CDI?

Basic Research

What is the biology of *C. difficile* spores that leads to clinical infection? How do spores interact with the human gastrointestinal immune system? What are the triggers for sporulation and germination of *C. difficile* in the human gastrointestinal tract? Where does spore germination occur in the human gastrointestinal tract? What is the role of sporulation in recurrent *C. difficile* disease? What is the role of bile acid metabolism and the potential for using bile acid metabolites for CDI treatment intervention?

What is the basic relationship of *C. difficile* to the human gut mucosa and immune system? Where in the gut do *C. difficile* organisms reside? What enables *C. difficile* to colonize patients? What are the critical constituents of the microbiota that provide colonization resistance to *C. difficile*? Is there a *C. difficile* biofilm in the gastrointestinal tract? Is mucosal adherence necessary for development of CDI? Is there a nutritional niche that allows *C. difficile* to establish colonization? What is the role of mucosal and systemic immunity in preventing clinical CDI? What causes *C. difficile* colonization to end? Do *C. difficile*

toxins enter the circulation during infection? What are the factors in infants and young children that influence susceptibility to *C. difficile* infection vs asymptomatic colonization?

Notes

Acknowledgments. The expert panel expresses its gratitude for thoughtful reviews of an earlier version by Curtis Collins, PharmD of the ASHP, Christopher Ohl, MD, and Ellie Goldstein, MD. The panel greatly appreciates National Jewish Health for assistance with the literature searches and Valery Lavergne, MD, Paul Alexander, PhD, and Genet Demisashi of the IDSA for their assistance and support in the development of these guidelines.

Disclaimer. The findings and conclusions in this report are those of the author(s), and do not necessarily represent the official position of the CDC or the US Department of Veterans Affairs.

Financial support. Support for this guideline was provided by the IDSA and SHEA.

Potential conflicts of interest. The following list is a reflection of what has been reported to IDSA. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest (COI) is determined by a review process that includes assessment by the Standards and Practice Guidelines Committee (SPGC) Chair, the SPGC liaison to the development Panel, the Board of Directors liaison to the SPGC, and, if necessary, the COI Task Force of the Board. This assessment of disclosed relationships for possible COI will be based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. For activities outside of the submitted work, D. G. has served as board member for Rebiotix, Merck, Actelion, Summit, and DaVolterra; has served as a consultant for Pfizer, Sanofi Pasteur, and MGB Pharma; received a grant from Seres Therapeutics; and holds patents and technology for nontoxicogenic *C. difficile* for the treatment and prevention of CDI under NTCD, LLC. For activities outside of the submitted work, S. J. has served on the advisory board member for Bio-k+, Synthetic Biologics, Summit, Therapeutics, and CutisPharma; has served on Pfizer's data and safety monitoring board for vaccine study; and has received payment for lectures from Merck. For activities outside of the submitted work, K. C. has received research grants from GenePOC, Accelerate, and BD Diagnostics; has received royalties from McGraw-Hill and ASM Press; and has received travel expenses as board member with ASM. For activities outside of the submitted work, S. C. has received payment as expert testimony for medical-legal consultation; has received research grants from the Agency for Health Research and Quality, CDC, and National Institutes of Health (NIH); and has received payment for lectures from IDSA, CDC, and American Academy of Pediatrics. For activities outside of the submitted work, E. R. D. has served as a consultant for Sanofi Pasteur, Nestle, Valneva, Pfizer, Rebiotix, GSK, and Merck; has received research grants from Sanofi Pasteur, Pfizer, Merck, and Rebiotix; and has received payment for lectures from Alere and Biofire. For activities outside of the submitted work, K. G. has received research grants from Merck & Co, Summit Pharmaceuticals, and Techlab, served as a consultant for bioMérieux, Merck & Co, and Summit Pharmaceuticals; and received payment for the development of educational presentation by bioMérieux and Merck & Co. For activities outside of the submitted work, C. K. has received research grants from the NIH, Institut Mérieux, and Aptalis; has received personal fees serving as scientific advisor for Facile Therapeutics, Summit (Oxford), Synthetic Biologics, Actelion, Artugen, First Light Diagnostics, Finch, GlaxoSmithKline, Merck, Seres Therapeutics, Summit, Vedanta, Celimmune, Cour Pharma, Takeda, Innovate, Valeant, and ImmunogenX; and has received payment for the development of educational presentations by Merck and Seres. For activities outside of the submitted work, V. L. has served as a consultant for Merck, and received payment for serving on the speaker's bureau for Merck. For activities outside of the submitted work,

J. S. has received grants from CDC Epicenters. For activities outside of the submitted work, M. W. has received research grants, consultancy/lecture fees from Actelion, Cubist, Astellas, Optimer, Sanofi Pasteur, Summit, Seres, bioMérieux, Da Volterra, Qiagen, and Pfizer; served as a consultant for Merck, Valneva, Alere, AstraZeneca, Durata, Nabriva, Pfizer, Roche, The Medicines Company, Abott, Basilea, and the European Tissue Symposium; and received research grants from Cerexa, Abbott, and the European Tissue Symposium. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Going from evidence to recommendations. *BMJ* **2008**; 336:1049–51.
- Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Incorporating considerations of resources use into grading recommendations. *BMJ* **2008**; 336:1170–3.
- Jaeschke R, Guyatt GH, Dellinger P, et al; GRADE Working Group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. *BMJ* **2008**; 337:a744.
- US GRADE Network. Approach and implications to rating the quality of evidence and strength of recommendations using the GRADE methodology, 2015. Available at: <http://www.gradeworkinggroup.org/>. Accessed 1 July 2015.
- Dubberke ER, Olsen MA. Burden of *Clostridium difficile* on the healthcare system. *Clin Infect Dis* **2012**; 55(Suppl 2):S88–92.
- Lessa FC, Mu Y, Bamberg WM, et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med* **2015**; 372:825–34.
- Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of *Clostridium difficile* and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. *Clin Infect Dis* **2012**; 55:216–23.
- US Centers for Medicare and Medicaid Services. CMS requirements: CMS resources for NHSN users 2015. Available at: <http://www.cdc.gov/nhsn/cms/>. Accessed 15 December 2015.
- US Centers for Medicare and Medicaid Services. Fiscal year (FY) 2016 results for the CMS hospital value-based purchasing program. **2015**. Available at: <https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2015-Fact-sheets-items/2015-10-26.html>. Accessed 15 December 2015.
- Wilcox MH, Gerding DN, Poxtton IR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent *Clostridium difficile* infection. *N Engl J Med* **2017**; 376:305–17.
- Zhang H, Morrison S, Tang YW. Multiplex polymerase chain reaction tests for detection of pathogens associated with gastroenteritis. *Clin Lab Med* **2015**; 35:461–86.
- Institute of Medicine of the National Academies. Clinical practice guidelines we can trust: standards for developing trustworthy clinical practice guidelines (CPGs). **2011**. Available at: <http://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx>. Accessed 1 March 2013.
- Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. *J Clin Epidemiol* **2015**; 68:597–600.
- Infectious Diseases Society of America. IDSA disclosure of interests policy for clinical practice guidelines. Handbook on clinical practice guideline development. **2013**. Available at: http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/Guidelines_By_Others/IDSA%20Handbook%20on%20CPG%20Development%20for%20Web%2010.13.pdf. Accessed 11 January 2018.
- Dubberke E, Butler A, Hota B, et al. Impact of community-onset infections on surveillance for *Clostridium difficile* infections: a multicenter study. *Infect Control Hosp Epidemiol* **2009**; 30:518–25.
- Centers for Disease Control and Prevention. Multidrug-resistant organism and *Clostridium difficile* infection (MDRO/CDI) module. **2016**. Available at: http://www.cdc.gov/nhsn/pdfs/pscmanual/12pscmdro_cdadcurrent.pdf. Accessed 9 March 2016.
- Centers for Disease Control and Prevention. The NHSN standardized infection ratio (SIR): a guide to the SIR. **2017**. Available at: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>. Accessed 11 January 2018.
- Gould CV, Edwards JR, Cohen J, et al; *Clostridium difficile* Infection Surveillance Investigators, Centers for Disease Control and Prevention. Effect of nucleic acid amplification testing on population-based incidence rates of *Clostridium difficile* infection. *Clin Infect Dis* **2013**; 57:1304–7.
- Moehring RW, Lofgren ET, Anderson DJ. Impact of change to molecular testing for *Clostridium difficile* infection on healthcare facility-associated incidence rates. *Infect Control Hosp Epidemiol* **2013**; 34:1055–61.

20. Zilberberg MD, Tabak YP, Sievert DM, et al. Using electronic health information to risk-stratify rates of *Clostridium difficile* infection in US hospitals. *Infect Control Hosp Epidemiol* **2011**; 32:649–55.
21. Dubberke ER, Butler AM, Yokoe DS, et al. Multicenter study of *Clostridium difficile* infection rates from 2000 to 2006. *Infect Control Hosp Epidemiol* **2010**; 31:1030–7.
22. Tenover FC, Novak-Weekley S, Woods CW, et al. Impact of strain type on detection of toxigenic *Clostridium difficile*: comparison of molecular diagnostic and enzyme immunoassay approaches. *J Clin Microbiol* **2010**; 48:3719–24.
23. Lee Y, Kim M, Kim H, Lee K. Comparison of sensitivity of enzyme immunoassays for toxin A and B in different *C. difficile* PCR ribotypes. *Ann Clin Lab Sci* **2014**; 44:38–41.
24. Thompson ND, Edwards JR, Dudeck MA, Fridkin SK, Magill SS. Evaluating the use of the case mix index for risk adjustment of healthcare-associated infection data: an illustration using *Clostridium difficile* infection data from the National Healthcare Safety Network. *Infect Control Hosp Epidemiol* **2016**; 37:19–25.
25. Centers for Disease Control and Prevention. Vital signs: prevention *Clostridium difficile* infection. *MMWR Morb Mortal Wkly Rep*. **2012**. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6109a3.htm>. Accessed 9 March 2016.
26. Centers for Disease Control and Prevention. Emerging Infections Program—healthcare-associated infections projects. **2015**. Available at: <http://www.cdc.gov/hai/eip/index.html>. Accessed 9 March 2016.
27. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community-associated *Clostridium difficile* infection, 2009 through 2011. *JAMA Intern Med* **2013**; 173:1359–67.
28. Magill SS, Edwards JR, Bamberg W, et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med* **2014**; 370:1198–208.
29. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated *Clostridium difficile* infection and of healthcare-associated infection due to methicillin-resistant *Staphylococcus aureus* in community hospitals. *Infect Control Hosp Epidemiol* **2011**; 32:387–90.
30. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). **2016**. Available at: <http://hcupnet.ahrq.gov/>. Accessed 9 March 2016.
31. Centers for Disease Control and Prevention. National and state healthcare-associated infections progress report. **2016**. Available at: <http://www.cdc.gov/HAI/pdfs/progress-report/hai-progress-report.pdf>. Accessed 9 March 2016.
32. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE, SHEA Long-Term-Care Committee. *Clostridium difficile* in long-term-care facilities for the elderly. *Infect Control Hosp Epidemiol* **2002**; 23:696–703.
33. Walker KJ, Gilliland SS, Vance-Bryan K, et al. *Clostridium difficile* colonization in residents of long-term care facilities: prevalence and risk factors. *J Am Geriatr Soc* **1993**; 41:940–6.
34. Hunter JC, Mu Y, Dumyati GK, et al. Burden of nursing home-onset *Clostridium difficile* infection in the United States: estimates of incidence and patient outcomes. *Open Forum Infect Dis* **2016**; 3:ofv196.
35. Brown KA, Jones M, Daneman N, et al. Importation, antibiotics, and *Clostridium difficile* infection in Veteran long-term care: a multilevel case-control study. *Ann Intern Med* **2016**; 164:787–94.
36. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* **2005**; 353:2442–9.
37. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of *Clostridium difficile*-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. *Infect Control Hosp Epidemiol* **2005**; 26:273–80.
38. Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality, and costs associated with *Clostridium difficile* infection. *Infect Dis Clin North Am* **2015**; 29:123–34.
39. Vallabhaneni S, Almendares O, Farley MM, et al. Epidemiology and factors associated with candidemia following *Clostridium difficile* infection in adults within metropolitan Atlanta, 2009–2013. *Epidemiol Infect* **2016**; 144:1440–4.
40. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent *Clostridium difficile* diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. *Clin Infect Dis* **1997**; 24:324–33.
41. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent *Clostridium difficile* disease: epidemiology and clinical characteristics. *Infect Control Hosp Epidemiol* **1999**; 20:43–50.
42. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to *Clostridium difficile*. *Clin Infect Dis* **2002**; 34:346–53.
43. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M; Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial *Clostridium difficile*-associated diarrhea in Canadian hospitals. *Infect Control Hosp Epidemiol* **2002**; 23:137–40.
44. Olson MM, Shanholtzer CJ, Lee JT Jr., Gerding DN. Ten years of prospective *Clostridium difficile*-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. *Infect Control Hosp Epidemiol* **1994**; 15:371–81.
45. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. *Ann Surg* **2002**; 235:363–72.
46. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for *Clostridium difficile* infection and colonization. *N Engl J Med* **2011**; 365:1693–703.
47. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent *Clostridium difficile* infection is associated with increased mortality. *Clin Microbiol Infect* **2015**; 21:164–70.
48. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med* **2005**; 353:2433–41.
49. Eggertson L. Quebec strain of *C. difficile* in 7 provinces. *CMAJ* **2006**; 174:607–8.
50. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* **2005**; 366:1079–84.
51. Health Protection Agency. Outbreak of *Clostridium difficile* infection in a hospital in southeast England. *CDR Wkly* **2005**; 15.
52. Kuijper E, Barbut F, Brazier J, et al. Update of *Clostridium difficile* infection due to PCR ribotype 027 in Europe, 2008. *Euro Surveill* **2008**; 13:18942.
53. Kuijper EJ, Debast SB, Van Kregten E, Vaessen N, Notermans DW, van den Broek PJ. *Clostridium difficile* ribotype 027, toxinotype III in The Netherlands [in Dutch]. *Ned Tijdschr Geneesk* **2005**; 149:2087–9.
54. Kato H, Ito Y, van den Berg R, Kuijper E, Arakawa Y. First isolation of *Clostridium difficile* 027 in Japan. *Euro Surveill* **2007**; 12:EO701113.
55. See I, Mu Y, Cohen J, et al. NAPI strain type predicts outcomes from *Clostridium difficile* infection. *Clin Infect Dis* **2014**; 58:1394–400.
56. Wilcox MH, Shetty N, Fawley WN, et al. Changing epidemiology of *Clostridium difficile* infection following the introduction of a national ribotyping-based surveillance scheme in England. *Clin Infect Dis* **2012**; 55:1056–63.
57. Goorhuis A, Bakker D, Corver J, et al. Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. *Clin Infect Dis* **2008**; 47:1162–70.
58. Jhung MA, Thompson AD, Killgore GE, et al. Toxinotype V *Clostridium difficile* in humans and food animals. *Emerg Infect Dis* **2008**; 14:1039–45.
59. Centers for Disease Control and Prevention. Severe *Clostridium difficile*-associated disease in populations previously at low risk—four states, 2005. *MMWR Morb Mortal Wkly Rep* **2005**; 54:1201–5.
60. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* **2005**; 294:2989–95.
61. James AH, Katz VL, Dotters DJ, Rogers RG. *Clostridium difficile* infection in obstetric and gynecologic patients. *South Med J* **1997**; 90:889–92.
62. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. *Clostridium difficile* associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. *Gut* **2004**; 53:673–7.
63. Kyne L, Merry C, O'Connell B, Keane C, O'Neill D. Community-acquired *Clostridium difficile* infection. *J Infect* **1998**; 36:287–8.
64. Terhes G, Urbán E, Söki J, Hamid KA, Nagy E. Community-acquired *Clostridium difficile* diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. *J Clin Microbiol* **2004**; 42:4316–8.
65. Kuntz JL, Johnson ES, Raebel MA, et al. Predicting the risk of *Clostridium difficile* infection following an outpatient visit: development and external validation of a pragmatic, prognostic risk score. *Clin Microbiol Infect* **2015**; 21:256–62.
66. Negrón ME, Rezaie A, Barkema HW, et al. Ulcerative colitis patients with *Clostridium difficile* are at increased risk of death, colectomy, and postoperative complications: a population-based inception cohort study. *Am J Gastroenterol* **2016**; 111:691–704.
67. Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of *Clostridium difficile* infection in patients with inflammatory bowel disease: the RECIDIVISM Study. *Am J Gastroenterol* **2016**; 111:1141–6.
68. Peng JC, Shen J, Zhu Q, Ran ZH. The impact of *Clostridium difficile* on surgical rate among ulcerative colitis patients: a systemic review and meta-analysis. *Saudi J Gastroenterol* **2015**; 21:208–12.
69. Donnelly JP, Wang HE, Locke JE, Mannon RB, Safford MM, Baddley JW. Hospital-onset *Clostridium difficile* infection among solid organ transplant recipients. *Am J Transplant* **2015**; 15:2970–7.

70. Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of *Clostridium difficile* infection among solid organ transplant recipients: a meta-analysis of published studies. *PLoS One* **2015**; 10:e0124483.
71. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, Edmonds PJ, Mahaparn P, Bruminhent J. The risks of incident and recurrent *Clostridium difficile*-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. *Dig Dis Sci* **2015**; 60:2913–22.
72. Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, et al. Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of *Clostridium difficile* infection: a systematic review and meta-analysis. *Int J Clin Pract* **2015**; 69:998–1006.
73. Zacharioudakis IM, Ziakas PD, Mylonakis E. *Clostridium difficile* infection in the hematopoietic unit: a meta-analysis of published studies. *Biol Blood Marrow Transplant* **2014**; 20:1641–65.
74. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med* **1989**; 320:204–10.
75. Curry SR, Muto CA, Schlackman JL, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in *Clostridium difficile* transmission. *Clin Infect Dis* **2013**; 57:1094–102.
76. Rivera EV, Woods S. Prevalence of asymptomatic *Clostridium difficile* colonization in a nursing home population: a cross-sectional study. *J Gend Specif Med* **2003**; 6:27–30.
77. Aronsson B, Molby R, Nord C. Antimicrobial agents and *Clostridium difficile* in acute enteric disease: epidemiological data from Sweden, 1980–1982. *J Infect Dis* **1985**; 151:476–81.
78. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of *Clostridium difficile* isolates from various patient populations. *Gastroenterology* **1981**; 81:5–9.
79. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxigenic *C. difficile* upon hospital admission, and risk of infection: a systematic review and meta-analysis. *Am J Gastroenterol* **2015**; 110:381–90; quiz 391.
80. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *N Engl J Med* **2000**; 342:390–7.
81. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea. *Lancet* **2001**; 357:189–93.
82. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by *Clostridium difficile* and decreased risk of subsequent diarrhoea. *Lancet* **1998**; 351:633–6.
83. Sambol SP, Tang JK, Merrigan MM, Johnson S, Gerding DN. Infection of hamsters with epidemiologically important strains of *Clostridium difficile*. *J Infect Dis* **2001**; 183:1760–6.
84. Bobulsky GS, Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ. *Clostridium difficile* skin contamination in patients with *C. difficile*-associated disease. *Clin Infect Dis* **2008**; 46:447–50.
85. Fawley WN, Wilcox MH. Molecular epidemiology of endemic *Clostridium difficile* infection. *Epidemiol Infect* **2001**; 126:343–50.
86. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of *Clostridium difficile*. *Clin Infect Dis* **2000**; 31:995–1000.
87. Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial *Clostridium difficile* diarrhea. *Am J Med* **1996**; 100:32–40.
88. Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of *Clostridium difficile* infection. *J Hosp Infect* **2003**; 54:109–14.
89. Shaughnessy MK, Micielli RL, DePestel DD, et al. Evaluation of hospital room assignment and acquisition of *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* **2011**; 32:201–6.
90. Brooks SE, Veal RO, Kramer M, Dore L, Schupf N, Adachi M. Reduction in the incidence of *Clostridium difficile*-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. *Infect Control Hosp Epidemiol* **1992**; 13:98–103.
91. Walker AS, Eyre DW, Wyllie DH, et al. Characterisation of *Clostridium difficile* hospital ward-based transmission using extensive epidemiological data and molecular typing. *PLoS Med* **2012**; 9:e1001172.
92. Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of *C. difficile* infection identified on whole-genome sequencing. *N Engl J Med* **2013**; 369:1195–205.
93. Brown K, Valenta K, Fisman D, Simor A, Daneman N. Hospital ward antibiotic prescribing and the risks of *Clostridium difficile* infection. *JAMA Intern Med* **2015**; 175:626–33.
94. Freedberg DE, Salmasian H, Cohen B, Abrams JA, Larson EL. Receipt of antibiotics in hospitalized patients and risk for *Clostridium difficile* infection in subsequent patients who occupy the same bed. *JAMA Intern Med* **2016**; 176:1801–8.
95. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of *Clostridium difficile* during and after treatment of *C. difficile* infection. *Infect Control Hosp Epidemiol* **2010**; 31:21–7.
96. McDonald L, Owings M, Jernigan D. *Clostridium difficile* infection in patients discharged from US short-stay hospitals, 1996–2003. *Emerg Infect Dis* **2006**; 12:409–15.
97. Pepin J, Valiquette L, Alary M, et al. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. *CMAJ* **2004**; 31:466–72.
98. Johnson S, Gerding DN. *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* **1998**; 26:1027–34; quiz 1035–6.
99. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for *Clostridium difficile* infection after exposure to antibiotics. *J Antimicrob Chemother* **2012**; 67:742–8.
100. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Quebec. *Clin Infect Dis* **2005**; 41:1254–60.
101. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of *Clostridium difficile* in four hospitals. *N Engl J Med* **1999**; 341:1645–51.
102. Thibault A, Miller MA, Gaese C. Risk factors for the development of *Clostridium difficile*-associated diarrhea during a hospital outbreak. *Infect Control Hosp Epidemiol* **1991**; 12:345–8.
103. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol* **2008**; 6:e280.
104. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolini R, de Lalla F. Prospective study of *Clostridium difficile* intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. *Antimicrob Agents Chemother* **1991**; 35:208–10.
105. Anand A, Glatt AE. *Clostridium difficile* infection associated with antineoplastic chemotherapy: a review. *Clin Infect Dis* **1993**; 17:109–13.
106. Morales Chamorro R, Serrano Blanch R, Méndez Vidal MJ, et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. *Clin Transl Oncol* **2005**; 7:258–61.
107. Bilgrami S, Feingold JM, Dorsky D, et al. Incidence and outcome of *Clostridium difficile* infection following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* **1999**; 23:1039–42.
108. Gorschlüter M, Glasmacher A, Hahn C, et al. *Clostridium difficile* infection in patients with neutropenia. *Clin Infect Dis* **2001**; 33:786–91.
109. Sanchez T, Brooks J, Sullivan P, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992–2002. *Clin Infect Dis* **2005**; 41:1621–7.
110. Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN. Acquisition of *Clostridium difficile* and *Clostridium difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med* **1998**; 129:1012–9.
111. Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent *Clostridium difficile* infection: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* **2015**; 36:452–60.
112. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in *Clostridium difficile* infection: a systematic review. *PLoS One* **2014**; 9:e98400.
113. Bauer MP, Nibbering PH, Poxton IR, Kuijper EJ, van Dissel JT. Humoral immune response as predictor of recurrence in *Clostridium difficile* infection. *Clin Microbiol Infect* **2014**; 20:1323–8.
114. Sahay T, Ananthakrishnan AN. Vitamin D deficiency is associated with community-acquired *Clostridium difficile* infection: a case-control study. *BMC Infect Dis* **2014**; 14:661.
115. Wang WJ, Gray S, Sison C, et al. Low vitamin D level is an independent predictor of poor outcomes in *Clostridium difficile*-associated diarrhea. *Therap Adv Gastroenterol* **2014**; 7:14–9.
116. Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of *Clostridium difficile* infection with proton pump inhibitor use by level of antibiotic exposure. *Pharmacoepidemiol Drug Saf* **2011**; 20:1035–42.
117. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. *Arch Intern Med* **2010**; 170:784–90.
118. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for *Clostridium difficile* diarrhoea. *J Hosp Infect* **2003**; 54:243–5.
119. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* **2004**; 171:33–8.

120. Novack L, Kogan S, Gimpelevich L, et al. Acid suppression therapy does not predispose to *Clostridium difficile* infection: the case of the potential bias. *PLoS One* **2014**; 9:e110790.
121. Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with *Clostridium difficile*-associated diarrhoea. *BMJ Open Gastroenterol* **2015**; 2:e000028.
122. McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent *Clostridium difficile* infection. *JAMA Intern Med* **2015**; 175:784–91.
123. Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for *Clostridium difficile* susceptibility. *Microbiome* **2014**; 2:42.
124. Benson L, Song X, Campos J, Singh N. Changing epidemiology of *Clostridium difficile*-associated disease in children. *Infect Control Hosp Epidemiol* **2007**; 28:1233–5.
125. Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of *Clostridium difficile* infection in children: a population-based study. *Clin Infect Dis* **2013**; 56:1401–6.
126. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of *Clostridium difficile*-associated disease among inpatients at children's hospitals in the United States, 2001–2006. *Pediatrics* **2008**; 122:1266–70.
127. Nylund CM, Goudie A, Garza JM, Fairbrother G, Cohen MB. *Clostridium difficile* infection in hospitalized children in the United States. *Arch Pediatr Adolesc Med* **2011**; 165:451–7.
128. Zilberberg MD, Shorr AE, Kollef MH. Increase in *Clostridium difficile*-related hospitalizations among infants in the United States, 2000–2005. *Pediatr Infect Dis J* **2008**; 27:1111–3.
129. Zilberberg MD, Tillotson GS, McDonald C. *Clostridium difficile* infections among hospitalized children, United States, 1997–2006. *Emerg Infect Dis* **2010**; 16:604–9.
130. Baker SS, Faden H, Sayej W, Patel R, Baker RD. Increasing incidence of community-associated atypical *Clostridium difficile* disease in children. *Clin Pediatr (Phila)* **2010**; 49:644–7.
131. Wendt JM, Cohen JA, Mu Y, et al. *Clostridium difficile* infection among children across diverse US geographic locations. *Pediatrics* **2014**; 133:651–8.
132. Kocielek LK, Sandora TJ. National variability in surveillance, testing, and infection prevention for *Clostridium difficile* infection in pediatric populations. *Am J Infect Control* **2013**; 41:933–5.
133. Kocielek LK, Patel SJ, Zheng X, Todd KM, Shulman ST, Gerding DN. Clinical and microbiologic assessment of cases of pediatric community-associated *Clostridium difficile* infection reveals opportunities for improved testing decisions. *Pediatr Infect Dis J* **2016**; 35:157–61.
134. Bolton RP, Tait SK, Dear PR, Losowsky MS. Asymptomatic neonatal colonisation by *Clostridium difficile*. *Arch Dis Child* **1984**; 59:466–72.
135. Delmée M, Verellen G, Avesani V, Francois G. *Clostridium difficile* in neonates: serogrouping and epidemiology. *Eur J Pediatr* **1988**; 147:36–40.
136. Donta ST, Myers MG. *Clostridium difficile* toxin in asymptomatic neonates. *J Pediatr* **1982**; 100:431–4.
137. Elstner CL, Lindsay AN, Book LS, Matsen JM. Lack of relationship of *Clostridium difficile* to antibiotic-associated diarrhea in children. *Pediatr Infect Dis* **1983**; 2:364–6.
138. Phua TJ, Rogers TR, Pallett AP. Prospective study of *Clostridium difficile* colonization and paracresol detection in the stools of babies on a special care unit. *J Hyg (Lond)* **1984**; 93:17–25.
139. Rousseau C, Lemée L, Le Monnier A, Poilane I, Pons JL, Collignon A. Prevalence and diversity of *Clostridium difficile* strains in infants. *J Med Microbiol* **2011**; 60:1112–8.
140. Tullus K, Aronsson B, Marcus S, Möllby R. Intestinal colonization with *Clostridium difficile* in infants up to 18 months of age. *Eur J Clin Microbiol Infect Dis* **1989**; 8:390–3.
141. Tvede M, Schiøtz PO, Krasilnikoff PA. Incidence of *Clostridium difficile* in hospitalized children. A prospective study. *Acta Paediatr Scand* **1990**; 79:292–9.
142. Ellis ME, Mandal BK, Dunbar EM, Bundell KR. *Clostridium difficile* and its cytotoxin in infants admitted to hospital with infectious gastroenteritis. *Br Med J (Clin Res Ed)* **1984**; 288:524–6.
143. Larson HE, Barclay FE, Honour P, Hill ID. Epidemiology of *Clostridium difficile* in infants. *J Infect Dis* **1982**; 146:727–33.
144. Toma S, Lesiak G, Magus M, Lo HL, Delmée M. Serotyping of *Clostridium difficile*. *J Clin Microbiol* **1988**; 26:426–8.
145. Emeruwa AC, Oguike JU. Incidence of cytotoxin producing isolates of *Clostridium difficile* in faeces of neonates and children in Nigeria. *Microbiologica* **1990**; 13:323–8.
146. Penders J, Stobberingh EE, van den Brandt PA, van Ree R, Thijs C. Toxigenic and non-toxigenic *Clostridium difficile*: determinants of intestinal colonisation and role in childhood atopic manifestations. *Gut* **2008**; 57:1025–6.
147. Stark PL, Lee A. *Clostridia* isolated from the feces of infants during the first year of life. *J Pediatr* **1982**; 100:362–5.
148. Bacon AE, Fekety R, Schaberg DR, Faix RG. Epidemiology of *Clostridium difficile* colonization in newborns: results using a bacteriophage and bacteriocin typing system. *J Infect Dis* **1988**; 158:349–54.
149. Kato H, Kato N, Watanabe K, et al. Application of typing by pulsed-field gel electrophoresis to the study of *Clostridium difficile* in a neonatal intensive care unit. *J Clin Microbiol* **1994**; 32:2067–70.
150. Martirosian G, Kuipers S, Verbrugh H, van Belkum A, Meisel-Mikolajczyk F. PCR ribotyping and arbitrarily primed PCR for typing strains of *Clostridium difficile* from a Polish maternity hospital. *J Clin Microbiol* **1995**; 33:2016–21.
151. Camorlinga M, Muñoz O, Guisacfré H, Torres J. Colonization by *Clostridium difficile* in hospitalized children: risk factors and typification of the isolated strains. *Arch Invest Med (Mex)* **1991**; 22:19–26.
152. Matsuki S, Ozaki E, Shozu M, et al. Colonization by *Clostridium difficile* of neonates in a hospital, and infants and children in three day-care facilities of Kanazawa, Japan. *Int Microbiol* **2005**; 8:43–8.
153. Jangi S, Lamont JT. Asymptomatic colonization by *Clostridium difficile* in infants: implications for disease in later life. *J Pediatr Gastroenterol Nutr* **2010**; 51:2–7.
154. Sherertz RJ, Sarubbi FA. The prevalence of *Clostridium difficile* and toxin in a nursery population: a comparison between patients with necrotizing enterocolitis and an asymptomatic group. *J Pediatr* **1982**; 100:435–9.
155. Stoesser N, Crook DW, Fung R, et al. Molecular epidemiology of *Clostridium difficile* strains in children compared with that of strains circulating in adults with *Clostridium difficile*-associated infection. *J Clin Microbiol* **2011**; 49:3994–6.
156. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated *Clostridium difficile* infection. *J Antimicrob Chemother* **2008**; 62:388–96.
157. Pant C, Anderson MP, Deshpande A, et al. Health care burden of *Clostridium difficile* infection in hospitalized children with inflammatory bowel disease. *Inflamm Bowel Dis* **2013**; 19:1080–5.
158. Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for *Clostridium difficile* infection in children. *Pediatr Infect Dis J* **2011**; 30:580–4.
159. Tai E, Richardson LC, Townsend J, Howard E, McDonald LC. *Clostridium difficile* infection among children with cancer. *Pediatr Infect Dis J* **2011**; 30:610–2.
160. Thompson CM Jr, Gilligan PH, Fisher MC, Long SS. *Clostridium difficile* cytotoxin in a pediatric population. *Am J Dis Child* **1983**; 137:271–4.
161. Nylund CM, Eide M, Gorman GH. Association of *Clostridium difficile* infections with acid suppression medications in children. *J Pediatr* **2014**; 165: 979–84.e1.
162. Brown KE, Knoderer CA, Nichols KR, Crumby AS. Acid-suppressing agents and risk for *Clostridium difficile* infection in pediatric patients. *Clin Pediatr (Phila)* **2015**; 54:1102–6.
163. Castagnola E, Battaglia T, Bandettini R, et al. *Clostridium difficile*-associated disease in children with solid tumors. *Support Care Cancer* **2009**; 17:321–4.
164. Pokorn M, Radsel A, Cizman M, et al. Severe *Clostridium difficile*-associated disease in children. *Pediatr Infect Dis J* **2008**; 27:944–6.
165. Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe *Clostridium difficile* infection in children. *Pediatr Infect Dis J* **2012**; 31:134–8.
166. Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. *Clostridium difficile* infection is associated with increased risk of death and prolonged hospitalization in children. *Clin Infect Dis* **2013**; 57:1–8.
167. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. *Ann Intern Med* **1974**; 81:429–33.
168. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for *Clostridium-difficile*-associated diarrhoea and colitis. *Lancet* **1983**; 2:1043–6.
169. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated *Clostridium difficile* colitis with oral vancomycin: comparison of two dosage regimens. *Am J Med* **1989**; 86:15–9.
170. Johnson S, Louie TJ, Gerding DN, et al; Polymer Alternative for CDI Treatment (PACT) Investigators. Vancomycin, metronidazole, or tolevamer for *Clostridium difficile* infection: results from two multinational, randomized, controlled trials. *Clin Infect Dis* **2014**; 59:345–54.
171. Dubberke ER, Han Z, Bobo L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for *Clostridium difficile* infections. *J Clin Microbiol* **2011**; 49:2887–93.
172. Peterson LR, Manson RU, Paule SM, et al. Detection of toxigenic *Clostridium difficile* in stool samples by real-time polymerase chain reaction for the diagnosis of *C. difficile*-associated diarrhea. *Clin Infect Dis* **2007**; 45:1152–60.
173. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol* **1997**; 32:920–4.
174. Burnham CA, Carroll KC. Diagnosis of *Clostridium difficile* infection: an ongoing conundrum for clinicians and for clinical laboratories. *Clin Microbiol Rev* **2013**; 26:604–30.

175. Wilcox MH. Overcoming barriers to effective recognition and diagnosis of *Clostridium difficile* infection. *Clin Microbiol Infect* **2012**; 18(Suppl 6):13–20.
176. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available *Clostridium difficile* toxin detection assays, a real-time PCR assay for *C. difficile* tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxicogenic culture methods. *J Clin Microbiol* **2009**; 47:3211–7.
177. Planché T, Aghaizu A, Holliman R, et al. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. *Lancet Infect Dis* **2008**; 8:777–84.
178. Crobach MJ, Planché T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* **2016**; 22(Suppl 4):S63–81.
179. Gerding DN, Olson MM, Peterson LR, et al. *Clostridium difficile*-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. *Arch Intern Med* **1986**; 146:95–100.
180. Bauer MP, Notermans DW, van Benthem BH, et al; ECDIS Study Group. *Clostridium difficile* infection in Europe: a hospital-based survey. *Lancet* **2011**; 377:63–73.
181. Garey KW, Graham G, Gerard L, et al. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. *Ann Pharmacother* **2006**; 40:1030–4.
182. Planché T, Wilcox M. Reference assays for *Clostridium difficile* infection: one or two gold standards? *J Clin Pathol* **2011**; 64:1–5.
183. Kaltsas A, Simon M, Unruh LH, et al. Clinical and laboratory characteristics of *Clostridium difficile* infection in patients with discordant diagnostic test results. *J Clin Microbiol* **2012**; 50:1303–7.
184. Longtin Y, Trottier S, Brochu G, et al. Impact of the type of diagnostic assay on *Clostridium difficile* infection and complication rates in a mandatory reporting program. *Clin Infect Dis* **2013**; 56:67–73.
185. Planché TD, Davies KA, Coen PG, et al. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of *C. difficile* infection. *Lancet Infect Dis* **2013**; 13:936–45.
186. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of *Clostridium difficile* infection in the molecular test era. *JAMA Intern Med* **2015**; 175:1792–801.
187. Humphries RM, Usan DZ, Rubin Z. Performance of *Clostridium difficile* toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. *J Clin Microbiol* **2013**; 51:869–73.
188. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* **2007**; 45:302–7.
189. Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for *Clostridium difficile* in hospitalized patients with diarrhea. *Am J Med* **1996**; 100:487–95.
190. Berry N, Sewell B, Jafri S, et al. Real-time polymerase chain reaction correlates well with clinical diagnosis of *Clostridium difficile* infection. *J Hosp Infect* **2014**; 87:109–14.
191. Aichinger E, Schleck CD, Harmsen WS, Nyre LM, Patel R. Nonutility of repeat laboratory testing for detection of *Clostridium difficile* by use of PCR or enzyme immunoassay. *J Clin Microbiol* **2008**; 46:3795–7.
192. Cardona DM, Rand KH. Evaluation of repeat *Clostridium difficile* enzyme immunoassay testing. *J Clin Microbiol* **2008**; 46:3686–9.
193. Debast SB, van Kregten E, Oskam KM, van den Berg T, Van den Berg RJ, Kuijper EJ. Effect on diagnostic yield of repeated stool testing during outbreaks of *Clostridium difficile*-associated disease. *Clin Microbiol Infect* **2008**; 14:622–4.
194. Garimella PS, Agarwal R, Katz A. The utility of repeat enzyme immunoassay testing for the diagnosis of *Clostridium difficile* infection: a systematic review of the literature. *J Postgrad Med* **2012**; 58:194–8.
195. Garey KW, Ghantaji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with *Clostridium difficile* infection. *J Antimicrob Chemother* **2011**; 66:2850–5.
196. Abujamel T, Cadnum JL, Jury LA, et al. Defining the vulnerable period for re-establishment of *Clostridium difficile* colonization after treatment of *C. difficile* infection with oral vancomycin or metronidazole. *PLoS One* **2013**; 8:e76269.
197. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic *Clostridium difficile* strain M3 for prevention of recurrent *C. difficile* infection: a randomized clinical trial. *JAMA* **2015**; 313:1719–27.
198. Sherwood RA. Faecal markers of gastrointestinal inflammation. *J Clin Pathol* **2012**; 65:981–5.
199. El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in *Clostridium difficile* infection. *Clin Infect Dis* **2013**; 56:1713–21.
200. El Feghaly RE, Stauber JL, Tarr PI, Haslam DB. Intestinal inflammatory biomarkers and outcome in pediatric *Clostridium difficile* infections. *J Peds* **2013**; 163:1697–704 e2.
201. Jiang ZD, DuPont HL, Garey K, et al. A common polymorphism in the interleukin 8 gene promoter is associated with *Clostridium difficile* diarrhea. *Am J Gastroenterol* **2006**; 101:1112–6.
202. Rousseau C, Poilane I, De Pontual L, Maherault AC, Le Monnier A, Collignon A. *Clostridium difficile* carriage in healthy infants in the community: a potential reservoir for pathogenic strains. *Clin Infect Dis* **2012**; 55:1209–15.
203. Parsons SJ, Fenton E, Dargaville P. *Clostridium difficile* associated severe enterocolitis: a feature of Hirschsprung's disease in a neonate presenting late. *J Paediatr Child Health* **2005**; 41:689–90.
204. Pozo F, Soler P, Ladrón de Guevara C. Pseudomembranous colitis associated with Hirschsprung's disease. *Clin Infect Dis* **1994**; 19:1160–1.
205. Valentini D, Vittucci AC, Grandin A, et al. Coinfection in acute gastroenteritis predicts a more severe clinical course in children. *Eur J Clin Microbiol Infect Dis* **2013**; 32:909–15.
206. González-Del Vecchio M, Álvarez-Uria A, Marin M, et al. Clinical significance of *Clostridium difficile* in children less than 2 years old: a case-control study. *Pediatr Infect Dis J* **2016**; 35:281–5.
207. Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent *Clostridium difficile* BI strain in a university hospital using a comprehensive “bundle” approach. *Clin Infect Dis* **2007**; 45:1266–73.
208. Weiss K, Boisvert A, Chagnon M, et al. Multipronged intervention strategy to control an outbreak of *Clostridium difficile* infection (CDI) and its impact on the rates of CDI from 2002 to 2007. *Infect Control Hosp Epidemiol* **2009**; 30:156–62.
209. Evans ME, Kralovic SM, Simbartl LA, Jain R, Roselle GA. Effect of a *Clostridium difficile* infection prevention initiative in Veterans Affairs acute care facilities. *Infect Control Hosp Epidemiol* **2016**; 37:720–2.
210. Waqar S, Nigh K, Sisler L, et al. Multidisciplinary performance improvement team for reducing health care-associated *Clostridium difficile* infection. *Am J Infect Control* **2016**; 44:352–4.
211. Koll BS, Ruiz RE, Calfee DP, et al. Prevention of hospital-onset *Clostridium difficile* infection in the New York metropolitan region using a collaborative intervention model. *J Healthc Qual* **2014**; 36:35–45.
212. Teltsch DY, Hanley J, Loo V, Goldberg P, Gursahaney A, Buckeridge DL. Infection acquisition following intensive care unit room privatization. *Arch Intern Med* **2011**; 171:32–8.
213. Islam J, Cheek E, Navani V, Rajkumar C, Cohen J, Llewelyn MJ. Influence of cohorting patients with *Clostridium difficile* infection on risk of symptomatic recurrence. *J Hosp Infect* **2013**; 85:17–21.
214. Cartmill TD, Shrimpton SB, Panigrahi H, Khanna V, Brown R, Poxton IR. Nosocomial diarrhoea due to a single strain of *Clostridium difficile*: a prolonged outbreak in elderly patients. *Age Ageing* **1992**; 21:245–9.
215. Salgado CD, Mauldin PD, Fogle PJ, Bosso JA. Analysis of an outbreak of *Clostridium difficile* infection controlled with enhanced infection control measures. *Am J Infect Control* **2009**; 37:458–64.
216. Landelle C, Verachten M, Legrand P, et al. Contamination of healthcare workers' hands with *Clostridium difficile* spores after caring for patients with *C. difficile* infection. *Infect Control Hosp Epidemiol* **2014**; 35:10–5.
217. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt *Clostridium difficile* nosocomial transmission. *Am J Med* **1990**; 88:137–40.
218. Perry C, Marshall R, Jones E. Bacterial contamination of uniforms. *J Hosp Infect* **2001**; 48:238–41.
219. Puzniak LA, Leet T, Mayfield J, Kollef M, Mundy LM. To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. *Clin Infect Dis* **2002**; 35:18–25.
220. Srinivasan A, Song X, Ross T, Merz W, Brower R, Perl TM. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. *Infect Control Hosp Epidemiol* **2002**; 23:424–8.
221. Sunkesula VC, Kundrapu S, Jury LA, Deshpande A, Sethi AK, Donskey CJ. Potential for transmission of spores by patients awaiting laboratory testing to confirm suspected *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* **2013**; 34:306–8.
222. Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent *Clostridium difficile* infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol* **2014**; 35:628–45.
223. Public Health England and Department of Health. *Clostridium difficile* infection: how to deal with the problem. **2008**. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/340851/Clostridium_difficile_infection_how_to_deal_with_the_problem.pdf. Accessed 9 March 2016.
224. Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. Acquisition of spores on gloved hands after contact with the skin of patients with *Clostridium difficile* infection and with environmental surfaces in their rooms. *Am J Infect Control* **2012**; 40:556–8.

225. Boyce JM. Using alcohol for hand antisepsis: dispelling old myths. *Infect Control Hosp Epidemiol* **2000**; 21:438–41.
226. Pittet D, Mourouga P, Perneger TV. Compliance with handwashing in a teaching hospital. *Infection control program*. *Ann Intern Med* **1999**; 130:126–30.
227. Deyneko A, Cordeiro F, Berlin L, Ben-David D, Perna S, Longtin Y. Impact of sink location on hand hygiene compliance after care of patients with *Clostridium difficile* infection: a cross-sectional study. *BMC Infect Dis* **2016**; 16:203.
228. Zellmer C, Blakney R, Van Hoof S, Safdar N. Impact of sink location on hand hygiene compliance for *Clostridium difficile* infection. *Am J Infect Control* **2015**; 43:387–9.
229. Clabots CR, Gerding SJ, Olson MM, Peterson LR, Gerding DN. Detection of asymptomatic *Clostridium difficile* carriage by an alcohol shock procedure. *J Clin Microbiol* **1989**; 27:2386–7.
230. Gordin FM, Schultz ME, Huber RA, Gill JA. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. *Infect Control Hosp Epidemiol* **2005**; 26:650–3.
231. Boyce JM, Ligi C, Kohan C, Dumigan D, Havill NL. Lack of association between the increased incidence of *Clostridium difficile*-associated disease and the increasing use of alcohol-based hand rubs. *Infect Control Hosp Epidemiol* **2006**; 27:479–83.
232. Kaier K, Hagist C, Frank U, Conrad A, Meyer E. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant *Staphylococcus aureus* infection and *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* **2009**; 30:346–53.
233. Knight N, Strait T, Anthony N, et al. *Clostridium difficile* colitis: a retrospective study of incidence and severity before and after institution of an alcohol-based hand rub policy. *Am J Infect Control* **2010**; 38:523–8.
234. Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and *Clostridium difficile*. *J Antimicrob Chemother* **2008**; 62:601–7.
235. Stone SP, Fuller C, Savage J, et al. Evaluation of the national Cleanyourhands campaign to reduce *Staphylococcus aureus* bacteraemia and *Clostridium difficile* infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. *BMJ* **2012**; 344:e3005.
236. Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of *Clostridium difficile*. *Infect Control Hosp Epidemiol* **2009**; 30:939–44.
237. Jabbar U, Leischner J, Kasper D, et al. Effectiveness of alcohol-based hand rubs for removal of *Clostridium difficile* spores from hands. *Infect Control Hosp Epidemiol* **2010**; 31:565–70.
238. Edmonds SL, Zapka C, Kasper D, et al. Effectiveness of hand hygiene for removal of *Clostridium difficile* spores from hands. *Infect Control Hosp Epidemiol* **2013**; 34:302–5.
239. Kundrapu S, Sunkesula V, Sitzlar BM, Fertelli D, Deshpande A, Donskey CJ. More cleaning, less screening: evaluation of the time required for monitoring versus performing environmental cleaning. *Infect Control Hosp Epidemiol* **2014**; 35:202–4.
240. Jury LA, Guerrero DM, Burant CJ, Cadnum JL, Donskey CJ. Effectiveness of routine patient bathing to decrease the burden of spores on the skin of patients with *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* **2011**; 32:181–4.
241. Manian FA, Meyer L, Jenne J. *Clostridium difficile* contamination of blood pressure cuffs: a call for a closer look at gloving practices in the era of universal precautions. *Infect Control Hosp Epidemiol* **1996**; 17:180–2.
242. Brooks S, Khan A, Stoica D, et al. Reduction in vancomycin-resistant *Enterococcus* and *Clostridium difficile* infections following change to tympanic thermometers. *Infect Control Hosp Epidemiol* **1998**; 19:333–6.
243. Jernigan JA, Siegman-Igra Y, Guerrant RC, Farr BM. A randomized crossover study of disposable thermometers for prevention of *Clostridium difficile* and other nosocomial infections. *Infect Control Hosp Epidemiol* **1998**; 19:494–9.
244. Vajravelu RK, Guerrero DM, Jury LA, Donskey CJ. Evaluation of stethoscopes as vectors of *Clostridium difficile* and methicillin-resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol* **2012**; 33:96–8.
245. Kim KH, Fekety R, Batts DH, et al. Isolation of *Clostridium difficile* from the environment and contacts of patients with antibiotic-associated colitis. *J Infect Dis* **1981**; 143:42–50.
246. Dumford DM 3rd, Nerandzic MM, Eckstein BC, Donskey CJ. What is on that keyboard? Detecting hidden environmental reservoirs of *Clostridium difficile* during an outbreak associated with North American pulsed-field gel electrophoresis type 1 strains. *Am J Infect Control* **2009**; 37:15–9.
247. Burns DA, Heeg D, Cartman ST, Minton NP. Reconsidering the sporulation characteristics of hypervirulent *Clostridium difficile* BI/NAP1/027. *PLoS One* **2011**; 6:e24894.
248. Dubberke ER, Reske KA, Noble-Wang J, et al. Prevalence of *Clostridium difficile* environmental contamination and strain variability in multiple health care facilities. *Am J Infect Control* **2007**; 35:315–8.
249. Starr JM, Campbell A, Renshaw E, Poxton IR, Gibson GJ. Spatio-temporal stochastic modelling of *Clostridium difficile*. *J Hosp Infect* **2009**; 71:49–56.
250. Eyre DW, Griffiths D, Vaughan A, et al. Asymptomatic *Clostridium difficile* colonisation and onward transmission. *PLoS One* **2013**; 8:e78445.
251. Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of *Clostridium difficile* from the hospital environment. *Am J Epidemiol* **1988**; 127:1289–94.
252. McMullen KM, Zack J, Coopersmith CM, Kollef M, Dubberke E, Warren DK. Use of hypochlorite solution to decrease rates of *Clostridium difficile*-associated diarrhea. *Infect Control Hosp Epidemiol* **2007**; 28:205–7.
253. Orenstein R, Aronhalt KC, McManus JE Jr, Fedraw LA. A targeted strategy to wipe out *Clostridium difficile*. *Infect Control Hosp Epidemiol* **2011**; 32:1137–9.
254. Sitzlar B, Deshpande A, Fertelli D, Kundrapu S, Sethi AK, Donskey CJ. An environmental disinfection odyssey: evaluation of sequential interventions to improve disinfection of *Clostridium difficile* isolation rooms. *Infect Control Hosp Epidemiol* **2013**; 34:459–65.
255. Boyce JM, Havill NL, Dumigan DG, Golebiewski M, Balogun O, Rizvani R. Monitoring the effectiveness of hospital cleaning practices by use of an adenosine triphosphate bioluminescence assay. *Infect Control Hosp Epidemiol* **2009**; 30:678–84.
256. Boyce JM, Havill NL, Otter JA, et al. Impact of hydrogen peroxide vapor room decontamination on *Clostridium difficile* environmental contamination and transmission in a healthcare setting. *Infect Control Hosp Epidemiol* **2008**; 29:723–9.
257. Barbut F, Menuet D, Verachten M, Girou E. Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of *Clostridium difficile* spores. *Infect Control Hosp Epidemiol* **2009**; 30:507–14.
258. Vianna PG, Dale CR Jr, Simmons S, Stibich M, Licitra CM. Impact of pulsed xenon ultraviolet light on hospital-acquired infection rates in a community hospital. *Am J Infect Control* **2016**; 44:299–303.
259. Horn K, Otter JA. Hydrogen peroxide vapor room disinfection and hand hygiene improvements reduce *Clostridium difficile* infection, methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant enterococci, and extended-spectrum β -lactamase. *Am J Infect Control* **2015**; 43:1354–6.
260. Nagaraja A, Visintainer P, Haas JP, Menz J, Wormser GP, Montecalvo MA. *Clostridium difficile* infections before and during use of ultraviolet disinfection. *Am J Infect Control* **2015**; 43:940–5.
261. Miller R, Simmons S, Dale C, Stachowiak J, Stibich M. Utilization and impact of a pulsed-xenon ultraviolet room disinfection system and multidisciplinary care team on *Clostridium difficile* in a long-term acute care facility. *Am J Infect Control* **2015**; 43:1350–3.
262. Haas JP, Menz J, Dusza S, Montecalvo MA. Implementation and impact of ultraviolet environmental disinfection in an acute care setting. *Am J Infect Control* **2014**; 42:586–90.
263. Manian FA, Griesnauer S, Bryant A. Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic *Clostridium difficile* infection rates. *Am J Infect Control* **2013**; 41:537–41.
264. Levin J, Riley LS, Parrish C, English D, Ahn S. The effect of portable pulsed xenon ultraviolet light after terminal cleaning on hospital-associated *Clostridium difficile* infection in a community hospital. *Am J Infect Control* **2013**; 41:746–8.
265. Kundrapu S, Sunkesula V, Jury LA, Sitzlar BM, Donskey CJ. Daily disinfection of high-touch surfaces in isolation rooms to reduce contamination of healthcare workers' hands. *Infect Control Hosp Epidemiol* **2012**; 33:1039–42.
266. Hacek DM, Ogle AM, Fisher A, Robicsek A, Peterson LR. Significant impact of terminal room cleaning with bleach on reducing nosocomial *Clostridium difficile*. *Am J Infect Control* **2010**; 38:350–3.
267. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of *Clostridium difficile* by hospitalized patients: evidence for colonized new admissions as a source of infection. *J Infect Dis* **1992**; 166:561–7.
268. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic *Clostridium difficile* strains among long-term care facility residents. *Clin Infect Dis* **2007**; 45:992–8.
269. Grigoras CA, Zervou FN, Zacharioudakis IM, Sietos CI, Mylonakis E. Isolation of *C. difficile* carriers alone and as part of a bundle approach for the prevention of *Clostridium difficile* infection (CDI): a mathematical model based on clinical study data. *PLoS One* **2016**; 11:e0156577.
270. Lanzas C, Dubberke ER. Effectiveness of screening hospital admissions to detect asymptomatic carriers of *Clostridium difficile*: a modeling evaluation. *Infect Control Hosp Epidemiol* **2014**; 35:1043–50.
271. Longtin Y, Paquet-Bolduc B, Gilca R, et al. Effect of detecting and isolating *Clostridium difficile* carriers at hospital admission on the incidence of *C*

- difficile* infections: a quasi-experimental controlled study. *JAMA Intern Med* **2016**; 176:796–804.
272. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial *Clostridium difficile*-associated diarrhea by restricting clindamycin use. *Ann Intern Med* **1994**; 120:272–7.
 273. McNulty C, Logan M, Donald IP, et al. Successful control of *Clostridium difficile* infection in an elderly care unit through use of a restrictive antibiotic policy. *J Antimicrob Chemother* **1997**; 40:707–11.
 274. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of *Clostridium difficile*-associated diarrhea and cost. *Ann Intern Med* **1998**; 128:989–95.
 275. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on *Clostridium difficile*-associated diarrhoea (CDAD) over a five-year period in a district general hospital. *J Hosp Infect* **2003**; 54:104–8.
 276. Carling P, Fung T, Killian A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. *Infect Control Hosp Epidemiol* **2003**; 24:699–706.
 277. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of *Clostridium difficile* diarrhoea. *J Antimicrob Chemother* **2004**; 54:168–72.
 278. Gaynes R, Rimland D, Killum E, et al. Outbreak of *Clostridium difficile* infection in a long-term care facility: association with gatifloxacin use. *Clin Infect Dis* **2004**; 38:640–5.
 279. Valiquette L, Cossette B, Garant MP, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of *Clostridium difficile*-associated disease caused by the hypervirulent NAP1/027 strain. *Clin Infect Dis* **2007**; 45(Suppl 2):S112–21.
 280. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce *Clostridium difficile* infection: a controlled interrupted time series. *J Antimicrob Chemother* **2007**; 59:990–5.
 281. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of *Clostridium difficile* infection. *J Antimicrob Chemother* **2011**; 66:2168–74.
 282. Elligsen M, Walker SA, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. *Infect Control Hosp Epidemiol* **2012**; 33:354–61.
 283. Dancer SJ, Kirkpatrick P, Corcoran DS, Christison F, Farmer D, Robertson C. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired *Clostridium difficile*, extended-spectrum β -lactamase-producing coliforms and methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents* **2013**; 41:137–42.
 284. Aldeyab MA, Devine MJ, Flanagan P, et al. Multihospital outbreak of *Clostridium difficile* ribotype 027 infection: epidemiology and analysis of control measures. *Infect Control Hosp Epidemiol* **2011**; 32:210–9.
 285. Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of *Clostridium difficile* infection in hospital settings. *J Antimicrob Chemother* **2012**; 67:2988–96.
 286. Jump RL, Olds DM, Seifi N, et al. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use. *Infect Control Hosp Epidemiol* **2012**; 33:1185–92.
 287. Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. *Clin Infect Dis* **2000**; 31:717–22.
 288. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. *Clin Infect Dis* **2011**; 53:42–8.
 289. Barlam TF, Cosgrove SE, Abbo LM, et al. Executive summary: implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis* **2016**; 62:1197–202.
 290. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of *Clostridium difficile* infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol* **2012**; 107:1011–9.
 291. Tleyjeh I, Bin Abdulhak A, Riaz M, et al. Association between acid-suppression therapy and *Clostridium difficile* infection: a systematic review and meta-analysis. *Clin Microbiol Infect* **2012**; 18:113.
 292. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent *Clostridium difficile* infection. *J Hosp Infect* **2008**; 70:298–304.
 293. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. *Clostridium difficile*-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. *Am J Gastroenterol* **2012**; 107:1001–10.
 294. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent *Clostridium difficile* infection among inpatients. *Am J Gastroenterol* **2013**; 108:1794–801.
 295. Rodríguez-Pardo D, Almirante B, Bartolomé RM, et al; Barcelona *Clostridium difficile* Study Group. Epidemiology of *Clostridium difficile* infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. *J Clin Microbiol* **2013**; 51:1465–73.
 296. Lin HJ, Hung YP, Liu HC, et al. Risk factors for *Clostridium difficile*-associated diarrhea among hospitalized adults with fecal toxigenic *C. difficile* colonization. *J Microbiol Immunol Infect* **2015**; 48:183–9.
 297. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in *Clostridium difficile* infection: a population-based study. *Mayo Clinic Proceedings* **2012**; 87:636–42.
 298. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and *Clostridium difficile* infection among hospitalized patients: systematic review and meta-analysis. *Open Med* **2013**; 7:e56–67.
 299. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. *Cochrane Database Syst Rev* **2013**; 5:CD006095.
 300. Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of *Clostridium difficile* infection possible with specific probiotics? *Int J Infect Dis* **2012**; 16:e786–92.
 301. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of *Lactobacillus acidophilus* CL1285 and *Lactobacillus casei* LBC80R for antibiotic-associated diarrhea and *Clostridium difficile*-associated diarrhea prophylaxis in adult patients. *Am J Gastroenterol* **2010**; 105:1636–41.
 302. Kotowska M, Albrecht P, Szajewska H. *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. *Aliment Pharmacol Ther* **2005**; 21:583–90.
 303. Enache-Angoulvant A, Hennequin C. Invasive *Saccharomyces* infection: a comprehensive review. *Clin Infect Dis* **2005**; 41:1559–68.
 304. Hennequin C, Kauffmann-Lacroix C, Eubert A, et al. Possible role of catheters in *Saccharomyces boulardii* fungemia. *Eur J Clin Microbiol Infect Dis* **2000**; 19:16–20.
 305. Gouriet F, Million M, Henri M, Fournier PE, Raoult D. *Lactobacillus rhamnosus* bacteremia: an emerging clinical entity. *Eur J Clin Microbiol Infect Dis* **2012**; 31:2469–80.
 306. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for *Clostridium difficile* infection in individuals taking concomitant antibiotics for other concurrent infections. *Clin Infect Dis* **2011**; 53:440–7.
 307. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of *Clostridium difficile*-associated disease. *Antimicrob Agents Chemother* **2008**; 52:2403–6.
 308. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of *Clostridium difficile* diarrhea and colitis. *Clin Infect Dis* **2009**; 48:598–605.
 309. Wilcox MH, Howe R. Diarrhoea caused by *Clostridium difficile*: response time for treatment with metronidazole and vancomycin. *J Antimicrob Chemother* **1995**; 36:673–9.
 310. Wenisch C, Parschall B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* **1996**; 22:813–8.
 311. Siegfried J, Dubrovskaya Y, Flagiello T, et al. Initial therapy for mild to moderate *Clostridium difficile* infection. *Infect Dis Clin Pract* **2016**; 24:210–6.
 312. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of *Clostridium difficile* colitis with metronidazole. *Clin Infect Dis* **2005**; 40:1586–90.
 313. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of *Clostridium difficile* colitis in Quebec, Canada. *Clin Infect Dis* **2005**; 40:1591–7.
 314. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol* **2010**; 31:431–55.
 315. Yamamoto T, Abe K, Anjiki H, Ishii T, Kuyama Y. Metronidazole-induced neurotoxicity developed in liver cirrhosis. *J Clin Med Res* **2012**; 4:295–8.
 316. Knorr JP, Javed I, Sahni N, Cankurtaran CZ, Ortiz JA. Metronidazole-induced encephalopathy in a patient with end-stage liver disease. *Case Reports Hepatol* **2012**; 2012:209258.
 317. Jardin CG, Palmer HR, Shah DN, et al. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based *Clostridium difficile* infection treatment policy. *J Hosp Infect* **2013**; 85:28–32.

318. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG. CSI: a severity index for *Clostridium difficile* infection at the time of admission. *J Hosp Infect* **2011**; 79:151–4.
319. Bauer MP, Hensgens MP, Miller MA, et al. Renal failure and leukocytosis are predictors of a complicated course of *Clostridium difficile* infection if measured on day of diagnosis. *Clin Infect Dis* **2012**; 55(Suppl 2):S149–53.
320. Miller MA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for *Clostridium difficile* infection which predicts response to therapy. *BMC Infect Dis* **2013**; 13:148.
321. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med* **2011**; 364:422–31.
322. Shah DN, Bhatt NS, Welch JK, Koo HL, Garey KW. Defining acute renal dysfunction as a criterion for the severity of *Clostridium difficile* infection in patients with community-onset vs hospital-onset infection. *J Hosp Infect* **2013**; 83:294–9.
323. Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S. *Clostridium difficile* infection and limitations of markers for severity in patients with hematologic malignancy. *Infect Control Hosp Epidemiol* **2013**; 34:127–32.
324. Cornely OA, Crook DW, Esposito R, et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. *Lancet Infect Dis* **2012**; 12:281–9.
325. Crook DW, Walker AS, Kean Y, et al; Study 3/4 Teams. Fidaxomicin versus vancomycin for *Clostridium difficile* infection: meta-analysis of pivotal randomized controlled trials. *Clin Infect Dis* **2012**; 55(Suppl 2):S93–103.
326. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and *Candida* species in patients treated with fidaxomicin versus vancomycin for *Clostridium difficile* infection. *Clin Infect Dis* **2012**; 55 Suppl 2:S121–6.
327. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of *Clostridium difficile*. *Antimicrob Agents Chemother* **2008**; 52:2813–7.
328. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe *Clostridium difficile* colitis: case series and review of the literature. *Clin Infect Dis* **2002**; 35:690–6.
329. Malamood M, Nellis E, Ehrlich AC, Friedenberg FK. Vancomycin enemas as adjunctive therapy for *Clostridium difficile* infection. *J Clin Med Res* **2015**; 7:422–7.
330. Pettit NN, DePestel DD, Fohl AL, Eyler R, Carver PL. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of *Clostridium difficile* infection. *Pharmacotherapy* **2015**; 35:119–26.
331. Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The Addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with *Clostridium difficile* infection. *Clin Infect Dis* **2015**; 61:934–41.
332. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent *Clostridium difficile* diarrhea. *Dis Colon Rectum* **2006**; 49:640–5.
333. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by *Clostridium difficile* toxin. *J Pediatr* **1991**; 118:633–7.
334. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe *Clostridium difficile* colitis. *Gut* **1997**; 41:366–70.
335. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent *Clostridium difficile* diarrhoea. *J Antimicrob Chemother* **2004**; 53:882–4.
336. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe *Clostridium difficile* infection. *Ann Pharmacother* **2011**; 45:1005–10.
337. Herpers BL, Vlamincx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory *Clostridium difficile* infection. *Clin Infect Dis* **2009**; 48:1732–5.
338. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant *Clostridium difficile* colitis during an epidemic caused by a hypervirulent strain. *Ann Surg* **2007**; 245:267–72.
339. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for *Clostridium difficile* colitis. *Dis Colon Rectum* **2004**; 47:1620–6.
340. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated *Clostridium difficile* associated disease. *Ann Surg* **2011**; 254:423–7; discussion 427–9.
341. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* **2000**; 38:2386–8.
342. Johnson S, Adelman A, Clabots CR, Peterson LR, Gerding DN. Recurrences of *Clostridium difficile* diarrhea not caused by the original infecting organism. *J Infect Dis* **1989**; 159:340–3.
343. Nair S, Yadav D, Corpuz M, Pitchumoni CS. *Clostridium difficile* colitis: factors influencing treatment failure and relapse—a prospective evaluation. *Am J Gastroenterol* **1998**; 93:1873–6.
344. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent *Clostridium difficile* infection. *Arch Intern Med* **2010**; 170:772–8.
345. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent *Clostridium difficile*-associated disease: a case-control analysis matched by propensity score. *J Clin Gastroenterol* **2012**; 46:397–400.
346. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of *Clostridium difficile* infection: fidaxomicin versus vancomycin. *Clin Infect Dis* **2012**; 55(Suppl 2):S154–61.
347. Spiceland CM, Khanna S, Pardi DS. Outcomes with fidaxomicin therapy in *Clostridium difficile* infection. *J Clin Gastroenterol* **2016**. doi:10.1097/MCG.0000000000000769.
348. Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC. Evaluation of metronidazole toxicity: a prospective study. *Int J Clin Pharmacol Res* **1999**; 19:83–8.
349. Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. *Clin Neuropharmacol* **2011**; 34:241–7.
350. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol* **2002**; 97:1769–75.
351. Lagrotteria D, Holmes S, Smieja M, Smail F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* **2006**; 43:547–52.
352. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis* **2000**; 31:1012–7.
353. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA* **1994**; 271:1913–8.
354. Wullt M, Hagglätt ML, Odenholt I. *Lactobacillus plantarum* 299v for the treatment of recurrent *Clostridium difficile*-associated diarrhoea: a double-blind, placebo-controlled trial. *Scand J Infect Dis* **2003**; 35:365–7.
355. Kaki R, Brooks A, Main C, Jayaratne P, Mertz D. Does extending *Clostridium difficile* treatment in patients who are receiving concomitant antibiotics reduce the rate of relapse? *Internet J Infect Dis* **2016**; 15:1–5.
356. Carignan A, Poulin S, Martin P, et al. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent *Clostridium difficile* infections. *Am J Gastroenterol* **2016**; 111:1834–40.
357. Van Hise NW, Bryant AM, Hennessey EK, Crannage AJ, Khoury JA, Manian FA. Efficacy of oral vancomycin in preventing recurrent *Clostridium difficile* infection in patients treated with systemic antimicrobial agents. *Clin Infect Dis* **2016**; 63:651–3.
358. Aas J, Gessert CE, Bakken JS. Recurrent *Clostridium difficile* colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. *Clin Infect Dis* **2003**; 36:580–5.
359. Bakken JS. Fecal bacteriotherapy for recurrent *Clostridium difficile* infection. *Anaerobe* **2009**; 15:285–9.
360. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis* **2011**; 53:994–1002.
361. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of *Clostridium difficile*-associated disease. *Aliment Pharmacol Ther* **2012**; 35:865–75.
362. MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent *Clostridium difficile*-associated diarrhoea: a UK case series. *QJM* **2009**; 102:781–4.
363. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent *Clostridium difficile* infection. *Am J Gastroenterol* **2012**; 107:1079–87.
364. Hamilton MJ, Weingarten AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent *Clostridium difficile* infection. *Am J Gastroenterol* **2012**; 107:761–7.
365. Jorup-Rönström C, Håkanson A, Sandell S, et al. Fecal transplant against relapsing *Clostridium difficile*-associated diarrhea in 32 patients. *Scand J Gastroenterol* **2012**; 47:548–52.
366. Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent *Clostridium difficile* infection. *Gastroenterology* **2012**; 142:490–6.

367. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* **2013**; 368:407–15.
368. Cammarota G, Masucci L, Ianaro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Aliment Pharmacol Ther* **2015**; 41:835–43.
369. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing *Clostridium difficile* infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. *Clin Infect Dis* **2014**; 58:1515–22.
370. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent *Clostridium difficile* infection: a randomized clinical trial. *JAMA* **2016**; 315:142–9.
371. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent *Clostridium difficile* infection: a randomized trial. *Ann Intern Med* **2016**; 165:609–16.
372. Bakken JS, Borody T, Brandt LJ, et al. Fecal Microbiota Transplantation Workgroup. Treating *Clostridium difficile* infection with fecal microbiota transplantation. *Clin Gastroenterol Hepatol* **2011**; 9:1044–9.
373. Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent *Clostridium difficile* infection: report on a case series. *Anaerobe* **2013**; 19:22–6.
374. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal Microbiota transplantation. *PLoS One* **2016**; 11: e0161174.
375. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of *Clostridium difficile* infection in immunocompromised patients. *Am J Gastroenterol* **2014**; 109:1065–71.
376. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of *Clostridium difficile* infection despite asymptomatic donors and lack of sick contacts. *Am J Gastroenterol* **2013**; 108:1367.
377. Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe *Clostridium difficile* infection following sequential fecal microbiota transplantation. *J Clin Gastroenterol* **2013**; 47:735–7.
378. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated *Clostridium difficile* infection: description of a protocol with high success rate. *Aliment Pharmacol Ther* **2015**; 42:470–6.
379. Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* **2016**; 14:1433–8.
380. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* **2013**; 11:1036–8.
381. Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory *Clostridium difficile* infection in patients with inflammatory bowel disease. *Inflamm Bowel Dis* **2016**; 22:2402–9.
382. Sammons JS, Gerber JS, Tamma PD, et al. Diagnosis and management of *Clostridium difficile* infection by pediatric infectious diseases physicians. *J Pediatric Infect Dis Soc* **2014**; 3:43–8.
383. Schwenk HT, Graham DA, Sharma TS, Sandora TJ. Vancomycin use for pediatric *Clostridium difficile* infection is increasing and associated with specific patient characteristics. *Antimicrob Agents Chemother* **2013**; 57:4307–13.
384. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and *Clostridium difficile* infection? *Clin Infect Dis* **1997**; 25(Suppl 2):S206–10.
385. Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* **2009**; 49:400–4.
386. Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. *Eur Rev Med Pharmacol Sci* **2013**; 17:1314–20.
387. Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing *Clostridium difficile* infection in a child: a proposed treatment protocol. *Pediatrics* **2010**; 126:e239–42.
388. Walia R, Garg S, Song Y, et al. Efficacy of fecal microbiota transplantation in 2 children with recurrent *Clostridium difficile* infection and its impact on their growth and gut microbiome. *J Ped Gastroenterol Nutr* **2014**; 59:565–70.
389. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of *Clostridium difficile* infection in the molecular test era. *JAMA Intern Med* **2015**; 175:1792–801.
390. Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of *Clostridium difficile*-associated diarrhea. *Antimicrob Agents Chemother* **2012**; 56:4043–5.